
<html lang="en"     class="pb-page"  data-request-id="bae6a664-6818-4a3f-9f1c-73855822766e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-23;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/jm300434z;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance" /></meta><meta name="dc.Creator" content="Andrew J.  Kale" /></meta><meta name="dc.Creator" content="Bradley S.  Moore" /></meta><meta name="dc.Description" content="The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib a..." /></meta><meta name="Description" content="The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 3, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300434z" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300434z" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300434z" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300434z" /></link>
        
    
    

<title>Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300434z" /></meta><meta property="og:title" content="Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0005.jpeg" /></meta><meta property="og:description" content="The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib and, most recently, the epoxyketone peptide carfilzomib. However, intrinsic and acquired resistance to PIs, for which the underlying mechanisms are poorly understood, may limit their efficacy. In this Perspective, we discuss recent advances in the molecular understanding of PI resistance through acquired bortezomib resistance in human cell lines and evolved salinosporamide A (marizomib) resistance in bacteria. Resistance mechanisms discussed include the up-regulation of proteasome subunits and mutations of the catalytic β-subunits. Additionally, we explore potential strategies to overcome PI resistance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300434z"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300434z">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300434z&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300434z&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300434z&amp;href=/doi/10.1021/jm300434z" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10317-10327</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm3005898" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+J.++Kale">Andrew J. Kale</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bradley+S.++Moore">Bradley S. Moore</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California—San Diego, La Jolla, California 92093, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California—San Diego, La Jolla, California 92093, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-822-6650. Fax: 858-534-1305. E-mail: <a href="/cdn-cgi/l/email-protection#bddfced0d2d2cfd8fdc8deced993d8d9c8"><span class="__cf_email__" data-cfemail="e684958b89899483a693859582c8838293">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300434z&amp;href=/doi/10.1021%2Fjm300434z" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10317–10327</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 14, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 April 2012</li><li><span class="item_label"><b>Published</b> online</span>3 October 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 December 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300434z" title="DOI URL">https://doi.org/10.1021/jm300434z</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10317%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%2BJ.%2BKale%252C%2BBradley%2BS.%2BMoore%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D23%26contentID%3Djm300434z%26title%3DMolecular%2BMechanisms%2Bof%2BAcquired%2BProteasome%2BInhibitor%2BResistance%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10327%26publicationDate%3DDecember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300434z"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2799</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">57</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300434z" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;J. Kale&quot;},{&quot;first_name&quot;:&quot;Bradley&quot;,&quot;last_name&quot;:&quot;S. Moore&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;10317-10327&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300434z&quot;},&quot;abstract&quot;:&quot;The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib and, most recently, the epoxyketone peptide carfilzomib. However, intrinsic and acquired resistance to PIs, for which the underlying mechanisms are poorly understood, may limit their efficacy. In this Perspective, we discuss recent advances in the molecular understanding of PI resistance through acquired bortezomib resistance in human cell lines and evolved salinosporamide A (marizomib) resistance in bacteria. Resistance mechanisms discussed include the up-regulation of proteasome subunits and mutations of the catalytic β-subunits. Additionally, we explore potential strategies to overcome PI resistance.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300434z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300434z" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300434z&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300434z" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300434z&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300434z" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300434z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300434z&amp;href=/doi/10.1021/jm300434z" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300434z" /></input><a href="/doi/pdf/10.1021/jm300434z" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300434z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300434z%26sid%3Dliteratum%253Aachs%26pmid%3D22978849%26genre%3Darticle%26aulast%3DKale%26date%3D2012%26atitle%3DMolecular%2BMechanisms%2Bof%2BAcquired%2BProteasome%2BInhibitor%2BResistance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D23%26spage%3D10317%26epage%3D10327%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jmcmar.2012.55.issue-23/production/jmcmar.2012.55.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0005.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib and, most recently, the epoxyketone peptide carfilzomib. However, intrinsic and acquired resistance to PIs, for which the underlying mechanisms are poorly understood, may limit their efficacy. In this Perspective, we discuss recent advances in the molecular understanding of PI resistance through acquired bortezomib resistance in human cell lines and evolved salinosporamide A (marizomib) resistance in bacteria. Resistance mechanisms discussed include the up-regulation of proteasome subunits and mutations of the catalytic β-subunits. Additionally, we explore potential strategies to overcome PI resistance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In eukaryotes, the regulated hydrolysis of cellular proteins is mediated by a ubiquitous macromolecular enzymatic complex, the 26S proteasome.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The proteasome acts as the central hub of nonlysosomal cellular proteolysis, mediating processes such as cell cycle control, cell differentiation, immune response, amino acid recycling, and apoptosis; consequently, its disruption by genetic mutation or small molecule inhibitors has significant deleterious effects via multiple downstream pathways.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To underscore its universal role, inhibition of the proteasome has been explored in the treatment of diverse maladies such as cancer,<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> viruses,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> stroke,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> cardiovascular disease,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> inflammation,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and transplant rejection.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Bortezomib (Velcade) was the first FDA approved proteasome inhibitor (PI), where it is used in the treatment of the hematological malignancies multiple myeloma (MM) and refractory mantle cell lymphoma (MCL),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and on July 20, 2012, carfilzomib (Kyprolis) became the second FDA-approved PI to treat advanced MM.</div><div class="NLM_p last">Despite the successes of bortezomib therapy, many patients are intrinsically resistant to bortezomib or become resistant during treatment.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> While much effort has gone into elucidating how PIs function at the molecular level and consequently combat cancer,<a onclick="showRef(event, 'ref4 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref4 ref8 ref9 ref10">(4, 8-10)</a> the mechanism(s) of PI resistance is (are) currently less understood.<a onclick="showRef(event, 'ref4 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref4 ref8 ref9 ref10">(4, 8-10)</a> In an effort to elucidate potential mechanisms of acquired PI resistance, many recent studies have established cell lines of various malignancies that are resistant to bortezomib.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(11-21)</a> In this Perspective we summarize the different mechanisms of PI resistance that include up-regulation and/or sequence mutation of the molecular target, the 20S proteasome β5-subunit, as acquired resistance mechanisms in various cancer cell lines. While these acquired resistance mechanisms have not yet been observed in patient samples, they may foreshadow acquired resistance in the clinic. We additionally explore potential strategies to overcome such resistance mechanisms in the next generation of small molecule PIs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Ubiquitin–Proteasome System</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 2.5 MDa eukaryotic 26S proteasome comprises a 700 kDa 20S core particle and the 19S regulatory base and lid (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The 19S structure serves as the gatekeeper of the catalytic 20S core particle for the recognition and unfolding of polyubiquitinated substrates. Proteins destined for proteasome-mediated destruction in eukaryotic cells are covalently tagged with ubiquitin (Ub), a small protein modifier. Briefly, Ub is transferred to target protein Lys residues by a cascade of three enzymes, E1, E2, and E3 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Ub may also be transferred to another Ub residue forming a poly-Ub chain, which signals the substrate protein for the 19S regulatory cap and subsequent proteasomal degradation. The quantity and specificity of ubiquitinating enzymes increase from E1 to E3. Only two E1 isoforms are known in humans, while there are over 30 E2’s and 300 E3's.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The ubiquitin–proteasome system has been well studied and extensively reviewed elsewhere.<a onclick="showRef(event, 'ref22 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref24">(22, 24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ubiquitin–proteasome system. Polyubiquitination of cellular proteins by the cascade of E1, E2, and E3 enzymes assigns substrate proteins for 26S proteasomal degradation. Poly-Ub proteins are recognized and unfolded by the 19S regulatory particle and fed into the proteolytic 20S core particle for destruction by the three catalytically active subunits, β5, β2, and β1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The 20S core particle contains four heptameric rings stacked in a cylindrical α<sub>7</sub>β<sub>7</sub>β<sub>7</sub>α<sub>7</sub> arrangement.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The α-subunits act as the exterior structural scaffold, while the interior β-subunits catalyze proteolytic activity. Each α- and β-subunit per heptameric ring is unique, requiring 14 genes for the 20S core alone. Upon assembly, prosequences of the proteolytic β-subunits are autocatalytically removed yielding the N-terminal Thr1, which serves as the nucleophile for proteolytic hydrolysis. Only three of the seven β-subunits in each heptameric ring are catalytically active: the <i>PSMB6</i> encoded β1-subunits catalyze caspase-like activity (C-L); the <i>PSMB7</i> encoded β2-subunits catalyze trypsin-like activity (T-L); the <i>PSMB</i>5 encoded β5-subunits catalyze chymotrypsin-like activity (CT-L). The substrate specificity of each β-subunit is determined by the interactions between the substrate amino acid side chains and the proteasome specificity pockets, including those in adjacent β-subunits, with the S1 binding pocket being the predominant driver. Mammals additionally possess γ-interferon inducible β1i, β2i, and β5i, which replace the constitutively expressed β1, β2, and β5, respectively.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Archaea and actinobacteria also possess a simplified 20S proteasome.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In contrast to eukaryotes, prokaryotic proteasome function is not essential for survival, likely because of a redundancy of proteolytic machinery.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Proteasome Inhibition in Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Proteasome inhibitors have flourished as anticancer agents because they potently and preferentially induce apoptosis in certain malignant cell types. The natural product lactacystin was first identified to induce apoptosis in the human monoblast U937 cell line,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> while chronic lymphocytic leukemia cells were found to be significantly more sensitive to lactacystin-induced TNFα-mediated apoptosis than were normal human lymphocytes.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Tumor growth was also suppressed in vivo by proteasome inhibition in mouse models of Burkitt’s lymphoma, and the induction of apoptosis preferentially targeted cancerous cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Finding that malignant cells were more susceptible to PI-induced apoptosis led to speculation that malignant cells may rely more heavily on proteasomal degradation for survival.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Elevated proteasome expression has indeed been observed in neoplastic cells, including various types of leukemia, indicating that increased proteasome activity is required to maintain survival during rapid proliferation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Basal proteasome activities have been shown to differ among cell lines and correlate to intrinsic bortezomib sensitivity<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> with cells intrinsically resistant to bortezomib displaying higher CT-L and C-L activities.<a onclick="showRef(event, 'ref20 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref20 ref31 ref32">(20, 31, 32)</a> However, while basal proteasome activities may serve as an indicator of intrinsic resistance, there is no evidence that they serve as a predictor of acquired resistance.</div><div class="NLM_p">The specific mechanism(s) by which proteasome inhibition translates into anticancer therapy is complex and may vary depending on the specific transformation. It was previously observed that in plasma cells undergoing late phase plasmacytic differentiation, proteasome activity decreased concomitantly with immunoglobulin accumulation, thereby overloading the proteasome, resulting in an accumulation of poly-Ub proteins followed by apoptosis.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> It was further shown that MM cells sensitive to PI treatment were more reliant on proteasomal degradation, had lower proteasome content and activity levels, and displayed a higher proteasomal load to capacity ratio relative to PI resistant MM cells, confirming the link between proteasome workload and intrinsic PI sensitivity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Many specific regulatory proteins have also been identified to be affected.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Inhibition of the NF-κB pathway is a frequently cited consequence of proteasome inhibition. Functional proteasomes are required to degrade IκBα, an inhibitor of NF-κB function. Proteasome inhibition allows IκBα levels to rise, thereby inhibiting NF-κB which leads to a decreased production of antiapoptotic factors, angiogenic factors, and apoptosis inhibitors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> As the NF-κB pathway is activated by many chemotherapeutic agents, PIs such as bortezomib may, when used in combination therapy, increase the effectiveness of such drugs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p last">Proteasome inhibition has also been reported to cause disregulation of cyclins, cyclin-dependent kinases, and other cell cycle regulatory proteins that disrupt cell division. Such inhibition may favor apoptosis by stabilizing proapoptotic proteins such as Bax and p53 while reducing antiapoptotic proteins such as the Bcl-2-family proteins.<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4, 8)</a> Additionally, antitumor activity has been attributed to the formation of reactive oxygen species and aggresomes, the unfolded protein response, the intrinsic mitochondrial apoptotic pathway, the death receptor pathway, and the ER stress response pathway.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> For more detailed information on the mechanisms of action of PIs in cancer therapy, we suggest the following reviews: refs <a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">4</a>, <a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">8</a>, <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">9</a>, <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Proteasome Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many small molecule inhibitors of the 20S proteasome, both synthetically prepared and naturally produced, have been discovered.<a onclick="showRef(event, 'ref2 ref3 ref6 ref34'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref6 ref34">(2, 3, 6, 34)</a> The predominant structural theme of PIs is a short peptide-like substrate mimic with an electrophilic modification to covalently capture the N-terminal Thr1O<sup>γ</sup> of one or more of the catalytic β-subunits. Electrophilic warheads include the reversibly inhibiting aldehydes and boronic acids or the irreversibly inhibiting vinylsulfones and epoxyketones. Potency and selectivity for each inhibitor are determined by both the nature of the electrophile and the interactions of the inhibitor with the active site binding pockets.<a onclick="showRef(event, 'ref6 ref35'); return false;" href="javascript:void(0);" class="ref ref6 ref35">(6, 35)</a> While the P1/S1 interaction is often considered the primary determinant of specificity, distal binding pockets may also influence substrate selectivity and inhibition potency.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Six PIs, all of which primarily target Thr1O<sup>γ</sup> of the β5-subunit, are either FDA approved or currently in clinical trials for the treatment of malignancies.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> A comparison of these PIs is found in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, and structures are provided in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. The development status of these PIs has recently been reviewed,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> and many thorough reviews of all known PI structures and catalytic mechanisms are currently available.<a onclick="showRef(event, 'ref2 ref3 ref6 ref34'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref6 ref34">(2, 3, 6, 34)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of selected proteasome inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Properties of Proteasome Inhibitors Explored for the Treatment of Malignancies</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">electrophile</th><th class="colsep0 rowsep0" align="center">developed by</th><th class="colsep0 rowsep0" align="center">P1 residue</th><th class="colsep0 rowsep0" align="center">reversibility</th><th class="colsep0 rowsep0" align="center">subunit target<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">boronate</td><td class="colsep0 rowsep0" align="left">Millennium Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">leucine</td><td class="colsep0 rowsep0" align="left">reversible</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM): β5, 7.9; β2, 590; β1, 53</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">59</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">boronate</td><td class="colsep0 rowsep0" align="left">Millennium Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">leucine</td><td class="colsep0 rowsep0" align="left">reversible</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM): β5, 3.4; β2, 3500; β1, 31</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">39</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">delanzomib (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">boronate</td><td class="colsep0 rowsep0" align="left">Teva Pharmaceutical Industries</td><td class="colsep0 rowsep0" align="left">leucine</td><td class="colsep0 rowsep0" align="left">slowly reversible</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM): β5, 3.5; β2, >100; β1, NI<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">40</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carfilzomib (<b>4</b>)</td><td class="colsep0 rowsep0" align="left">epoxyketone</td><td class="colsep0 rowsep0" align="left">Onyx Pharmaceuticals, Inc.</td><td class="colsep0 rowsep0" align="left">leucine</td><td class="colsep0 rowsep0" align="left">irreversible</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>inact</sub>/<i>K</i><sub>i</sub> (M<sup>–1</sup> s<sup>–1</sup>): β5, 33 000; β2, <100; β1, < 100</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">41</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oprozomib (<b>5</b>)</td><td class="colsep0 rowsep0" align="left">epoxyketone</td><td class="colsep0 rowsep0" align="left">Onyx Pharmaceuticals, Inc.</td><td class="colsep0 rowsep0" align="left">phenylalanine</td><td class="colsep0 rowsep0" align="left">irreversible</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM):<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> β5, ∼10; β2, β1, NI at 50</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">43</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">salinosporamide A (<b>6</b>)</td><td class="colsep0 rowsep0" align="left">β-lactone</td><td class="colsep0 rowsep0" align="left">Nereus Pharmaceuticals, Inc.</td><td class="colsep0 rowsep0" align="left">hydroxycyclohexenylalanine</td><td class="colsep0 rowsep0" align="left">irreversible</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM): β5, 3.5; β2, 28; β1, 430</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">59</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values reported from the different studies cannot be directly compared because of differences in assay conditions but rather are indicative of active site specificity of a particular inhibitor.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">NI: not inhibitory</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Estimated from graph. Inhibition of CT-L activity includes β5 and β5i subunits.</p></div></div></div><div class="NLM_p">The synthetic boronates are the most clinically successful class of PIs to date. Boronates act as an electron acceptor, forming reversible tetrahedral boronic esters with Thr1O<sup>γ</sup>. Bortezomib (<b>1</b>) was the first PI approved by the FDA and is prescribed in the treatment of MM and MCL.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Bortezomib primarily inhibits the β5-subunit with low nanomolar potency but also inhibits the β1-subunit to a lesser extent.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Despite its high potency, <b>1</b> maintains several drawbacks such as peripheral neuropathy,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> an inability to dose orally, and susceptibility to innate and acquired resistance of unknown mechanisms. The FDA recently approved subcutaneous administration of <b>1</b> which has been shown to be as effective as intravenous administration while reducing peripheral neuropathy.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Several second generation PIs are currently in development aiming to improve upon <b>1</b>’s shortcomings. For instance, the prodrug MLN9708,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> which hydrolyzes in vivo to the active MLN2238 (<b>2</b>), and delanzomib<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (<b>3</b>, CEP-18770) are both orally available boronate PIs currently in clinical development.</div><div class="NLM_p last">Three PIs with alternative warheads are currently in development as well. Carfilzomib<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>4</b>), which was recently FDA approved, and the orally bioactive analogue oprozomib<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> (<b>5</b>, ONX 0912), are highly potent, selective, and irreversible epoxyketone warhead PIs derived from the bacterial natural product epoxomicin.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Epoxyketones bind irreversibly to the β-subunit first by hemiacetal formation between the ketone and Thr1O<sup>γ</sup> followed by attack of the epoxide residue by the N-terminal amino group, resulting in a stable morpholino ring.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This intricate mechanism provides minimal cross-reactivity against other proteases such as trypsin, chymotrypsin, and cathepsins.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Lastly, salinosporamide A (<b>6</b>, NPI-0052 or marizomib) is a β-lactone natural product PI produced by the marine bacterium <i>Salinispora tropica</i>.<a onclick="showRef(event, 'ref2 ref45'); return false;" href="javascript:void(0);" class="ref ref2 ref45">(2, 45)</a> Unlike lactacystin and its β-lactone derivative omuralide, the unique mechanism of a secondary halide displacement generates a stable cyclic ether that blocks hydrolysis, thereby rendering <b>6</b> an irreversible inhibitor.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Mechanisms of Acquired Resistance to Proteasome Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite <b>1</b> being more efficacious than other chemotherapeutic agents in the treatment of certain hematological malignancies, intrinsic and acquired resistance remain significant impairments to treatment.<a onclick="showRef(event, 'ref8 ref37 ref46'); return false;" href="javascript:void(0);" class="ref ref8 ref37 ref46">(8, 37, 46)</a> Currently, the mechanisms behind PI resistance are poorly understood. In an effort to elucidate potential mechanisms of acquired PI resistance, many recent studies have elicited acquired <b>1</b> resistance in various cancer cell lines by chronic exposure to the drug.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(11-21)</a> The results of these cell line studies, while far from uniform, illustrate a common theme: up-regulation of proteasome subunits and/or mutation of the β5-subunit encoding gene <i>PSMB5</i>. These data from different resistant lines were established and analyzed by multiple investigators as summarized in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Tables S1 and S2">Supporting Information Tables S1 and S2</a>. Proteasome subunit up-regulation at both the mRNA transcription and protein translation levels have been observed. The maximum <b>1</b> tolerance achieved and the time required to develop resistance varied widely by cell line. Cross-resistance to other β5-subunit PIs was also frequently observed (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S1">Supporting Information Table S1</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Regulatory Changes in <i>PSMB5</i> mRNA and β5-Subunit Protein Levels in Cell Lines with Acquired <b>1</b> Resistance</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ref</th><th class="colsep0 rowsep0" align="center">cancer cell type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">selective Btz concn (nM)</th><th class="colsep0 rowsep0" align="center"><i>PSMB5</i> regulation<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">β5-subunit regulation<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">proteasome CT-L activity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a></td><td class="colsep0 rowsep0" align="left">Burkitt’s lymphoma</td><td class="colsep0 rowsep0" align="left">Namalwa<sup>ad</sup></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">(<1.5×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a></td><td class="colsep0 rowsep0" align="left">monocytic/macrophage</td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>30</sub></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">(0.4×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">(up to 60×)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">(1.3–1.4×)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>50</sub></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">(0.5×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">(up to 60×)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">(1.3–1.4×)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>100</sub></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">(0.6×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">(up to 60×)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">(1.3–1.4×)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>200</sub></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">(0.9×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">(up to 60×)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">(1.3–1.4×)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>(−100)</sub></td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">(0.4×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">(minor)</td><td class="colsep0 rowsep0" align="left">(1.3–1.4×)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a></td><td class="colsep0 rowsep0" align="left">lymphoblastic lymphoma/leukemia</td><td class="colsep0 rowsep0" align="left">JurkatB1</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB5</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">14</a></td><td class="colsep0 rowsep0" align="left">lymphoblastic lymphoma/leukemia</td><td class="colsep0 rowsep0" align="left">JurkatB-G322A</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">(1.7× ± 0.5×)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">⊗</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB-C323T</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">(0.9× ± 0.1×)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">⊗</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB-G322A/C326T</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">(1.3× ± 0.2×)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">⊗</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>, <a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">51</a></td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">HL-60a</td><td class="colsep0 rowsep0" align="left">40<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">⊗</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">β1/β5 (1.5×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t2fn8" aria-label="h">h</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">myeloma</td><td class="colsep0 rowsep0" align="left">AMO-1a</td><td class="colsep0 rowsep0" align="left">NR<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">β1/β5 (4.5×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t2fn8" aria-label="h">h</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">plasmocytoid lymphoma</td><td class="colsep0 rowsep0" align="left">ARH-77a</td><td class="colsep0 rowsep0" align="left">NR<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">⊗</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">KMS-11/BTZ</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">⊗</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">OPM-2/BTZ</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">⊗</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a></td><td class="colsep0 rowsep0" align="left">MCL</td><td class="colsep0 rowsep0" align="left">HBL2-BR</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">⊗</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">(<2×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JEKO-BR</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">⊗</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">(1.4×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a></td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">8226/BTZ7</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">(5×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8226/BTZ100</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">(15×)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">CEM/BTZ7</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">↑ (minor)</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CEM/BTZ200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">↑ (minor)</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">19</a></td><td class="colsep0 rowsep0" align="left">HT-29 adenocarcinoma</td><td class="colsep0 rowsep0" align="left">BR100</td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t2fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">(3–4×)</td><td class="colsep0 rowsep0" align="left">(3.3×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BR200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">(3–4×)</td><td class="colsep0 rowsep0" align="left">(3.5×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">20</a></td><td class="colsep0 rowsep0" align="left">non-small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">H460BTZR<sub>80</sub></td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H460BTZR<sub>200</sub></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">A549BTZR<sub>40</sub></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">A549BTZR<sub>100</sub></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SW1573BTZR<sub>30</sub></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SW1573BTZR<sub>150</sub></td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(1.3–1.8×)</td><td class="colsep0 rowsep0" align="left">↓</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a></td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">8226/7B</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">↑ (large)</td><td class="colsep0 rowsep0" align="left">↑</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Changes relative to the parental strain (1×): ↑, up-regulation; ↓, down-regulation; ⊗, no change.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Estimated value from figure in publication.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">β5 level proportional to level of resistance.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Assayed in the absence of bortezomib.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Activity varied by selective concentration, but each line was not quantified.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">6 months without bortezomib.</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">Maintained at 20 nM bortezomib.</p></div><div class="footnote" id="t2fn8"><sup>h</sup><p class="last">β5 (CT-L) and β1 (C-L) activity could not be differentiated from each other.</p></div><div class="footnote" id="t2fn9"><sup>i</sup><p class="last">After previous selection at 200 nM.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. β5-Subunit Mutations Observed in Cancer Cell Lines with Acquired <b>1</b> Resistance<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ref</th><th class="colsep0 rowsep0" align="center">cancer cell type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">selective Btz concn (nM)</th><th class="colsep0 rowsep0" align="center">β5-subunit mutation</th><th class="colsep0 rowsep0" align="center">cellular Btz resistance<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a></td><td class="colsep0 rowsep0" align="left">monocytic/macrophage</td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>30</sub></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">NR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>100</sub></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(79)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ<sub>(−100)</sub></td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">NR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a></td><td class="colsep0 rowsep0" align="left">lymphoblastic lymphoma/leukemia</td><td class="colsep0 rowsep0" align="left">JurkatB1</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">A49T (het)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB2</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">A49T (het)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">(2.6–4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB3</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">A49T (het)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB5</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">A49T (het)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB2/1000</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">A49T (hom)</td><td class="colsep0 rowsep0" align="left">(26.8–54.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">14</a></td><td class="colsep0 rowsep0" align="left">lymphoblastic lymphoma/leukemia</td><td class="colsep0 rowsep0" align="left">JurkatB-G322A</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB-C323T</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">A49V</td><td class="colsep0 rowsep0" align="left">(39.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JurkatB-G322A/C326T</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">A49T/A50V</td><td class="colsep0 rowsep0" align="left">(66.7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">KMS-11/BTZ</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(24.7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">OPM-2/BTZ</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(16.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a></td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">8226/BTZ7</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">T21A</td><td class="colsep0 rowsep0" align="left">(4.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8226/BTZ100</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(39.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">CEM/BTZ7</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">C52F</td><td class="colsep0 rowsep0" align="left">(10.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CEM/BTZ200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">A49V/C52F</td><td class="colsep0 rowsep0" align="left">(170.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">monocytic/macrophage</td><td class="colsep0 rowsep0" align="left">THP1/BTZ100N</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">M45V</td><td class="colsep0 rowsep0" align="left">NR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">THP1/BTZ500</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">M45I/A49T</td><td class="colsep0 rowsep0" align="left">NR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">19</a></td><td class="colsep0 rowsep0" align="left">HT-29 adenocarcinoma</td><td class="colsep0 rowsep0" align="left">BR100</td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">C63F<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">(32)<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BR200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">C63F<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">(34)<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">20</a></td><td class="colsep0 rowsep0" align="left">non-small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">H460BTZR<sub>80</sub></td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H460BTZR<sub>200</sub></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">A49T</td><td class="colsep0 rowsep0" align="left">(22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">A549BTZR<sub>40</sub></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">M45V</td><td class="colsep0 rowsep0" align="left">(8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">A549BTZR<sub>100</sub></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">M45V/A49T</td><td class="colsep0 rowsep0" align="left">(19)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SW1573BTZR<sub>30</sub></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">C52F</td><td class="colsep0 rowsep0" align="left">(18)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SW1573BTZR<sub>150</sub></td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">C52F</td><td class="colsep0 rowsep0" align="left">(70)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Abbreviations: Btz, bortezomib; het, heterozygous; hom, homozygous.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Resistance factor relative to parental cell line.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">100 nM selection, then 0 nM for 6 months.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">An additional silent mutation was observed.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Selected at 200 nM bortezomib for 7 months, then clonal selection at 100 nM.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">An R24C prosequence mutation was also observed.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">After 3 days in the absence of bortezomib.</p></div></div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Resistance by Up-Regulation of Proteasomal Subunits</h3><div class="NLM_p">Alterations in mRNA transcription of the β5-subunit encoding <i>PSMB5</i> gene (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) have varied from slightly decreased<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> to unchanged,<a onclick="showRef(event, 'ref14 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref17">(14, 17)</a> to slightly increased,<a onclick="showRef(event, 'ref13 ref15 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref13 ref15 ref18 ref19">(13, 15, 18, 19)</a> and to substantially increased (5- to 15-fold).<a onclick="showRef(event, 'ref18 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref21">(18, 21)</a> In cases where transcription levels of other proteasome related genes were quantified, <i>PSMB6</i> and <i>PSMB7</i> also varied from unchanged<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> to a 5-fold increase (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S2">Supporting Information Table S2</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Both <i>PSMB5</i> and <i>PSMB7</i>, but not <i>PSMB6</i>, were up-regulated in <b>1</b> resistant HT-29 adenocarcinoma cells.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Oerlemans et al. performed microarray transcriptional analysis on their 30 and 100 nM resistant human monocytic lines as well as the 100 nM resistant line after 6 months in the absence of <b>1</b>. No discernible link between gene expression and resistance was observed.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Evaluating proteasomal subunit up-regulation at the protein level serves as a more direct measurement of proteasome up-regulation. In most cases where <b>1</b> resistance was observed, β5-subunit protein levels increased (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Although many studies did not quantify the change in proteasome subunit protein levels, the degree of β5 increase has ranged from minor to as much as 60-fold.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, no clear quantitative correlation between level of resistance and the extent of β5-subunit expression has been observed.</div><div class="NLM_p">Many of these studies quantified either mRNA or protein levels but not both. In cases where both were analyzed,<a onclick="showRef(event, 'ref12 ref15 ref17 ref18 ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref12 ref15 ref17 ref18 ref19 ref21">(12, 15, 17-19, 21)</a> it appears that mRNA transcription levels are not a strong indicator of protein expression levels. In one case, <i>PSMB5</i> transcription was unchanged but a 60-fold increase in β5-subunit protein was observed.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Silencing of <i>PSMB5</i> mRNA expression in these cells did prevent up-regulation of the β5-subunit and restored bortezomib sensitivity and induced apoptosis. In another case, <i>PSMB5</i> transcription from 7 and 100 nM bortezomib resistant lines increased by 5× and 15×, respectively, relative to the parental cells.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, while both showed β5-subunit protein up-regulation relative to the parental line, there was no difference in protein concentration between these two resistant cell lines despite the 3-fold difference in mRNA transcription. On the basis of these studies, mRNA transcription levels should not be used as a proxy for proteasome content or activity.</div><div class="NLM_p">Bortezomib resistant cell lines displayed conflicting regulation of the immunoproteasome components. One study found a complete shift in favor of the 19S–20S proteasome at the expense of the 11S and immunosubunits,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> while another study found up-regulation of the 11S and down-regulation of the 19S regulatory particle with no change in immunosubunit expression.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Franke et al. observed a specific shift away from β5i toward β5 in resistant MM cells, but no alteration of β5/β5i ratio was demonstrated in resistant acute lymphoblastic lymphoma cells.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The 11S regulatory particle was also up-regulated in a <b>1</b> resistant acute myeloid leukemia cell line.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In a study of three <b>1</b> resistant non-small-cell lung cancer lines, two showed up-regulation of the immunosubunits while the third showed no change.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Taken together, immunoproteasome regulation appears to vary widely among and within <b>1</b> resistant cancer cell line types.</div><div class="NLM_p last">To assess proteasome subunit regulation, microarray analysis was used on over 100 patients with myeloma to identify changes in gene regulation that correlated to progression of the malignancy.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Several proteasome pathway genes were up-regulated 48 h after <b>1</b> was administered in combination with thalidomide and dexamethasone relative to treatment with only thalidomide and dexamethasone. These genes included <i>PSMD4</i>, encoding one of the non-ATPase 19S regulatory cap proteins, and <i>PSMB2</i>, <i>PSMB3</i>, and <i>PSMB4,</i> all encoding noncatalytic 20S β-subunits. Shaughnessy et al. suggest that this up-regulation is due to preferential killing of normal plasma cells and survival of cells with existing up-regulation as opposed to drug induced up-regulation in all cells. None of the catalytic β-subunit encoding genes were found to be differentially regulated. In another study, proteasome activity was visualized in primary cells taken from patients with chronic lymphocytic leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia using fluorescent probes.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> While the stoichiometry of the β1, β2, and β5 subunits remained the same, the activity varied even within the same cancer types but remained consistent per patient over several weeks. A correlation was observed that in myeloma and non-Hodgkin’s lymphoma, cells with the lowest β1 + β5 activity levels, relative to β2, were the most sensitive to <b>1</b>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Resistance by β5-Subunit Mutations</h3><div class="NLM_p">Many <b>1</b> resistant cell lines have been found to possess mutations in the β5-subunit encoding gene <i>PSMB5</i> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Most of these mutations encode amino acid substitutions located in the S1 binding pocket. In particular, substitution of Ala49 with Thr or Val has been observed independently in six different studies.<a onclick="showRef(event, 'ref12 ref13 ref14 ref16 ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref16 ref18 ref20">(12-14, 16, 18, 20)</a> Additional mutations in or near the S1 binding pocket include A50V, C52F, M45V, M45I, C63F, and T21A. X-ray crystallographic analysis of <b>1</b> bound to the 20S proteasome β5-subunits of the <i>Saccharomyces cerevisiae</i> previously revealed a hydrogen bonding network between <b>1</b>, a structured water molecule, and several amino acid residues of the S1 binding pocket, including Ala49, Ala50, and Thr21 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Although these hydrogen bonding interactions originate from backbone atoms, side chain substitutions may alter backbone positioning and disrupt the bonding network. Met45 was additionally shown to move 2.7 Å to accommodate bortezomib’s P1 leucine residue.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Mutation of Met45 may diminish binding by constricting the S1 pocket or reducing favorable hydrophobic interactions. Cys52 is located behind the S1 binding pocket and may hinder movement of Met45. Ala49 is positioned at the entrance of the S1 binding pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b). Increasing the size of the side chain may stearically hinder the binding of both inhibitors and substrates. While no crystal structures of such mutated proteasomes have yet been reported, computational modeling has shown that they should decrease both substrate and inhibitor binding.<a onclick="showRef(event, 'ref13 ref18'); return false;" href="javascript:void(0);" class="ref ref13 ref18">(13, 18)</a> Cleavage of the fluorogenic substrate succinyl-Leu-Leu-Val-Tyr-amc (LLVY-amc) also appears to be reduced in the resistant cell lines. However, no alternative fluorogenic substrates have been tested to check for a shift in proteolytic specificity, which could be precipitated by S1 pocket mutations.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Substrate binding analysis of <b>1</b> and the β5-subunit of the <i>Saccharomyces cerevisiae</i> 20S proteasome. (a) Dashed lines represent H-bonding with the distance shown in Å. Mutations observed at Ala49, Ala50, and Thr21 may disrupt H-bonding and decrease PI binding. Reproduced in part from <i>Structure</i> (<a href="http://www.sciencedirect.com/science/journal/09692126" class="extLink">http://www.sciencedirect.com/science/journal/09692126</a>), Vol. 14, Groll, M., Berkers, C. R., Ploegh, H. L., and Ovaa, H., “Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome”, pp 451–456, Copyright 2006, with permission from Elsevier.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (b) Crystal structure of the S1 binding pocket with <b>1</b> bound. Image was created using PDB file <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16">2F16</a>, and chain K was rendered in PyMol.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The role of one <i>PSMB5</i> mutation in acquired PI resistance was verified in a T cell lymphoblastic lymphoma cell line. The parental line was mutated by retroviral infection to encode the same A49T seen in the <b>1</b> resistant line.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> These cells were resistant to <b>1</b> induced apoptosis, and the inhibition of CT-L activity was decreased. The same mutation was also transfected into parental KMS-11 MM cells and shown to induce <b>1</b> resistance but not to the full extent of KMS-11/BTZ cells, suggesting that other factors also contribute to resistance.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Mutations were observed in cell lines at resistance levels as low as 7 nM <b>1</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> which is below the clinically used concentration.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Franke et al. showed that mutations were observed in cell lines that were developed in as little as 4 months and that upon repeating the <b>1</b> desensitizing process, the same cell line developed a different set of mutations.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The authors argued that this observation supports de novo mutation as opposed to the selection of preexisting mutations. Although cell lines with different mutations varied greatly in their level of <b>1</b> resistance, it has not been conclusively shown in vitro that any specific mutation is fully responsible for the acquired level of resistance or that one mutation confers greater resistance than another.</div><div class="NLM_p">Few studies have searched for mutations in other proteasome subunits. Ri et al. reported no mutations in the β1 or β6 subunit encoding genes,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and the study by Franke et al. did not find mutations in <i>PSMB6</i> or <i>PSMB7</i>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Suzuki et al. has reported a F50I mutation in the prosequence of the β5i encoding <i>LMP7</i> gene of the BR200 strain.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It should also be appreciated that not all bortezomib resistant cell lines contained <i>PSMB5</i> mutations. MM<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and MCL<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> cell lines, each resistant to 100 nM <b>1</b>, were both found to be free of mutations.</div><div class="NLM_p last">Many potent PIs, including <b>6</b>, lactacystin, and epoxomicin, are produced by actinomycete bacteria. As the actinobacteria are the only family of eubacteria known to possess 20S proteasome machinery, in which all seven α-subunits and all seven β-subunits are identical, it raises the question of self-resistance. A recent study of the marine actinobacterium <i>Salinispora tropica</i>, which produces the drug candidate <b>6</b>, revealed that a secondary 20S proteasome β-subunit (SalI) is encoded within the biosynthetic gene cluster of <b>6</b>.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In vitro analysis of the heterologously expressed α/SalI complex revealed that it was markedly less susceptible than the primary <i>S. tropica</i> 20S proteasome to inhibition by both <b>1</b> and <b>6</b>. Additionally, the proteolytic specificity of the α/SalI complex activity shifted away from the CT-like LLVY-amc substrate, instead preferring a methionine P1 residue of the Z-Val-Lys-Met-amc (VKM-amc) substrate, suggesting that a more flexible P1 amino acid is accommodated in the constricted S1 binding pocket and underscoring the need to explore alternative fluorogenic substrates against mutated proteasome subunits. Genetic comparison between SalI and the housekeeping β-subunit, β<sub>1</sub>, exposed M45F and A49V mutations located within the S1 binding pocket. Site directed mutagenesis of both β<sub>1</sub> and SalI revealed that position 45 played surprisingly little role in resistance, whereas alteration of position 49 significantly affected inhibitor resistance, substrate specificity, and prosequence cleavage. While the subunit topology and cellular function of the 20S proteasome in humans and actinobacteria are not identical, it is striking that equivalent mutations are utilized in both systems to achieve PI resistance.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Resistance by Efflux Pumps</h3><div class="NLM_p">One additional strategy for acquired drug resistance is achieved through multidrug resistance (MDR) efflux pumps. Resistance to the peptidyl aldehyde PI Ac-Leu-Leu-Nle-al (ALLN) in Chinese hamster ovary cells was reportedly caused by the up-regulation of P-glycoprotein (Pgp) transmembrane pump via up-regulation of the encoding multidrug resistance gene <i>mdr1</i>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This verified that Pgp could export linear peptides, the primary structural scaffold of most PIs. Another MDR pump, MRP1, was later established to also export hydrophobic linear peptides, including ALLN, in various cancer cell lines.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Acute myeloid leukemia cell lines overexpressing Pgp were shown to display slight (∼2×) <b>1</b> resistance, whereas cell lines overexpressing MRP1 were not resistant.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Epoxyketone inhibitors <b>4</b> and <b>5</b> were recently shown to be substrates of Pgp, resulting in 114- and 23-fold resistance, respectively, when Pgp was up-regulated in CEM/VLB cell lines.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> However, no additional reports have attributed MDR resistance to <b>1</b> or <b>4</b>, and several studies have ruled it out,<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref20'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref20">(11-14, 20)</a> suggesting that multidrug resistance is not a significant factor in PI resistance.</div><div class="NLM_p">In most cases, acquired <b>1</b> resistance in cell lines appears to be a stable transformation. In resistant monocytic/macrophage cells transferred to <b>1</b>-free media for 7 days, <i>PSMB5</i> expression was unaltered but β5 levels decreased by 2.5-fold.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> After 6 months, these cells still retained 35-fold <b>1</b> resistance. β5-subunit levels and the encoding mRNA both decreased over this time but were rapidly restored upon reintroduction of <b>1</b>.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Rüchrick et al. confirmed that the resistance phenotype was stable over 14 days, and de Wilt et al. and Lü et al. both confirmed resistance after 2 months in the absence of <b>1</b>.<a onclick="showRef(event, 'ref14 ref15 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref20">(14, 15, 20)</a> Suzuki et al. similarly observed an increase in <b>1</b> resistance after cells were cultured for 40 days in the absence of <b>1</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> However, Pérez-Galán et al. reported that resistance to <b>1</b>, which was not caused by a β5-subunit mutation, was gradually lost over time.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">It is reiterated that to date, the <b>1</b> resistance mechanisms discussed here have only been observed in cancer cell lines. Although the sample size is small, no <i>PSMB5</i> mutations have yet been observed in primary patient cell samples.<a onclick="showRef(event, 'ref16 ref17 ref55'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref55">(16, 17, 55)</a> However, as the recent cell line data indicate that such mutations are potential resistance mechanisms, the clinical relevance will remain unknown without further analysis of patients' <i>PSMB5</i> sequences.</div><div class="NLM_p last">Many of the studies reviewed here explored changes in cellular biochemistry beyond the proteasome. Several reports showed that poly-Ub proteins failed to accumulate under <b>1</b> treatment in resistant lines.<a onclick="showRef(event, 'ref11 ref12 ref15 ref16 ref18 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref15 ref16 ref18 ref20 ref21">(11, 12, 15, 16, 18, 20, 21)</a> However, ubiquitinated proteins did accumulate when <b>1</b> levels significantly higher than the selective concentration were used.<a onclick="showRef(event, 'ref12 ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref12 ref18 ref20">(12, 18, 20)</a> No changes in growth rate or morphology were observed for most of the resistant cell lines.<a onclick="showRef(event, 'ref12 ref13 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref15">(12, 13, 15)</a> Balsas et al. observed that resistant cells were significantly larger in size and nearly doubled in cellular DNA content.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Rückrich et al. observed a 75% reduction of total protein biosynthesis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> whereas Ri et al. observed no alteration of protein synthesis levels in bortezomib resistant lines.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Pérez-Galán et al. also observed that intrinsically resistance cells and those that acquired resistance were associated with plasmacytic differentiation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Perspectives for Circumventing Acquired PI Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Overcoming intrinsic and acquired resistance to PIs such as <b>1</b> will greatly improve efficacy in the clinic. However, the roots of clinical resistance are complex and not well understood. It is apparent that multiple mechanisms of resistance are possible with no one solution adequate to ensure effective treatment in all patients. On the basis of the mechanisms of acquired PI resistance in cancer cell lines reviewed here, we may begin to strategize methods to overcome PI resistance in the event that they are identified in patents. Possibilities include the use of irreversible β-subunit inhibitors, modifying the P1 residue to target mutated β5-subunits, targeting alternative proteasome subunits, targeting proteasome complex assembly, inhibiting upstream ubiquitination pathway enzymes, and targeting proteins outside the ubiquitin–proteasome pathway.</div><div class="NLM_p">Several reports have identified acquired mutations of the <i>PSMB5</i> gene in bortezomib resistant cell lines. These mutations appear to alter the S1 binding pocket, which slow or prevent PI binding and often confer resistance to other PIs that target the catalytic site of the β5-subunit. As <b>1</b> and all inhibitors currently being explored in clinical trials primarily target the β5-subunit active site, they will all likely be susceptible to this mechanism of resistance. However, the administration of <b>3</b> along with <b>1</b> was shown to delay progression of MM in a patient who had become resistant to <b>1</b>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> As both <b>1</b>and <b>3</b> are boronates that target the β5-subunit, it is unclear how <b>3</b> was able to overcome resistance.</div><div class="NLM_p">Irreversible inhibitors such as <b>4</b> and <b>6</b> may be less susceptible to resistance by β5-subunit mutations. While a modified S1 binding site may slow binding kinetics, as evidenced by elevated IC<sub>50</sub> values, the binding event must only take place once before permanently deactivating the catalytic site. As an example, MM 8226/BTZ100 cells, which possess an A49T mutation, showed 39.5-fold resistance to <b>1</b> but only 9.7-fold resistance to <b>4</b> and 10.1-fold resistance to <b>5</b> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S1">Supporting Information Table S1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In one study, <b>1</b> resistant MM cell lines were established by prolonged exposure to <b>1</b> to examine the ability of <b>4</b> to overcome <b>1</b> resistance. While some cross-resistance was observed for <b>4</b>, it did retain greater antiproliferative effectiveness.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Carfilzomib also retained antiproliferative and cytotoxic effectiveness on <b>1</b> resistant primary patient samples as well.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In a study of HT-29 adenocarcinoma cells, proteasome up-regulation and subunit mutations resulted in a rapid recovery of proteasome activity following exposure to <b>1</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> While some cross-resistance was observed for the irreversible inhibitor <b>4</b>, it was shown to diminish proteasome activity over a longer time period and to retain cytotoxicity toward the <b>1</b> resistant cell.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Epoxyketone <b>5</b> was also shown to induce apoptosis in vitro in two <b>1</b> resistant patient samples, although the specific mechanism of this resistance was not known in this case.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The irreversible PI <b>6</b> induced apoptosis in MM cells that were resistant to <b>1</b>, which was attributed to activation of different apoptotic pathways.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Substantially more clinical data will be needed to validate these anecdotal observations. Furthermore, it remains to be seen what level of resistance to these irreversible inhibitors develops when they are used as the selecting agent.</div><div class="NLM_p">If target sequence modification is confirmed as a clinically relevant form of PI resistance, it would be ideal to develop inhibitors with specificity for the mutated proteasomes. As the same mutations, such as A49T or A49V, have been observed in several independently derived <b>1</b> resistant cell lines as well as the <b>6</b>-producing bacterium <i>S. tropica</i>,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> a second generation of PIs tuned specifically for these active site alterations could be developed. A library of PI analogues with various P1 residues, as has been established previously when developing inhibitors for the wild-type proteasome,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> could be assayed in vitro against a 20S complex containing a mutated β5-subunit. Proteasome inhibitors specific for other catalytic subunits such as β1, β2, or the immunosubunits could potentially be used to circumvent β5-subunit mutations. As the cell lines with acquired <b>1</b> resistance displayed conflicting regulatory changes for immunoproteasome subunits, it is unclear if immunoproteasome specific inhibitors would be of use in combating bortezomib resistance.</div><div class="NLM_p">Several allosteric effectors of proteasome activity that bind away from the active sites have recently been reported. PR-39 is a 39 amino acid peptide found to be a reversible inhibitor of the α7 subunit of the 20S proteasome and believed to interfere with 26S assembly from 19S and 20S components.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> PR-39 was shown to induce angiogenesis in cell cultures and mice and to possess anti-inflammatory activity.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> It additionally stimulated angiogenesis by increasing cellular HIF-1α protein levels via inhibition of ubiquitin-dependent proteasomal degradation.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Anti-inflammatory activity resulted from inhibition of IκBα degradation that prevents activation of NFκB-dependent gene expression, yet overall proteasomal protein degradation was not impaired.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> While not druggable, PR-39 may serve as a lead for the development of proteasome assembly inhibitors. The antimalarial drug chloroquine was reported to inhibit both eukaryotic and archaeal 20S proteasomes.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> NMR experiments identified chloroquine as uniquely binding between the α and β subunits. Binding distal from the active sites was confirmed by the simultaneous binding of the PI MG132. However, chloroquine is clinically irrelevant, as it only inhibits the proteasome at high micromolar concentrations. A screening of compounds with the chloroquine pharmacophore identified 5-amino-8-hydroxyquinoline (<b>7</b>, 5AHQ) as a more potent inhibitor of the 20S proteasome with an IC<sub>50</sub> in the low micromolar to submicromolar range.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> 5AHQ inhibited CT-L proteasome activity (T-L and C-L activities were not tested) in both intact cells and cellular extracts of various myeloma and leukemia cell lines. Oral administration in mice was shown to inhibit tumor growth, and cell death was also preferentially induced in cancerous cells. 5AHQ was found to act as a noncompetitive inhibitor of the α7 subunit in NMR experiments with the α<sub>7</sub>–α<sub>7</sub> “half-proteasome”. However, it has yet to be verified that <b>7</b> does not also bind to any β-subunits or if there are other cellular targets. 5AHQ shows promising activity in many bortezomib resistant cell lines resulting from β5-subunit mutation or overexpression,<a onclick="showRef(event, 'ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref20">(18, 20)</a> and no resistance has been observed yet to <b>7</b>, which remains effective in bortezomib-resistant cell lines.<a onclick="showRef(event, 'ref12 ref18'); return false;" href="javascript:void(0);" class="ref ref12 ref18">(12, 18)</a></div><div class="NLM_p last">Multiple strategies to treat PI resistant cancers by inhibition of alternative targets have been recently reported. As inhibition of the proteasome appears to combat cancer by decreasing proteolysis of various cellular proteins, this effect could also be achieved by inhibiting the upstream ubiquitinating enzymes E1, E2, and E3 or deubiquitinating enzymes. As the specificity of E1, E2, and E3 increases, so too does the enzyme diversity. Targeting the primary E1 enzyme should prevent proteasomal degradation of most cellular proteins and therefore have a similar effect to inhibition of the proteasome. For example, the E1 inhibitor 1-(3-chloro-4-fluorophenyl)-4-[(5-nitro-2-furyl)methylene]-3,5-pyrazolidinedione (PYZD-4409) was recently shown to preferentially induce cell death in malignant leukemia cells and delay tumor growth in a murine leukemia model, achieving a similar affect as a PI with an alternative target.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Inhibiting a specific E3 could target individual cellular proteins, allowing for more controlled therapy. Disruption of the ubiquitination system with small molecule inhibitors is an active area of study and has been recently reviewed.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Summary and Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The emergence of PIs over the past 10 years has been a major breakthrough in the treatment of hematological malignancies. However, both intrinsic and acquired PI resistances remain major obstacles. In an effort to better understand the mechanisms of acquired PI resistance, recent investigations of various cancer cell lines that were progressively desensitized to bortezomib revealed up-regulation of the proteasome at both the mRNA and protein level as well as mutations in the β5-subunit. The data revealed that changes in mRNA transcriptional levels do not necessarily correlate to changes in protein levels. Additionally, no clear quantitative link has been established between β5-subunit up-regulation and acquired resistance. The development of mutations in cell lines was observed in as little as a few months at clinically relevant concentrations of <b>1</b>. These mutations in the S1 binding pocket appear to form de novo and may also modulate proteolytic specificity as seen in the <b>6</b> resistant actinobacterial proteasome β-subunit SalI. Therefore, analysis of proteasome activity with the fluorogenic LLVY-amc substrate may underestimate the actual proteolytic activity. A shift in proteolytic specificity could allow the continued destruction of cellular proteins with a reduced susceptibility to the PI. However, caution should be used, as no mutations have yet been confirmed in patient samples and more patient testing will be required to establish the clinical relevance of these cell line resistance mechanisms.</div><div class="NLM_p last">It is clear that overcoming the acquired resistance mechanisms reviewed here will require the development of PIs beyond β5-subunit inhibitors. As all PIs that are currently FDA approved or under investigation in clinical trials covalently bind the N-terminal threonine of the β5-subunit, all will likely be susceptible to β5-subunit up-regulation or mutation. However, inhibitors of proteasome assembly, allosteric effectors, or ubiquitination pathway enzymes will not be susceptible to the resistance mechanisms described here. The development of Ub pathway enzyme inhibitors will achieve the same effect as PIs, the disregulation of cellular protein destruction, with an alternative target. The development of E3 inhibitors will be especially useful, as they may pinpoint treatment to specific oncogenic proteins.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15"><a href="/doi/suppl/10.1021/jm300434z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Proteasome inhibitor cross-resistance and a comprehensive overview of PI resistant cell lines (two tables). This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300434z/suppl_file/jm300434z_si_001.pdf">jm300434z_si_001.pdf (347.84 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300434z" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bradley S. Moore</span> - <span class="hlFld-Affiliation affiliation">Center for
Marine Biotechnology
and Biomedicine, Scripps Institution of Oceanography, University of California—San Diego, La Jolla,
California 92093, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and
Pharmaceutical Sciences, University of California—San
Diego, La Jolla, California 92093, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0b6978666464796e4b7e68786f256e6f7e"><span class="__cf_email__" data-cfemail="3c5e4f5153534e597c495f4f5812595849">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew J. Kale</span> - <span class="hlFld-Affiliation affiliation">Center for
Marine Biotechnology
and Biomedicine, Scripps Institution of Oceanography, University of California—San Diego, La Jolla,
California 92093, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Andrew J. Kale</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew J. Kale</b> completed his B.S. in Biology at the University of Minnesota—Twin Cities in 2005. Since 2007, he has studied under Bradley S. Moore at the Scripps Institution of Oceanography where he earned his Ph.D. in Marine Biology in 2012. His work has focused on the characterization of proteasome inhibitor biosynthesis and self-resistance in the marine actinomycete <i>Salinispora tropica.</i></p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Bradley S. Moore</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Bradley S. Moore</b> is Professor of Oceanography and Pharmaceutical Sciences at the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California—San Diego. He holds degrees in Chemistry from the University of Hawaii (B.S., 1988) and the University of Washington (Ph.D., 1994), was a postdoc at the University of Zurich, Switzerland (1994–1995), and held prior faculty appointments at the University of Washington (1996–1999) and University of Arizona (1999–2005). His research interests involve exploring and exploiting microbial genomes to discover new biosynthetic enzymes, secondary metabolic pathways, and natural products for drug discovery and development.</p></figure></div><div class="ack" id="ACK-d42e2388-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We appreciate generous financial support from the NIH through Grant CA127622 to support our work on salinosporamide biosynthesis and resistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> Abbreviations Used</h2><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">proteasome inhibitor</p></td></tr><tr><td class="NLM_term">Btz</td><td class="NLM_def"><p class="first last">bortezomib</p></td></tr><tr><td class="NLM_term">Ub</td><td class="NLM_def"><p class="first last">ubiquitin</p></td></tr><tr><td class="NLM_term">CT-L</td><td class="NLM_def"><p class="first last">chymotrypsin-like</p></td></tr><tr><td class="NLM_term">T-L</td><td class="NLM_def"><p class="first last">trypsin-like</p></td></tr><tr><td class="NLM_term">C-L</td><td class="NLM_def"><p class="first last">caspase-like</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">ALLN</td><td class="NLM_def"><p class="first last">Ac-Leu-Leu-Nle-al</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">LLVY-amc</td><td class="NLM_def"><p class="first last">Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin</p></td></tr><tr><td class="NLM_term">VKM-amc</td><td class="NLM_def"><p class="first last">Z-Val-Lys-Met-7-amino-4-methylcoumarin</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Murata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yashiroda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of proteasome assembly</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fnrm2630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19165213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=104-115&author=S.+Murataauthor=H.+Yashirodaauthor=K.+Tanaka&title=Molecular+mechanisms+of+proteasome+assembly"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of proteasome assembly</span></div><div class="casAuthors">Murata, Shigeo; Yashiroda, Hideki; Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 26S proteasome is a highly conserved protein degrdn. machine that consists of the 20S proteasome and 19S regulatory particles, which include 14 and 19 different polypeptides, resp.  How the proteasome components are assembled is a fundamental question towards understanding the process of protein degrdn. and its functions in diverse biol. processes.  Several proteasome-dedicated chaperones are involved in the efficient and correct assembly of the 20S proteasome.  These chaperones help the initiation and progression of the assembly process by transiently assocg. with proteasome precursors.  By contrast, little is known about the assembly of the 19S regulatory particles, but several hints have emerged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7BlzwswLvLVg90H21EOLACvtfcHk0lhIuxu7-d0c-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVChtQ%253D%253D&md5=acfc193c4fb9d0fefa21b43d9cc611b3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2630%26sid%3Dliteratum%253Aachs%26aulast%3DMurata%26aufirst%3DS.%26aulast%3DYashiroda%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520proteasome%2520assembly%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D104%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Borissenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groll, M.</span><span> </span><span class="NLM_article-title">20S proteasome and its inhibitors: crystallographic knowledge for drug development</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&author=L.+Borissenkoauthor=M.+Groll&title=20S+proteasome+and+its+inhibitors%3A+crystallographic+knowledge+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520proteasome%2520and%2520its%2520inhibitors%253A%2520crystallographic%2520knowledge%2520for%2520drug%2520development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D687%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Genin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboud-Ravaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, J.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.2174%2F156802610790725515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20166955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1ent7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=232-256&author=E.+Geninauthor=M.+Reboud-Ravauxauthor=J.+Vidal&title=Proteasome+inhibitors%3A+recent+advances+and+new+perspectives+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry</span></div><div class="casAuthors">Genin, E.; Reboud-Ravaux, M.; Vidal, J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-256</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The search for proteasome inhibitors began fifteen years ago.  These inhibitors proved to be powerful tools for investigating many important cellular processes regulated by the ubiquitin-proteasome pathway.  Targeting the proteasome pathway can also lead to new treatments for disorders like cancer, muscular dystrophies, inflammation and immune diseases.  This is already true for cancer; the FDA approved bortezomib, a potent proteasome inhibitor, for treating multiple myeloma in 2003, and mantle cell lymphoma in 2006.  The chem. structures identified in some of the early proteasome inhibitors have led to the development of new anti-cancer drugs (CEP-18770, Carfilzomib, NPI-0052).  All these mols. are covalent bonding inhibitors that react with the catalytic Thr1-Oγ of the three types of active site.  This review covers recent developments in medicinal chem. of natural and synthetic proteasome inhibitors.  Advances in non-covalent inhibitors that have no reactive group will be highlighted as they should minimize side-effects.  New structures and new modes of action have been recently identified that open the door to new drug candidates for treating a range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv2fNL-WAY3LVg90H21EOLACvtfcHk0ljvltj__JeSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1ent7Y%253D&md5=ef6b9b743b0c4f4981ad9138beceb90d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802610790725515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790725515%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DE.%26aulast%3DReboud-Ravaux%26aufirst%3DM.%26aulast%3DVidal%26aufirst%3DJ.%26atitle%3DProteasome%2520inhibitors%253A%2520recent%2520advances%2520and%2520new%2520perspectives%2520in%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D232%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Nencioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunebach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballestrero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brossart, P.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: antitumor effects and beyond</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=30-36&author=A.+Nencioniauthor=F.+Grunebachauthor=F.+Patroneauthor=A.+Ballestreroauthor=P.+Brossart&title=Proteasome+inhibitors%3A+antitumor+effects+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNencioni%26aufirst%3DA.%26aulast%3DGrunebach%26aufirst%3DF.%26aulast%3DPatrone%26aufirst%3DF.%26aulast%3DBallestrero%26aufirst%3DA.%26aulast%3DBrossart%26aufirst%3DP.%26atitle%3DProteasome%2520inhibitors%253A%2520antitumor%2520effects%2520and%2520beyond%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D30%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Woodle, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloway, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brailey, P.</span><span> </span><span class="NLM_article-title">Proteasome inhibitor therapy for antibody-mediated rejection</span> <span class="citation_source-journal">Pediatr. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1111%2Fj.1399-3046.2011.01543.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21884344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GmtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=548-556&author=E.+S.+Woodleauthor=R.+C.+Walshauthor=R.+R.+Allowayauthor=A.+Girnitaauthor=P.+Brailey&title=Proteasome+inhibitor+therapy+for+antibody-mediated+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitor therapy for antibody-mediated rejection</span></div><div class="casAuthors">Woodle, E. S.; Walsh, R. C.; Alloway, R. R.; Girnita, A.; Brailey, P.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Transplantation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>CODEN:
                <span class="NLM_cas:coden">PETRF6</span>;
        ISSN:<span class="NLM_cas:issn">1397-3142</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  AMR is being recognized with increasing efficiency, but continues to present a significant threat to renal allograft survival.  Traditional therapies for AMR (IVIG, plasmapheresis, rituximab, and antilymphocyte prepns.) in general have provided inconsistent results and do not deplete the source of antibody prodn., viz., the mature plasma cell.  Recently, the first plasma cell-targeted therapy in humans has been developed using bortezomib (a first in class PI) for AMR treatment in kidney transplant recipients.  Initial experience with bortezomib involved treatment of refractory AMR.  Subsequently, the efficacy of bortezomib in primary therapy for AMR was demonstrated.  In a multicenter collaborative effort, the initial results with bortezomib in AMR have been confirmed and expanded to pediatric and adult heart transplant recipients.  More recently, results from a prospective, staged desensitization trial has shown that bortezomib alone can substantially reduce anti-HLA antibody levels.  These results demonstrate the significant potential of proteasome inhibition in addressing humoral barriers.  However, the major advantage of proteasome inhibition lies in the numerous potential strategies for achieving synergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXj42bdoxjbVg90H21EOLACvtfcHk0ljvltj__JeSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GmtrrE&md5=d8e97c39d8bc3826ea2174a740e25d88</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3046.2011.01543.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3046.2011.01543.x%26sid%3Dliteratum%253Aachs%26aulast%3DWoodle%26aufirst%3DE.%2BS.%26aulast%3DWalsh%26aufirst%3DR.%2BC.%26aulast%3DAlloway%26aufirst%3DR.%2BR.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DBrailey%26aufirst%3DP.%26atitle%3DProteasome%2520inhibitor%2520therapy%2520for%2520antibody-mediated%2520rejection%26jtitle%3DPediatr.%2520Transplant.%26date%3D2011%26volume%3D15%26spage%3D548%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kisselev, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Linden, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H. S.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: an expanding army attacking a unique target</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.chembiol.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22284358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=99-115&author=A.+F.+Kisselevauthor=W.+A.+van+der+Lindenauthor=H.+S.+Overkleeft&title=Proteasome+inhibitors%3A+an+expanding+army+attacking+a+unique+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitors: An Expanding Army Attacking a Unique Target</span></div><div class="casAuthors">Kisselev, Alexei F.; van der Linden, Wouter A.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention.  The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles.  The 20S core contains three types of active sites.  Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades.  One, bortezomib, is used clin. for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection.  Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers.  Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives.  In addn., inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc-6qcZILhrVg90H21EOLACvtfcHk0liFe5EQsFt-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D&md5=a4eca9d710b209d5455c2eaa58dfd0bc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520inhibitors%253A%2520an%2520expanding%2520army%2520attacking%2520a%2520unique%2520target%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D99%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Cheriyath, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, M. A.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors</span> <span class="citation_source-journal">Drugs R&D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.2165%2F00126839-200708010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17249845" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1-12&author=V.+Cheriyathauthor=B.+S.+Jacobsauthor=M.+A.+Hussein&title=Proteasome+inhibitors+in+the+clinical+setting%3A+benefits+and+strategies+to+overcome+multiple+myeloma+resistance+to+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F00126839-200708010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200708010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCheriyath%26aufirst%3DV.%26aulast%3DJacobs%26aufirst%3DB.%2BS.%26aulast%3DHussein%26aufirst%3DM.%2BA.%26atitle%3DProteasome%2520inhibitors%2520in%2520the%2520clinical%2520setting%253A%2520benefits%2520and%2520strategies%2520to%2520overcome%2520multiple%2520myeloma%2520resistance%2520to%2520proteasome%2520inhibitors%26jtitle%3DDrugs%2520R%2526D%26date%3D2007%26volume%3D8%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, D. J.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors in cancer therapy: lessons from the first decade</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F1078-0432.CCR-07-2218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18347166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1649-1657&author=R.+Z.+Orlowskiauthor=D.+J.+Kuhn&title=Proteasome+inhibitors+in+cancer+therapy%3A+lessons+from+the+first+decade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors in cancer therapy: lessons from the first decade</span></div><div class="casAuthors">Orlowski, Robert Z.; Kuhn, Deborah J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis.  First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells.  They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clin. efficacy and toxicity, and some of their limitations in the form of resistance pathways.  Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a std. of care.  Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases.  This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCNIRIVHoPx7Vg90H21EOLACvtfcHk0liFe5EQsFt-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejt74%253D&md5=f1639611d273422351658c10b4d8e9ad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2218%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26atitle%3DProteasome%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520lessons%2520from%2520the%2520first%2520decade%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">McConkey, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span> </span><span class="NLM_article-title">Mechanisms of proteasome inhibitor action and resistance in cancer</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.drup.2008.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18818117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2ku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=164-179&author=D.+J.+McConkeyauthor=K.+Zhu&title=Mechanisms+of+proteasome+inhibitor+action+and+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of proteasome inhibitor action and resistance in cancer</span></div><div class="casAuthors">McConkey, David J.; Zhu, Keyi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">164-179</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors (PIs), such as bortezomib, carfilzomib or NPI-0052, have excellent clin. activity in patients with multiple myeloma and mantle cell lymphoma, and they are currently being evaluated in combination with other agents in patients with solid tumors.  Although they exert broad effects on cancer cells, their ability to (1) stabilize pro-apoptotic members of the BCL-2 family, (2) inhibit the two major pathways leading to NFκB activation, and (3) cause the build-up of misfolded proteins appear to be particularly important.  In addn., PIs may disrupt tumor-stromal interactions that drive NFκB activation and angiogenesis and in such a way sensitize cancer cells to other agents.  Still, drug resistance ultimately emerges in all tumors that initially respond to PIs.  This review provides an overview of the current thinking about how PIs may kill cancer cells exemplified for pancreatic cancer and the possible mechanisms involved in resistance to PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRdveVSdECeLVg90H21EOLACvtfcHk0liFe5EQsFt-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2ku7fJ&md5=ec7aec08dd2fb4837a9819117e67601a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2008.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2008.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DMcConkey%26aufirst%3DD.%2BJ.%26aulast%3DZhu%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520proteasome%2520inhibitor%2520action%2520and%2520resistance%2520in%2520cancer%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2008%26volume%3D11%26spage%3D164%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Naujokat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, S.</span><span> </span><span class="NLM_article-title">Role and function of the 26S proteasome in proliferation and apoptosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">965</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=965-980&author=C.+Naujokatauthor=S.+Hoffmann&title=Role+and+function+of+the+26S+proteasome+in+proliferation+and+apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaujokat%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DS.%26atitle%3DRole%2520and%2520function%2520of%2520the%252026S%2520proteasome%2520in%2520proliferation%2520and%2520apoptosis%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D965%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fuchs, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berges, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opelz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naujokat, C.</span><span> </span><span class="NLM_article-title">Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=270-283&author=D.+Fuchsauthor=C.+Bergesauthor=G.+Opelzauthor=V.+Danielauthor=C.+Naujokat&title=Increased+expression+and+altered+subunit+composition+of+proteasomes+induced+by+continuous+proteasome+inhibition+establish+apoptosis+resistance+and+hyperproliferation+of+Burkitt+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuchs%26aufirst%3DD.%26aulast%3DBerges%26aufirst%3DC.%26aulast%3DOpelz%26aufirst%3DG.%26aulast%3DDaniel%26aufirst%3DV.%26aulast%3DNaujokat%26aufirst%3DC.%26atitle%3DIncreased%2520expression%2520and%2520altered%2520subunit%2520composition%2520of%2520proteasomes%2520induced%2520by%2520continuous%2520proteasome%2520inhibition%2520establish%2520apoptosis%2520resistance%2520and%2520hyperproliferation%2520of%2520Burkitt%2520lymphoma%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D103%26spage%3D270%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Oerlemans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zantwijk, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debipersad, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojtekova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijden, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ylstra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkmans, B. A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span> </span><span class="NLM_article-title">Molecular basis of bortezomib resistance: proteasome subunit β5 (<i>PSMB5</i>) gene mutation and overexpression of PSMB5 protein</span> <span class="citation_source-journal">Blood.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span><span class="NLM_x">–</span> <span class="NLM_lpage">2499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=2489-2499&author=R.+Oerlemansauthor=N.+E.+Frankeauthor=Y.+G.+Assarafauthor=J.+Cloosauthor=I.+van+Zantwijkauthor=C.+R.+Berkersauthor=G.+L.+Schefferauthor=K.+Debipersadauthor=K.+Vojtekovaauthor=C.+Lemosauthor=J.+W.+van+der+Heijdenauthor=B.+Ylstraauthor=G.+J.+Petersauthor=G.+L.+Kaspersauthor=B.+A.+C.+Dijkmansauthor=R.+J.+Scheperauthor=G.+Jansen&title=Molecular+basis+of+bortezomib+resistance%3A+proteasome+subunit+%CE%B25+%28PSMB5%29+gene+mutation+and+overexpression+of+PSMB5+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2BZantwijk%26aufirst%3DI.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DDebipersad%26aufirst%3DK.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3DLemos%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3DYlstra%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DKaspers%26aufirst%3DG.%2BL.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%2BC.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DMolecular%2520basis%2520of%2520bortezomib%2520resistance%253A%2520proteasome%2520subunit%2520%25CE%25B25%2520%2528PSMB5%2529%2520gene%2520mutation%2520and%2520overexpression%2520of%2520PSMB5%2520protein%26jtitle%3DBlood.%26date%3D2008%26volume%3D112%26spage%3D2489%26epage%3D2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lü, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. M.</span><span> </span><span class="NLM_article-title">Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1124%2Fjpet.108.138131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18502982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=423-431&author=S.+Q.+L%C3%BCauthor=J.+M.+Yangauthor=X.+M.+Songauthor=S.+L.+Gongauthor=H.+Zhouauthor=L.+P.+Guoauthor=N.+X.+Songauthor=X.+C.+Baoauthor=P.+P.+Chenauthor=J.+M.+Wang&title=Point+mutation+of+the+proteasome+%CE%B25+subunit+gene+is+an+important+mechanism+of+bortezomib+resistance+in+bortezomib-selected+variants+of+Jurkat+T+cell+lymphoblastic+lymphoma%2Fleukemia+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line</span></div><div class="casAuthors">Lu, Shuqing; Yang, Jianmin; Song, Xianmin; Gong, Shenglan; Zhou, Hong; Guo, Lieping; Song, Ningxia; Bao, Xiaochen; Chen, Pingping; Wang, Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T lymphoblastic lymphoma/leukemia cell lines, designated the JurkatBs, from the parental Jurkat line via repeated drug selection.  There were no significant differences in the growth curves or colony formation between the JurkatB cells and parental Jurkat cells.  The effects of bortezomib on cytotoxicity, cell cycle arrest, and induction of apoptosis were decreased in JurkatB cells compared with parental Jurkat cells.  A mutation in the proteasome β5 subunit (PSMB5) gene (G322A), which encodes an amino acid change from Ala to Thr at polypeptide position 108, was detected by sequencing full-length cDNA clones and direct polymerase chain reaction products of the PSMB5 gene.  Bortezomib caused less inhibition of chymotrypsin-like activity in resistant cells.  When the G322A mutant PSMB5 was retrovirally introduced into parental Jurkat cells, it conferred bortezomib resistance to these cells, resulting in decreased cytotoxicity, apoptosis, and inhibition of chymotrypsin-like activity.  The predicted structure of A108T-mutated PSMB5 shows a conformational change that suggests decreased affinity to bortezomib.  In short, the G322A mutation of the PSMB5 gene is a novel mechanism for bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn09QDIJWXl7Vg90H21EOLACvtfcHk0ljOYPmpx8BDLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVWqsr8%253D&md5=922a0fd3626c460deb44e821f6807dde</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.138131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.138131%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%2BQ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DSong%26aufirst%3DX.%2BM.%26aulast%3DGong%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%2BP.%26aulast%3DSong%26aufirst%3DN.%2BX.%26aulast%3DBao%26aufirst%3DX.%2BC.%26aulast%3DChen%26aufirst%3DP.%2BP.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26atitle%3DPoint%2520mutation%2520of%2520the%2520proteasome%2520%25CE%25B25%2520subunit%2520gene%2520is%2520an%2520important%2520mechanism%2520of%2520bortezomib%2520resistance%2520in%2520bortezomib-selected%2520variants%2520of%2520Jurkat%2520T%2520cell%2520lymphoblastic%2520lymphoma%252Fleukemia%2520line%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D423%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Lü, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. M.</span><span> </span><span class="NLM_article-title">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.exphem.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19426847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A280%3ADC%252BD1MvjtVCitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=831-837&author=S.+Q.+L%C3%BCauthor=J.+M.+Yangauthor=Z.+L.+Chenauthor=S.+L.+Gongauthor=H.+Zhouauthor=X.+Q.+Xuauthor=J.+M.+Wang&title=Different+mutants+of+PSMB5+confer+varying+bortezomib+resistance+in+T+lymphoblastic+lymphoma%2Fleukemia+cells+derived+from+the+Jurkat+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span></div><div class="casAuthors">Lu Shuqing; Yang Jianmin; Chen Zhilong; Gong Shenglan; Zhou Hong; Xu Xiaoqian; Wang Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To investigate the relationship between bortezomib resistance and mutations in the proteasome beta5 subunit (PSMB5) gene.  MATERIALS AND METHODS:  Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection.  Mutations were detected by sequencing the complementary DNA of the PSMB5 gene.  Mutated clones were selected by limited dilution and cultured without bortezomib.  Messenger RNA expression levels of PSMB5 in these mutated clones were measured by quantitative reverse transcription polymerase chain reaction.  The degree of resistance was determined by cytotoxicity at various bortezomib concentrations.  The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin.  RESULTS:  In addition to the previously reported PSMB5 G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones containing these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained.  After being cultured without bortezomib for >2 months, no significant difference in PSMB5 messenger RNA levels was detected between these JurkatB cells and parental Jurkat cells.  JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, respectively, to bortezomib compared to Jurkat cells.  There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells.  The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between.  CONCLUSION:  Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSno336RtLX5O98rul4nhSdfW6udTcc2eYSsRxUQ2pW7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvjtVCitg%253D%253D&md5=6f79014204a2fcce65e26e640bb006a4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%2BQ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DGong%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%2BQ.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26atitle%3DDifferent%2520mutants%2520of%2520PSMB5%2520confer%2520varying%2520bortezomib%2520resistance%2520in%2520T%2520lymphoblastic%2520lymphoma%252Fleukemia%2520cells%2520derived%2520from%2520the%2520Jurkat%2520cell%2520line%26jtitle%3DExp.%2520Hematol.%26date%3D2009%26volume%3D37%26spage%3D831%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Rückrich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdoes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalbacher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driessen, C.</span><span> </span><span class="NLM_article-title">Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1098-1105&author=T.+R%C3%BCckrichauthor=M.+Krausauthor=J.+Gogelauthor=A.+Beckauthor=H.+Ovaaauthor=M.+Verdoesauthor=H.+S.+Overkleeftauthor=H.+Kalbacherauthor=C.+Driessen&title=Characterization+of+the+ubiquitin%E2%80%93proteasome+system+in+bortezomib-adapted+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCckrich%26aufirst%3DT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKalbacher%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520the%2520ubiquitin%25E2%2580%2593proteasome%2520system%2520in%2520bortezomib-adapted%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1098%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Bortezomib-resistant myeloma cell lines: a role for mutated <i>PSMB5</i> in preventing the accumulation of unfolded proteins and fatal ER stress</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1506-1512&author=M.+Riauthor=S.+Iidaauthor=T.+Nakashimaauthor=H.+Miyazakiauthor=F.+Moriauthor=A.+Itoauthor=A.+Inagakiauthor=S.+Kusumotoauthor=T.+Ishidaauthor=H.+Komatsuauthor=Y.+Shiotsuauthor=R.+Ueda&title=Bortezomib-resistant+myeloma+cell+lines%3A+a+role+for+mutated+PSMB5+in+preventing+the+accumulation+of+unfolded+proteins+and+fatal+ER+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRi%26aufirst%3DM.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DF.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DInagaki%26aufirst%3DA.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DBortezomib-resistant%2520myeloma%2520cell%2520lines%253A%2520a%2520role%2520for%2520mutated%2520PSMB5%2520in%2520preventing%2520the%2520accumulation%2520of%2520unfolded%2520proteins%2520and%2520fatal%2520ER%2520stress%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1506%26epage%3D1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Pérez-Galán, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mora-Jensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weniger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzatti, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stennett, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavachari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetler-Stevenson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunleavy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestner, A.</span><span> </span><span class="NLM_article-title">Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=542-552&author=P.+P%C3%A9rez-Gal%C3%A1nauthor=H.+Mora-Jensenauthor=M.+A.+Wenigerauthor=A.+L.+Shafferauthor=E.+G.+Rizzattiauthor=C.+M.+Chapmanauthor=C.+C.+Moauthor=L.+S.+Stennettauthor=C.+Raderauthor=P.+C.+Liuauthor=N.+Raghavachariauthor=M.+Stetler-Stevensonauthor=C.+Yuanauthor=S.+Pittalugaauthor=I.+Maricauthor=K.+M.+Dunleavyauthor=W.+H.+Wilsonauthor=L.+M.+Staudtauthor=A.+Wiestner&title=Bortezomib+resistance+in+mantle+cell+lymphoma+is+associated+with+plasmacytic+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Gal%25C3%25A1n%26aufirst%3DP.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DWeniger%26aufirst%3DM.%2BA.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRizzatti%26aufirst%3DE.%2BG.%26aulast%3DChapman%26aufirst%3DC.%2BM.%26aulast%3DMo%26aufirst%3DC.%2BC.%26aulast%3DStennett%26aufirst%3DL.%2BS.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%2BC.%26aulast%3DRaghavachari%26aufirst%3DN.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DDunleavy%26aufirst%3DK.%2BM.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DBortezomib%2520resistance%2520in%2520mantle%2520cell%2520lymphoma%2520is%2520associated%2520with%2520plasmacytic%2520differentiation%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D542%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewerth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Meerloo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojtekova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zantwijk, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweegman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geerke, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span> </span><span class="NLM_article-title">Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=757-768&author=N.+E.+Frankeauthor=D.+Niewerthauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=K.+Vojtekovaauthor=C.+H.+van+Zantwijkauthor=S.+Zweegmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=D.+P.+Geerkeauthor=A.+D.+Schimmerauthor=G.+J.+L.+Kaspersauthor=G.+Jansenauthor=J.+Cloos&title=Impaired+bortezomib+binding+to+mutant+%CE%B25+subunit+of+the+proteasome+is+the+underlying+basis+for+bortezomib+resistance+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3Dvan%2BZantwijk%26aufirst%3DC.%2BH.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGeerke%26aufirst%3DD.%2BP.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DImpaired%2520bortezomib%2520binding%2520to%2520mutant%2520%25CE%25B25%2520subunit%2520of%2520the%2520proteasome%2520is%2520the%2520underlying%2520basis%2520for%2520bortezomib%2520resistance%2520in%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2011%26volume%3D26%26spage%3D757%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Suzuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arastu-Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsagel, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of bortezomib resistant adenocarcinoma cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e27996&author=E.+Suzukiauthor=S.+Demoauthor=E.+Deuauthor=J.+Keatsauthor=S.+Arastu-Kapurauthor=P.+L.+Bergsagelauthor=M.+K.+Bennettauthor=C.+J.+Kirk&title=Molecular+mechanisms+of+bortezomib+resistant+adenocarcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DDeu%26aufirst%3DE.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520mechanisms%2520of%2520bortezomib%2520resistant%2520adenocarcinoma%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De27996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">de Wilt, L. H. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Meerloo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruyt, F. A. E.</span><span> </span><span class="NLM_article-title">Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=207-217&author=L.+H.+A.+M.+de+Wiltauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=J.+Cloosauthor=A.+D.+Schimmerauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=F.+A.+E.+Kruyt&title=Proteasome-based+mechanisms+of+intrinsic+and+acquired+bortezomib+resistance+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWilt%26aufirst%3DL.%2BH.%2BA.%2BM.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DKruyt%26aufirst%3DF.%2BA.%2BE.%26atitle%3DProteasome-based%2520mechanisms%2520of%2520intrinsic%2520and%2520acquired%2520bortezomib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D207%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Balsas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan-Malo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.leukres.2011.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21978467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=212-218&author=P.+Balsasauthor=P.+Galan-Maloauthor=I.+Marzoauthor=J.+Naval&title=Bortezomib+resistance+in+a+myeloma+cell+line+is+associated+to+PSM%CE%B25+overexpression+and+polyploidy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy</span></div><div class="casAuthors">Balsas, Patricia; Galan-Malo, Patricia; Marzo, Isabel; Naval, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-218</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM), though a no. of patients show resistance to this drug.  To study the cellular basis of this resistance we have generated a MM cell line displaying enhanced (5-6-fold) resistance to bortezomib by serial cultivation of RPMI 8226 cells with increasing concns. of this drug.  Bortezomib-resistant cells (8226/7B) became bigger in size than parental cells and nearly doubled the amt. of DNA per cell, evolving from hypotriploidy to near-tetraploidy. 8226/7B displayed lowered Noxa accumulation and reduced caspase-3 activation in response to bortezomib.  Resistant 8226/7B cells overexpressed the PSMβ5 proteasome subunit, the mol. target of bortezomib, both at the mRNA and protein level.  No mutations were detected in the PSMβ5 gene.  Bortezomib-resistant cells were roughly as sensitive as parental cells to other chemotherapeutic drugs, including doxorubicin, melphalan, vincristine, BMS-214662 and BMS-345541.  8226/7B cells showed partial and high cross-resistance to the proteasome inhibitors epoxomicin and MG-132, resp.  Co-treatment with the histone deacetylase inhibitor trichostatin A (TSA) potentiated bortezomib-induced apoptosis in parental RPMI 8226 cells but did not revert bortezomib resistance in 8226/7B cells.  Therefore, treatment of bortezomib-refractory myeloma with drugs targeting mol. structures other than proteasome seems to be the more suitable therapeutic strategy to overcome bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4fMGrGcs_rVg90H21EOLACvtfcHk0lhKVcRizD4VSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVemtw%253D%253D&md5=efa85279e50aa27c59a1876d90640462</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2011.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2011.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DBalsas%26aufirst%3DP.%26aulast%3DGalan-Malo%26aufirst%3DP.%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DBortezomib%2520resistance%2520in%2520a%2520myeloma%2520cell%2520line%2520is%2520associated%2520to%2520PSM%25CE%25B25%2520overexpression%2520and%2520polyploidy%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D212%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Finley, D.</span><span> </span><span class="NLM_article-title">Recognition and processing of ubiquitin-protein conjugates by the proteasome</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1146%2Fannurev.biochem.78.081507.101607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19489727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=477-513&author=D.+Finley&title=Recognition+and+processing+of+ubiquitin-protein+conjugates+by+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition and processing of ubiquitin-protein conjugates by the proteasome</span></div><div class="casAuthors">Finley, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">477-513</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The proteasome is an intricate mol. machine, which serves to degrade proteins following their conjugation to ubiquitin.  Substrates dock onto the proteasome at its 19-subunit regulatory particle via a diverse set of ubiquitin receptors and are then translocated into an internal chamber within the 28-subunit proteolytic core particle (CP), where they are hydrolyzed.  The substrate is threaded into the CP through a narrow gated channel, and thus translocation requires unfolding of the substrate.  Six distinct ATPases in the regulatory particle appear to form a ring complex and to drive unfolding as well as translocation.  ATP-dependent, degrdn.-coupled deubiquitination of the substrate is required both for efficient substrate degrdn. and for preventing the degrdn. of the ubiquitin tag.  However, the proteasome also contains deubiquitinating enzymes (DUBs) that can remove ubiquitin before substrate degrdn. initiates, thus allowing some substrates to dissoc. from the proteasome and escape degrdn.  Here, the authors examine the key elements of this mol. machine and how they cooperate in the processing of proteolytic substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiMN2MjjcyS7Vg90H21EOLACvtfcHk0lhKVcRizD4VSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Ghurw%253D&md5=a8d286d88577011670470b65d304e808</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.78.081507.101607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.78.081507.101607%26sid%3Dliteratum%253Aachs%26aulast%3DFinley%26aufirst%3DD.%26atitle%3DRecognition%2520and%2520processing%2520of%2520ubiquitin-protein%2520conjugates%2520by%2520the%2520proteasome%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2009%26volume%3D78%26spage%3D477%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Xu, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skrtic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavareh, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketela, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2251-2259&author=G.+W.+Xuauthor=M.+Aliauthor=T.+E.+Woodauthor=D.+Wongauthor=N.+Macleanauthor=X.+M.+Wangauthor=M.+Grondaauthor=M.+Skrticauthor=X.+M.+Liauthor=R.+Hurrenauthor=X.+L.+Maoauthor=M.+Venkatesanauthor=R.+B.+Zavarehauthor=T.+Ketelaauthor=J.+C.+Reedauthor=D.+Roseauthor=J.+Moffatauthor=R.+A.+Bateyauthor=S.+Dhe-Paganonauthor=A.+D.+Schimmer&title=The+ubiquitin-activating+enzyme+E1+as+a+therapeutic+target+for+the+treatment+of+leukemia+and+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DSkrtic%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DZavareh%26aufirst%3DR.%2BB.%26aulast%3DKetela%26aufirst%3DT.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DRose%26aufirst%3DD.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DThe%2520ubiquitin-activating%2520enzyme%2520E1%2520as%2520a%2520therapeutic%2520target%2520for%2520the%2520treatment%2520of%2520leukemia%2520and%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2251%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hochstrasser, M.</span><span> </span><span class="NLM_article-title">Origin and function of ubiquitin-like proteins</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">458</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fnature07958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19325621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Klsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=422-429&author=M.+Hochstrasser&title=Origin+and+function+of+ubiquitin-like+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and function of ubiquitin-like proteins</span></div><div class="casAuthors">Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7237</span>),
    <span class="NLM_cas:pages">422-429</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Eukaryotic proteins can be modified through attachment to various small mols. and proteins.  One such modification is conjugation to ubiquitin and ubiquitin-like proteins (UBLs), which controls an enormous range of physiol. processes.  Bound UBLs mainly regulate the interactions of proteins with other macromols., e.g., binding to the proteasome or recruitment to chromatin.  The various UBL systems use related enzymes to attach specific UBLs to proteins (or other mols.), and most of these attachments are transient.  There is increasing evidence suggesting that such UBL-protein modification evolved from prokaryotic sulfurtransferase systems or related enzymes.  Moreover, proteins similar to UBL-conjugating enzymes and UBL-deconjugating enzymes seem to have already been widespread at the time of the last common ancestor (LCA) of eukaryotes, suggesting that UBL-protein conjugation did not 1st evolve in eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaZQ06CJ5q7Vg90H21EOLACvtfcHk0liTAFWyKKLwCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Klsbg%253D&md5=da78b38ccb5d49faaac5acf75119ddb4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature07958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07958%26sid%3Dliteratum%253Aachs%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DOrigin%2520and%2520function%2520of%2520ubiquitin-like%2520proteins%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D422%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bochtler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstetter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span> </span><span class="NLM_article-title">Molecular machines for protein degradation</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1002%2Fcbic.200400313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=15678420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=222-256&author=M.+Grollauthor=M.+Bochtlerauthor=H.+Brandstetterauthor=T.+Clausenauthor=R.+Huber&title=Molecular+machines+for+protein+degradation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular machines for protein degradation</span></div><div class="casAuthors">Groll, Michael; Bochtler, Matthias; Brandstetter, Hans; Clausen, Tim; Huber, Robert</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-256</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  One of the most precisely regulated processes in living cells is intracellular protein degrdn.  The main component of the degrdn. machinery is the 20S proteasome present in both eukaryotes and prokaryotes.  In addn., there exist other proteasome-related protein-degrdn. machineries, like HslVU protease in eubacteria.  Peptides generated by proteasomes and related systems can be used by the cell, e.g., for antigen presentation.  However, most of the peptides must be degraded to single amino acids, which are further used in cell metab. and for the synthesis of new proteins.  Tricorn protease and its interacting factors work downstream of the proteasome and process the peptides into amino acids.  Here, the authors summarize the current state of knowledge about protein-degrdn. systems, focusing in particular on the 20S proteasome, HslVU protease, tricorn protease and its interacting factors, and DegP protease.  The structural information about these protein complexes opens new possibilities for identifying, characterizing, and elucidating the mode of action of natural and synthetic inhibitors, which affects their function.  Some of these compds. may find therapeutic applications in contemporary medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFH-O3dirM-bVg90H21EOLACvtfcHk0liTAFWyKKLwCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVKhtbs%253D&md5=04ca944e381d6ed59067c9286df1bd56</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400313%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBochtler%26aufirst%3DM.%26aulast%3DBrandstetter%26aufirst%3DH.%26aulast%3DClausen%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DR.%26atitle%3DMolecular%2520machines%2520for%2520protein%2520degradation%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D222%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Darwin, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, C. F.</span><span> </span><span class="NLM_article-title">The proteasome of <i>Mycobacterium tuberculosis</i> is required for resistance to nitric oxide</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1966</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1126%2Fscience.1091176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=14671303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ams7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=1963-1966&author=K.+H.+Darwinauthor=S.+Ehrtauthor=J.+C.+Gutierrez-Ramosauthor=N.+Weichauthor=C.+F.+Nathan&title=The+proteasome+of+Mycobacterium+tuberculosis+is+required+for+resistance+to+nitric+oxide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide</span></div><div class="casAuthors">Darwin, K. Heran; Ehrt, Sabine; Gutierrez-Ramos, Jose-Carlos; Weich, Nadine; Nathan, Carl F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5652</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The prodn. of nitric oxide and other reactive nitrogen intermediates (RNI) by macrophages helps to control infection by Mycobacterium tuberculosis (Mtb).  However, the protection is imperfect and infection persists.  To identify genes that Mtb requires to resist RNI, the authors screened 10,100 Mtb transposon mutants for hypersusceptibility to acidified nitrite.  They found 12 mutants with insertions in seven genes representing six pathways, including the repair of DNA (uvrB) and the synthesis of a flavin cofactor (fbiC).  Five mutants had insertions in proteasome-assocd. genes.  An Mtb mutant deficient in a presumptive proteasomal ATPase was attenuated in mice, and exposure to proteasomal protease inhibitors markedly sensitized wild-type Mtb to RNI.  Thus, the mycobacterial proteasome serves as a defense against oxidative or nitrosative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejml3OLRZJLVg90H21EOLACvtfcHk0liTAFWyKKLwCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ams7c%253D&md5=0fa331331948788703fc2a3a87c78e68</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.1091176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1091176%26sid%3Dliteratum%253Aachs%26aulast%3DDarwin%26aufirst%3DK.%2BH.%26aulast%3DEhrt%26aufirst%3DS.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26aulast%3DWeich%26aufirst%3DN.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26atitle%3DThe%2520proteasome%2520of%2520Mycobacterium%2520tuberculosis%2520is%2520required%2520for%2520resistance%2520to%2520nitric%2520oxide%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D1963%26epage%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Imajoh-Ohmi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span> </span><span class="NLM_article-title">Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">217</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1995&pages=1070-1077&author=S.+Imajoh-Ohmiauthor=T.+Kawaguchiauthor=S.+Sugiyamaauthor=K.+Tanakaauthor=S.+Omuraauthor=H.+Kikuchi&title=Lactacystin%2C+a+specific+inhibitor+of+the+proteasome%2C+induces+apoptosis+in+human+monoblast+U937+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImajoh-Ohmi%26aufirst%3DS.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DLactacystin%252C%2520a%2520specific%2520inhibitor%2520of%2520the%2520proteasome%252C%2520induces%2520apoptosis%2520in%2520human%2520monoblast%2520U937%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D217%26spage%3D1070%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Delic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masdehors, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosset, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binet, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdelenat, H.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fbjc.1998.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=9569046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADyaK1cXisVKhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1998&pages=1103-1107&author=J.+Delicauthor=P.+Masdehorsauthor=S.+Omuraauthor=J.+M.+Cossetauthor=J.+Dumontauthor=J.+L.+Binetauthor=H.+Magdelenat&title=The+proteasome+inhibitor+lactacystin+induces+apoptosis+and+sensitizes+chemo-+and+radioresistant+human+chronic+lymphocytic+leukaemia+lymphocytes+to+TNF-%CE%B1-initiated+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-α-initiated apoptosis</span></div><div class="casAuthors">Delic, J.; Masdehors, P.; Omura, S.; Cosset, J. -M.; Dumont, J.; Binet, J. -L.; Magdelenat, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1103-1107</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">Apoptosis can be triggered by cytotoxic agents and radiation currently used in cancer treatment.  However, the apoptotic response appears to vary between cell types (normal or transformed) and between types of malignancy.  Thus, irradn. induces apoptosis in normal human lymphocytes but not in lymphocytes derived from a subset of chronic lymphocytic leukemia (CLL).  Moreover, in this subset, spontaneous apoptosis is inhibited by irradn.  Why irradn. does not allow the initiation of the apoptotic death pathway could be explained, at least in part, and in agreement with recent findings on exptl. models, by the activation of the transcriptional factor NF-κB, which is able to inhibit apoptotic cell response.  Low doses (at which no effect is obsd. with normal human lymphocytes) of the highly specific proteasome inhibitor lactacystin are sufficient to trigger apoptosis in these malignant cells.  Proteasome inhibition by lactacystin prevents the nuclear translocation of both p50 and p65 NF-κB subunits and sensitizes these cells to apoptosis by tumor necrosis factor (TNF)-α treatment.  As this subset of CLL is totally resistant to any treatment, proteasome inhibition by lactacystin provides a new therapeutic approach to be explored, considering the sensitivity of malignant CLL-derived lymphocytes to be quite different from that of normal human lymphocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3COCNaHCirVg90H21EOLACvtfcHk0ljwLbn3w_zcPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVKhs74%253D&md5=5430d590d55a0ebadda258c6a953f5d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.183%26sid%3Dliteratum%253Aachs%26aulast%3DDelic%26aufirst%3DJ.%26aulast%3DMasdehors%26aufirst%3DP.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DCosset%26aufirst%3DJ.%2BM.%26aulast%3DDumont%26aufirst%3DJ.%26aulast%3DBinet%26aufirst%3DJ.%2BL.%26aulast%3DMagdelenat%26aufirst%3DH.%26atitle%3DThe%2520proteasome%2520inhibitor%2520lactacystin%2520induces%2520apoptosis%2520and%2520sensitizes%2520chemo-%2520and%2520radioresistant%2520human%2520chronic%2520lymphocytic%2520leukaemia%2520lymphocytes%2520to%2520TNF-%25CE%25B1-initiated%2520apoptosis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D77%26spage%3D1103%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eswara, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafond-Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, C. V.</span><span> </span><span class="NLM_article-title">Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4342-4348&author=R.+Z.+Orlowskiauthor=J.+R.+Eswaraauthor=A.+Lafond-Walkerauthor=M.+R.+Greverauthor=M.+Orlowskiauthor=C.+V.+Dang&title=Tumor+growth+inhibition+induced+in+a+murine+model+of+human+Burkitt%E2%80%99s+lymphoma+by+a+proteasome+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DEswara%26aufirst%3DJ.%2BR.%26aulast%3DLafond-Walker%26aufirst%3DA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DTumor%2520growth%2520inhibition%2520induced%2520in%2520a%2520murine%2520model%2520of%2520human%2520Burkitt%25E2%2580%2599s%2520lymphoma%2520by%2520a%2520proteasome%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4342%26epage%3D4348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F1535-7163.MCT-11-0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22072815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2034-2042&author=T.+Hideshimaauthor=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Mechanism+of+action+of+proteasome+inhibitors+and+deacetylase+inhibitors+and+the+biological+basis+of+synergy+in+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span></div><div class="casAuthors">Hideshima, Teru; Richardson, Paul G.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2034-2042</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Novel agents, including the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade.  Despite these advances, many patients relapse or do not benefit from the currently available therapies; thus, multiple myeloma remains an incurable disease.  Deacetylase inhibitors (DACi), including panobinostat and vorinostat, have recently emerged as novel agents being evaluated in the treatment of multiple myeloma.  Deacetylases are a group of enzymes with effects on various intracellular proteins, including histones, transcription factors, and mol. chaperones.  Although DACi inhibit cell growth and induce apoptosis in multiple myeloma cells as a single agent, synergistic activity has been obsd. when they were used in combination with bortezomib.  The mechanistic basis of synergy is multifactorial and includes disruption of protein degrdn. and inhibition of the interaction of multiple myeloma cells with the tumor microenvironment.  This review summarizes recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma and examines the biol. basis of their synergistic effects.  Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clin. trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma.  Mol Cancer Ther; 10(11); 2034-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTic1RyTJsbVg90H21EOLACvtfcHk0ljwLbn3w_zcPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ&md5=741285acef164545c3388037dc42f73f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0433%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMechanism%2520of%2520action%2520of%2520proteasome%2520inhibitors%2520and%2520deacetylase%2520inhibitors%2520and%2520the%2520biological%2520basis%2520of%2520synergy%2520in%2520multiple%2520myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2034%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Masdehors, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merle-Beral, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdelenat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delic, J.</span><span> </span><span class="NLM_article-title">Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=269-274&author=P.+Masdehorsauthor=H.+Merle-Beralauthor=K.+Maloumauthor=S.+Omuraauthor=H.+Magdelenatauthor=J.+Delic&title=Deregulation+of+the+ubiquitin+system+and+p53+proteolysis+modify+the+apoptotic+response+in+B-CLL+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasdehors%26aufirst%3DP.%26aulast%3DMerle-Beral%26aufirst%3DH.%26aulast%3DMaloum%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DMagdelenat%26aufirst%3DH.%26aulast%3DDelic%26aufirst%3DJ.%26atitle%3DDeregulation%2520of%2520the%2520ubiquitin%2520system%2520and%2520p53%2520proteolysis%2520modify%2520the%2520apoptotic%2520response%2520in%2520B-CLL%2520lymphocytes%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D269%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pengo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calbi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenci, S.</span><span> </span><span class="NLM_article-title">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3040</span><span class="NLM_x">–</span> <span class="NLM_lpage">3049</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1182%2Fblood-2008-08-172734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19164601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3040-3049&author=G.+Bianchiauthor=L.+Olivaauthor=P.+Cascioauthor=N.+Pengoauthor=F.+Fontanaauthor=F.+Cerrutiauthor=A.+Orsiauthor=E.+Pasqualettoauthor=A.+Mezghraniauthor=V.+Calbiauthor=G.+Palladiniauthor=N.+Giulianiauthor=K.+C.+Andersonauthor=R.+Sitiaauthor=S.+Cenci&title=The+proteasome+load+versus+capacity+balance+determines+apoptotic+sensitivity+of+multiple+myeloma+cells+to+proteasome+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span></div><div class="casAuthors">Bianchi, Giada; Oliva, Laura; Cascio, Paolo; Pengo, Niccolo; Fontana, Francesca; Cerruti, Fulvia; Orsi, Andrea; Pasqualetto, Elena; Mezghrani, Alexandre; Calbi, Valeria; Palladini, Giovanni; Giuliani, Nicola; Anderson, Kenneth C.; Sitia, Roberto; Cenci, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the mechanisms of action and bases of individual susceptibility remain unclear.  Recent work linked PI sensitivity to protein synthesis and proteasome activity, raising the question whether different levels of proteasome expression and workload underlie PI sensitivity in MM cells (MMCs).  Exploiting human MM lines characterized by differential PI sensitivity, we report that highly sensitive MMCs express lower proteasome levels and higher proteasomal workload than relatively PI-resistant MMCs, resulting in the accumulation of polyubiquitinated proteins at the expense of free ubiquitin (proteasome stress).  Manipulating proteasome expression or workload alters apoptotic sensitivity to PI, demonstrating a cause-effect relationship between proteasome stress and apoptotic responses in MMCs.  Intracellular immunostaining in primary, patient-derived MMCs reveals that polyubiquitinated proteins hallmark neoplastic plasma cells, in pos. correlation with Ig content, both intra- and interpatient.  Moreover, overall proteasome activity of primary MMCs inversely correlates with apoptotic sensitivity to PI.  Altogether, our data indicate that the balance between proteasome workload and degradative capacity represents a crit. determinant of apoptotic sensitivity of MMCs to PI, potentially providing a framework for identifying indicators of responsiveness and designing novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZB8ZrWDyLbVg90H21EOLACvtfcHk0lgHGQLbuY7icQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D&md5=dd9f98f07f06ba2d312a54228d96ceef</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-08-172734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-08-172734%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DPengo%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DF.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCalbi%26aufirst%3DV.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCenci%26aufirst%3DS.%26atitle%3DThe%2520proteasome%2520load%2520versus%2520capacity%2520balance%2520determines%2520apoptotic%2520sensitivity%2520of%2520multiple%2520myeloma%2520cells%2520to%2520proteasome%2520inhibition%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3040%26epage%3D3049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Cenci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelouard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masciarelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattioli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagliavacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span> </span><span class="NLM_article-title">Progressively impaired proteasomal capacity during terminal plasma cell differentiation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1104</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1104-1113&author=S.+Cenciauthor=A.+Mezghraniauthor=P.+Cascioauthor=G.+Bianchiauthor=F.+Cerrutiauthor=A.+Fraauthor=H.+Lelouardauthor=S.+Masciarelliauthor=L.+Mattioliauthor=L.+Olivaauthor=A.+Orsiauthor=E.+Pasqualettoauthor=P.+Pierreauthor=E.+Ruffatoauthor=L.+Tagliavaccaauthor=R.+Sitia&title=Progressively+impaired+proteasomal+capacity+during+terminal+plasma+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DFra%26aufirst%3DA.%26aulast%3DLelouard%26aufirst%3DH.%26aulast%3DMasciarelli%26aufirst%3DS.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DRuffato%26aufirst%3DE.%26aulast%3DTagliavacca%26aufirst%3DL.%26aulast%3DSitia%26aufirst%3DR.%26atitle%3DProgressively%2520impaired%2520proteasomal%2520capacity%2520during%2520terminal%2520plasma%2520cell%2520differentiation%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1104%26epage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Moore, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eustáquio, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, R. P.</span><span> </span><span class="NLM_article-title">Advances in and applications of proteasome inhibitors</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.cbpa.2008.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18656549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=434-440&author=B.+S.+Mooreauthor=A.+S.+Eust%C3%A1quioauthor=R.+P.+McGlinchey&title=Advances+in+and+applications+of+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in and applications of proteasome inhibitors</span></div><div class="casAuthors">Moore, Bradley S.; Eustaquio, Alessandra S.; McGlinchey, Ryan P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-440</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the recent US Food and Drug Administration approval of bortezomib (Velcade) for the treatment of relapsed multiple myeloma, the proteasome has emerged as a new therapeutic target with diverse pathol.  Drug discovery programs in academia and the pharmaceutical industry have developed a range of low nanomolar synthetic and natural inhibitors of the 20S proteasome core particle that have entered human clin. trials as significant anticancer and antiinflammatory leads.  Moreover, proteasome inhibitors continue to serve as valuable research tools in cellular biol. through the elucidation of important biol. processes assocd. with the ubiquitin-proteasome pathway of protein degrdn.  This review will highlight recent advances in the development and application of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOuBSm-tslrVg90H21EOLACvtfcHk0lgHGQLbuY7icQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsrvE&md5=1b47064214a39584a0dc4ecca8a254d3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DB.%2BS.%26aulast%3DEust%25C3%25A1quio%26aufirst%3DA.%2BS.%26aulast%3DMcGlinchey%26aufirst%3DR.%2BP.%26atitle%3DAdvances%2520in%2520and%2520applications%2520of%2520proteasome%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D434%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogyo, M.</span><span> </span><span class="NLM_article-title">Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2FS1074-5521%2802%2900144-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=12031672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVWis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=655-662&author=M.+Grollauthor=T.+Nazifauthor=R.+Huberauthor=M.+Bogyo&title=Probing+structural+determinants+distal+to+the+site+of+hydrolysis+that+control+substrate+specificity+of+the+20S+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Probing Structural Determinants Distal to the Site of Hydrolysis that Control Substrate Specificity of the 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Nazif, Tamim; Huber, Robert; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The 20S proteasome is a large multicomponent protease complex.  Relatively little is known about the mechanisms that control substrate specificity of its multiple active sites.  We present here the crystal structure at 2.95 A resoln. of a β2-selective inhibitor (MB1) bound to the yeast 20S proteasome core particle (CP).  This structure is compared to the structure of the CP bound to a general inhibitor (MB2) that covalently modified all three (β1, β2, β5) catalytic subunits.  These two inhibitors differ only in their P3 and P4 residues, thereby highlighting binding interactions distal to the active site threonine that control abs. substrate specificity of the complex.  Comparisons of the CP-bound structures of MB1, MB2, and the natural products epoxomicin and TMC-95A also provide information regarding general binding modes for several classes of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFy2YLpjvm-LVg90H21EOLACvtfcHk0lh3-NZ1bEOlhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVWis70%253D&md5=4ef255415612e227382546e12eb521b7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2802%2900144-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252802%252900144-8%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DNazif%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DProbing%2520structural%2520determinants%2520distal%2520to%2520the%2520site%2520of%2520hydrolysis%2520that%2520control%2520substrate%2520specificity%2520of%2520the%252020S%2520proteasome%26jtitle%3DChem.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P. E.</span><span> </span><span class="NLM_article-title">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.drudis.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20116451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=243-249&author=L.+R.+Dickauthor=P.+E.+Fleming&title=Building+on+bortezomib%3A+second-generation+proteasome+inhibitors+as+anti-cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span></div><div class="casAuthors">Dick, Lawrence R.; Fleming, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the proteasome (a highly abundant enzymic complex responsible for intracellular protein turnover) is an effective anti-cancer therapeutic approach, as demonstrated by the first-in-class agent bortezomib.  Various new proteasome inhibitors are now in development, including peptide boronic acid analogs MLN9708 and CEP-18770, peptide epoxyketones carfilzomib and PR-047, and NPI-0052, a β-lactone compd.  All are potent inhibitors of proteasome activity in vitro but show differences in enzyme binding kinetics, which might affect their pharmacol. and result in different efficacy and safety profiles.  Here, we review the second-generation proteasome inhibitors and assess the potential pharmacol. impact of their different chem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuklkNi02WRbVg90H21EOLACvtfcHk0lh3-NZ1bEOlhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D&md5=6a6ceeb81601f467ea56debc9f607738</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DFleming%26aufirst%3DP.%2BE.%26atitle%3DBuilding%2520on%2520bortezomib%253A%2520second-generation%2520proteasome%2520inhibitors%2520as%2520anti-cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D243%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ruschak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slassi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">Novel proteasome inhibitors to overcome bortezomib resistance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1093%2Fjnci%2Fdjr160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21606441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2011&pages=1007-1017&author=A.+M.+Ruschakauthor=M.+Slassiauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Novel+proteasome+inhibitors+to+overcome+bortezomib+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Proteasome Inhibitors to Overcome Bortezomib Resistance</span></div><div class="casAuthors">Ruschak, Amy M.; Slassi, Malik; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1007-1017</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins and thereby regulates protein levels within the cell.  Given this important role in maintaining cellular homeostasis, it is perhaps somewhat surprising that proteasome inhibitors have a therapeutic window.  Proteasome inhibitors have demonstrated clin. efficacy in the treatment of multiple myeloma and mantle cell lymphoma and are under evaluation for the treatment of other malignancies.  Bortezomib is the first and only Food and Drug Administration-approved proteasome inhibitor that inhibits this enzyme complex in a reversible fashion.  Although bortezomib improves clin. outcomes when used as a single agent, most patients do not respond to this drug and those who do respond almost uniformly relapse.  As such, efforts are underway to develop proteasome inhibitors that act through mechanisms distinct from that of bortezomib.  Specifically, inhibitors that bind the active site of the proteasome and inhibit the complex irreversibly have been developed and are in advanced clin. trials.  Inhibitors that act on sites of the proteasome outside of the catalytic center have also been identified and are in preclin. development.  In this review, we discuss the structure and function of the proteasome.  We then focus on the mol. biol., chem., and the preclin. and clin. efficacy of novel proteasome inhibitors as strategies to inhibit this target and overcome some forms of bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWeUjDj5ezAbVg90H21EOLACvtfcHk0lh3-NZ1bEOlhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKqsrs%253D&md5=52b263bbfd39bf18a543a382610c762f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr160%26sid%3Dliteratum%253Aachs%26aulast%3DRuschak%26aufirst%3DA.%2BM.%26aulast%3DSlassi%26aufirst%3DM.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DNovel%2520proteasome%2520inhibitors%2520to%2520overcome%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D103%26spage%3D1007%26epage%3D1017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pylypenko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosicki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karamanesht, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leleu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grishunina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masliak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robak, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shubina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnulf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deraedt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span> </span><span class="NLM_article-title">Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2FS1470-2045%2811%2970081-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21507715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A280%3ADC%252BC3MvnvVWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=431-440&author=P.+Moreauauthor=H.+Pylypenkoauthor=S.+Grosickiauthor=I.+Karamaneshtauthor=X.+Leleuauthor=M.+Grishuninaauthor=G.+Rekhtmanauthor=Z.+Masliakauthor=T.+Robakauthor=A.+Shubinaauthor=B.+Arnulfauthor=M.+Kropffauthor=J.+Cavetauthor=D.+L.+Esseltineauthor=H.+B.+Fengauthor=S.+Girgisauthor=H.+van+de+Veldeauthor=W.+Deraedtauthor=J.+L.+Harousseau&title=Subcutaneous+versus+intravenous+administration+of+bortezomib+in+patients+with+relapsed+multiple+myeloma%3A+a+randomised%2C+phase+3%2C+non-inferiority+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study</span></div><div class="casAuthors">Moreau Philippe; Pylypenko Halyna; Grosicki Sebastian; Karamanesht Ievgenii; Leleu Xavier; Grishunina Maria; Rekhtman Grigoriy; Masliak Zvenyslava; Robak Tadeusz; Shubina Anna; Arnulf Bertrand; Kropff Martin; Cavet James; Esseltine Dixie-Lee; Feng Huaibao; Girgis Suzette; van de Velde Helgi; Deraedt William; Harousseau Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative.  We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma.  METHODS:  This randomised, phase 3 study was undertaken at 53 centres in ten countries in Europe, Asia, and South America.  Patients aged 18 years and older with relapsed multiple myeloma after one to three previous lines of therapy were randomly assigned to receive up to eight 21-day cycles of bortezomib 1·3 mg/m(2), on days 1, 4, 8, and 11, by subcutaneous injection or intravenous infusion.  Randomisation was by an interactive voice response system based on a computer-generated randomisation schedule, stratified by number of previous lines and disease stage.  Patients and treating physicians were not masked to treatment allocation.  The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in all patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug (response-evaluable population).  Non-inferiority was defined as retaining 60% of the intravenous treatment effect.  This study is registered with ClinicalTrials.gov, number NCT00722566, and is ongoing for long-term follow-up.  FINDINGS:  222 patients were randomly assigned to receive subcutaneous (n=148) or intravenous (n=74) bortezomib.  The response-evaluable population consisted of 145 patients in the subcutaneous group and 73 in the intravenous group.  Patients received a median of eight cycles (range one to ten) in both groups.  ORR after four cycles was 42% in both groups (61 patients in subcutaneous group and 31 in intravenous group; ORR difference -0·4%, 95% CI -14·3 to 13·5), showing non-inferiority (p=0·002).  After a median follow-up of 11·8 months (IQR 7·9-16·8) in the subcutaneous group and 12·0 months (8·1-15·6) in the intravenous group, there were no significant differences in time to progression (median 10·4 months, 95% CI 8·5-11·7, vs 9·4 months, 7·6-10·6; p=0·387) and 1-year overall survival (72·6%, 95% CI 63·1-80·0, vs 76·7%, 64·1-85·4; p=0·504) with subcutaneous versus intravenous bortezomib.  Grade 3 or worse adverse events were reported in 84 (57%) patients in the subcutaneous group versus 52 (70%) in the intravenous group; the most common were thrombocytopenia (19 [13%] vs 14 [19%]), neutropenia (26 [18%] vs 13 [18%]), and anaemia (18 [12%] vs six [8%]).  Peripheral neuropathy of any grade (56 [38%] vs 39 [53%]; p=0·044), grade 2 or worse (35 [24%] vs 30 [41%]; p=0·012), and grade 3 or worse (nine [6%] vs 12 [16%]; p=0·026) was significantly less common with subcutaneous than with intravenous administration.  Subcutaneous administration was locally well tolerated.  INTERPRETATION:  Subcutaneous bortezomib offers non-inferior efficacy to standard intravenous administration, with an improved safety profile.  FUNDING:  Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMW7KnkpVTZkbxh97K6Vt6fW6udTcc2ebU76IbBuy0krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvnvVWqtw%253D%253D&md5=032dbef9cc436c2b6c4716af52d0b34d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970081-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970081-X%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DPylypenko%26aufirst%3DH.%26aulast%3DGrosicki%26aufirst%3DS.%26aulast%3DKaramanesht%26aufirst%3DI.%26aulast%3DLeleu%26aufirst%3DX.%26aulast%3DGrishunina%26aufirst%3DM.%26aulast%3DRekhtman%26aufirst%3DG.%26aulast%3DMasliak%26aufirst%3DZ.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DShubina%26aufirst%3DA.%26aulast%3DArnulf%26aufirst%3DB.%26aulast%3DKropff%26aufirst%3DM.%26aulast%3DCavet%26aufirst%3DJ.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DH.%2BB.%26aulast%3DGirgis%26aufirst%3DS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DDeraedt%26aufirst%3DW.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26atitle%3DSubcutaneous%2520versus%2520intravenous%2520administration%2520of%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%253A%2520a%2520randomised%252C%2520phase%25203%252C%2520non-inferiority%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D431%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kupperman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannerman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzzese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfredi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolen, J.</span><span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+C.+Leeauthor=Y.+Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0ljmOqrpFFoprQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DCao%26aufirst%3DY.%2BY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagno, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coscia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massaia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allievi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescalli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Giovine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Feudis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strepponi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferracini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussolati, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camussi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernareggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2765</span><span class="NLM_x">–</span> <span class="NLM_lpage">2775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2765-2775&author=R.+Pivaauthor=B.+Ruggeriauthor=M.+Williamsauthor=G.+Costaauthor=I.+Tamagnoauthor=D.+Ferreroauthor=V.+Giaiauthor=M.+Cosciaauthor=S.+Peolaauthor=M.+Massaiaauthor=G.+Pezzoniauthor=C.+Allieviauthor=N.+Pescalliauthor=M.+Cassinauthor=S.+di+Giovineauthor=P.+Nicoliauthor=P.+de+Feudisauthor=I.+Strepponiauthor=I.+Roatoauthor=R.+Ferraciniauthor=B.+Bussolatiauthor=G.+Camussiauthor=S.+Jones-Bolinauthor=K.+Hunterauthor=H.+Zhaoauthor=A.+Neriauthor=A.+Palumboauthor=C.+Berkersauthor=H.+Ovaaauthor=A.+Bernareggiauthor=G.+Inghirami&title=CEP-18770%3A+a+novel%2C+orally+active+proteasome+inhibitor+with+a+tumor-selective+pharmacologic+profile+competitive+with+bortezomib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DTamagno%26aufirst%3DI.%26aulast%3DFerrero%26aufirst%3DD.%26aulast%3DGiai%26aufirst%3DV.%26aulast%3DCoscia%26aufirst%3DM.%26aulast%3DPeola%26aufirst%3DS.%26aulast%3DMassaia%26aufirst%3DM.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DPescalli%26aufirst%3DN.%26aulast%3DCassin%26aufirst%3DM.%26aulast%3Ddi%2BGiovine%26aufirst%3DS.%26aulast%3DNicoli%26aufirst%3DP.%26aulast%3Dde%2BFeudis%26aufirst%3DP.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRoato%26aufirst%3DI.%26aulast%3DFerracini%26aufirst%3DR.%26aulast%3DBussolati%26aufirst%3DB.%26aulast%3DCamussi%26aufirst%3DG.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DNeri%26aufirst%3DA.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DCEP-18770%253A%2520a%2520novel%252C%2520orally%2520active%2520proteasome%2520inhibitor%2520with%2520a%2520tumor-selective%2520pharmacologic%2520profile%2520competitive%2520with%2520bortezomib%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2765%26epage%3D2775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallone, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineaux, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span> </span><span class="NLM_article-title">Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6383</span><span class="NLM_x">–</span> <span class="NLM_lpage">6391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+activity+of+PR-171%2C+a+novel+irreversible+inhibitor+of+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0ljRD9NyTlXLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520PR-171%252C%2520a%2520novel%2520irreversible%2520inhibitor%2520of%2520the%2520proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6383%26epage%3D6391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Zhou, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchamuel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwonek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. F.</span><span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.+J.+Zhouauthor=M.+A.+Aujayauthor=M.+K.+Bennettauthor=M.+Dajeeauthor=S.+D.+Demoauthor=Y.+Fangauthor=M.+N.+Hoauthor=J.+Jiangauthor=C.+J.+Kirkauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+D.+Shenkauthor=J.+Shieldsauthor=P.+J.+Shwonekauthor=T.+Stantonauthor=C.+C.+M.+Sunauthor=C.+Sylvainauthor=T.+M.+Wooauthor=J.+F.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0ljRD9NyTlXLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%2BC.%2BM.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Roccaro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Runnels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">4051</span><span class="NLM_x">–</span> <span class="NLM_lpage">4060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1182%2Fblood-2009-09-243402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20110419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4051-4060&author=A.+M.+Roccaroauthor=A.+Saccoauthor=M.+Aujayauthor=H.+T.+Ngoauthor=A.+K.+Azabauthor=F.+Azabauthor=P.+Quangauthor=P.+Maisoauthor=J.+Runnelsauthor=K.+C.+Andersonauthor=S.+Demoauthor=I.+M.+Ghobrial&title=Selective+inhibition+of+chymotrypsin-like+activity+of+the+immunoproteasome+and+constitutive+proteasome+in+Waldenstrom+macroglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span></div><div class="casAuthors">Roccaro, Aldo M.; Sacco, Antonio; Aujay, Monette; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Demo, Susan; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4051-4060</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clin. trials.  Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects.  Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematol. tumors.  We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S.  Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor κB (NF-κB) inhibition, caspase cleavage, and initiation of the unfolded protein response.  Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells.  These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBDkasuJTbVg90H21EOLACvtfcHk0ljQCU1pVnD4ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D&md5=6a1bdb8c763db89328adc15bc4a29f6f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243402%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DH.%2BT.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DRunnels%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520chymotrypsin-like%2520activity%2520of%2520the%2520immunoproteasome%2520and%2520constitutive%2520proteasome%2520in%2520Waldenstrom%2520macroglobulinemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4051%26epage%3D4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Meng, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, B. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elofsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, C. M.</span><span> </span><span class="NLM_article-title">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">10403</span><span class="NLM_x">–</span> <span class="NLM_lpage">10408</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1073%2Fpnas.96.18.10403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=10468620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10403-10408&author=L.+H.+Mengauthor=R.+Mohanauthor=B.+H.+B.+Kwokauthor=M.+Elofssonauthor=N.+Sinauthor=C.+M.+Crews&title=Epoxomicin%2C+a+potent+and+selective+proteasome+inhibitor%2C+exhibits+in+vivo+antiinflammatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span></div><div class="casAuthors">Meng, Lihao; Mohan, Royce; Kwok, Benjamin H. B.; Elofsson, Mikael; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10403-10408</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The proteasome (multicatalytic protease) regulates cellular processes as diverse as cell cycle progression and NF-κB activation.  The potent antitumor natural product epoxomicin specifically targets the proteasome.  Using biotinylated epoxomicin as a mol. probe showed that epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome.  Enzymic analyses with purified bovine erythrocyte proteasome revealed that epoxomicin potently inhibited primarily the chymotrypsin-like activity.  The trypsin-like and peptidyl-glutamyl peptide hydrolyzing catalytic activities were also inhibited at 100- and 1000-fold slower rates, resp.  In contrast to peptide aldehyde proteasome inhibitors, epoxomicin did not inhibit the nonproteasomal proteases, such as trypsin, chymotrypsin, papain, calpain, and cathepsin B, at concns. up to 50 μM.  Epoxomicin was a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS.  Epoxomicin also effectively inhibited the NF-κB activation in vitro and potently blocked the in vivo inflammation in the murine ear edema assay.  The results define epoxomicin as a novel proteasome inhibitor that may be useful in exploring the role of proteasome in various in vivo and in vitro systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXsPAKuQJ_LVg90H21EOLACvtfcHk0ljQCU1pVnD4ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D&md5=df0b5cdcccf546d60dc4e01d885d554b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10403%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKwok%26aufirst%3DB.%2BH.%2BB.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEpoxomicin%252C%2520a%2520potent%2520and%2520selective%2520proteasome%2520inhibitor%252C%2520exhibits%2520in%2520vivo%2520antiinflammatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D10403%26epage%3D10408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Gulder, T. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. S.</span><span> </span><span class="NLM_article-title">Salinosporamide natural products: potent 20S proteasome inhibitors as promising cancer chemotherapeutics</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">9346</span><span class="NLM_x">–</span> <span class="NLM_lpage">9367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1002%2Fanie.201000728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSls7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=9346-9367&author=T.+A.+M.+Gulderauthor=B.+S.+Moore&title=Salinosporamide+natural+products%3A+potent+20S+proteasome+inhibitors+as+promising+cancer+chemotherapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Salinosporamide Natural Products: Potent 20S Proteasome Inhibitors as Promising Cancer Chemotherapeutics</span></div><div class="casAuthors">Gulder, Tobias A. M.; Moore, Bradley S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">9346-9367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors are rapidly evolving as potent treatment options in cancer therapy.  One of the most promising drug candidates of this type is salinosporamide A from the bacterium Salinispora tropica.  This marine natural product possesses a complex, densely functionalized γ-lactam-β-lactone pharmacophore, which is responsible for its irreversible binding to its target, the β subunit of the 20S proteasome.  Salinosporamide A entered phase I clin. trials for the treatment of multiple myeloma only three years after its discovery.  The strong biol. activity and the challenging structure of this compd. have fueled intense academic and industrial research in recent years, which has led to the development of more than ten syntheses, the elucidation of its biosynthetic pathway, and the generation of promising structure-activity relationships and oncol. data.  Salinosporamide A thus serves as an intriguing example of the successful interplay of modern drug discovery and biomedical research, medicinal chem. and pharmacol., natural product synthesis and anal., as well as biosynthesis and bioengineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFXG8gnUHQLVg90H21EOLACvtfcHk0li7OVN4rlO0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSls7zL&md5=f15906343033c261c03c2b1e750cdbfd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fanie.201000728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201000728%26sid%3Dliteratum%253Aachs%26aulast%3DGulder%26aufirst%3DT.%2BA.%2BM.%26aulast%3DMoore%26aufirst%3DB.%2BS.%26atitle%3DSalinosporamide%2520natural%2520products%253A%2520potent%252020S%2520proteasome%2520inhibitors%2520as%2520promising%2520cancer%2520chemotherapeutics%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D9346%26epage%3D9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlogie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkumar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srkalovic, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limentani, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkein, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A phase 2 study of bortezomib in relapsed, refractory myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1056%2FNEJMoa030288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=12826635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2609-2617&author=P.+G.+Richardsonauthor=B.+Barlogieauthor=J.+Berensonauthor=S.+Singhalauthor=S.+Jagannathauthor=D.+Irwinauthor=S.+V.+Rajkumarauthor=G.+Srkalovicauthor=M.+Alsinaauthor=R.+Alexanianauthor=D.+Siegelauthor=R.+Z.+Orlowskiauthor=D.+Kuterauthor=S.+A.+Limentaniauthor=S.+Leeauthor=T.+Hideshimaauthor=D.-L.+Esseltineauthor=M.+Kauffmanauthor=J.+Adamsauthor=D.+P.+Schenkeinauthor=K.+C.+Anderson&title=A+phase+2+study+of+bortezomib+in+relapsed%2C+refractory+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of bortezomib in relapsed, refractory myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Barlogie, Bart; Berenson, James; Singhal, Seema; Jagannath, Sundar; Irwin, David; Rajkumar, S. Vincent; Srkalovic, Gordan; Alsina, Melissa; Alexanian, Raymond; Siegel, David; Orlowski, Robert Z.; Kuter, David; Limentani, Steven A.; Lee, Stephanie; Hideshima, Teru; Esseltine, Dixie-Lee; Kauffman, Michael; Adams, Julian; Schenkein, David P.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2609-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclin. and phase 1 studies to have antimyeloma activity.  Methods: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently.  Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 wk, followed by 1 wk without treatment, for up to eight cycles (24 wk).  In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen.  The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee.  Results: Of 193 patients who could be evaluated, 92 % had been treated with three or more of the major classes of agents for myeloma, and in 91 %, the myeloma was refractory to the therapy received most recently.  The rate of response to bortezomib was 35 %, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation.  The median overall survival was 16 mo, with a median duration of response of 12 mo.  Grade 3 adverse events included thrombocytopenia (in 28 % of patients), fatigue (in 12 %), peripheral neuropathy (in 12 %), and neutropenia (in 11 %).  Grade 4 events occurred in 14 % of patients.  Conclusions: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvlvB12o1xbVg90H21EOLACvtfcHk0li7OVN4rlO0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D&md5=7d7ef72077f270a421a538557b3bf9ca</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030288%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DBarlogie%26aufirst%3DB.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DRajkumar%26aufirst%3DS.%2BV.%26aulast%3DSrkalovic%26aufirst%3DG.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlexanian%26aufirst%3DR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DKuter%26aufirst%3DD.%26aulast%3DLimentani%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DEsseltine%26aufirst%3DD.-L.%26aulast%3DKauffman%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%2BP.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520phase%25202%2520study%2520of%2520bortezomib%2520in%2520relapsed%252C%2520refractory%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2609%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Shaughnessy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usmani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuck, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanamura, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaissie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waheed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlogie, B.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">3512</span><span class="NLM_x">–</span> <span class="NLM_lpage">3524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=3512-3524&author=J.+D.+Shaughnessyauthor=P.+Quauthor=S.+Usmaniauthor=C.+J.+Heuckauthor=Q.+Zhangauthor=Y.+Zhouauthor=E.+Tianauthor=I.+Hanamuraauthor=F.+van+Rheeauthor=E.+Anaissieauthor=J.+Epsteinauthor=B.+Nairauthor=O.+Stephensauthor=R.+Williamsauthor=S.+Waheedauthor=Y.+Alsayedauthor=J.+Crowleyauthor=B.+Barlogie&title=Pharmacogenomics+of+bortezomib+test-dosing+identifies+hyperexpression+of+proteasome+genes%2C+especially+PSMD4%2C+as+novel+high-risk+feature+in+myeloma+treated+with+total+therapy+3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaughnessy%26aufirst%3DJ.%2BD.%26aulast%3DQu%26aufirst%3DP.%26aulast%3DUsmani%26aufirst%3DS.%26aulast%3DHeuck%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DE.%26aulast%3DHanamura%26aufirst%3DI.%26aulast%3Dvan%2BRhee%26aufirst%3DF.%26aulast%3DAnaissie%26aufirst%3DE.%26aulast%3DEpstein%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DB.%26aulast%3DStephens%26aufirst%3DO.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DWaheed%26aufirst%3DS.%26aulast%3DAlsayed%26aufirst%3DY.%26aulast%3DCrowley%26aufirst%3DJ.%26aulast%3DBarlogie%26aufirst%3DB.%26atitle%3DPharmacogenomics%2520of%2520bortezomib%2520test-dosing%2520identifies%2520hyperexpression%2520of%2520proteasome%2520genes%252C%2520especially%2520PSMD4%252C%2520as%2520novel%2520high-risk%2520feature%2520in%2520myeloma%2520treated%2520with%2520total%2520therapy%25203%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D3512%26epage%3D3524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückrich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driessen, C.</span><span> </span><span class="NLM_article-title">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fsj.leu.2404414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17024115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=84-92&author=M.+Krausauthor=T.+R%C3%BCckrichauthor=M.+Reichauthor=J.+Gogelauthor=A.+Beckauthor=W.+Kammerauthor=C.+R.+Berkersauthor=D.+Burgauthor=H.+Overkleeftauthor=H.+Ovaaauthor=C.+Driessen&title=Activity+patterns+of+proteasome+subunits+reflect+bortezomib+sensitivity+of+hematologic+malignancies+and+are+variable+in+primary+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span></div><div class="casAuthors">Kraus, M.; Rueckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasomal proteolysis relies on the activity of six catalytically active proteasomal subunits (β1, β2, β5, β1i, β2i and β5i).  Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells.  In primary leukemia samples, we obsd. remarkable variability in the amts. of active β1/1i-, β2/2i- and β5/5i-type of subunits, contrasting with their const. protein expression.  Bortezomib inhibited β5- and β1-type, but to a lesser extend β2-type of subunits in live primary cells in vitro and in vivo.  When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual β1/β5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells.  In a panel of cell lines from hematol. malignancies, the ratio between β2-type and (β1+β5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity.  We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematol. malignancies toward bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSfjpxWwrmrVg90H21EOLACvtfcHk0lg6hC_SIsJ3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL&md5=a7e3c1e5930d38f7359836967ee8c066</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404414%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DR%25C3%25BCckrich%26aufirst%3DT.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DKammer%26aufirst%3DW.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DActivity%2520patterns%2520of%2520proteasome%2520subunits%2520reflect%2520bortezomib%2520sensitivity%2520of%2520hematologic%2520malignancies%2520and%2520are%2520variable%2520in%2520primary%2520human%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D84%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+bortezomib+in+complex+with+the+yeast+20S+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lis-GsXZw6Q0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Kale, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. S.</span><span> </span><span class="NLM_article-title">Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1257</span><span class="NLM_x">–</span> <span class="NLM_lpage">1264</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb2002544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1257-1264&author=A.+J.+Kaleauthor=R.+P.+McGlincheyauthor=A.+Lechnerauthor=B.+S.+Moore&title=Bacterial+self-resistance+to+the+natural+proteasome+inhibitor+salinosporamide+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb2002544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb2002544%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DA.%2BJ.%26aulast%3DMcGlinchey%26aufirst%3DR.%2BP.%26aulast%3DLechner%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DB.%2BS.%26atitle%3DBacterial%2520self-resistance%2520to%2520the%2520natural%2520proteasome%2520inhibitor%2520salinosporamide%2520A%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D1257%26epage%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Sharma, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitelman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimke, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoni, R. D.</span><span> </span><span class="NLM_article-title">Peptide transport by the multidrug resistance pump</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">5731</span><span class="NLM_x">–</span> <span class="NLM_lpage">5734</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=5731-5734&author=R.+C.+Sharmaauthor=S.+Inoueauthor=J.+Roitelmanauthor=R.+T.+Schimkeauthor=R.+D.+Simoni&title=Peptide+transport+by+the+multidrug+resistance+pump"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%2BC.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DRoitelman%26aufirst%3DJ.%26aulast%3DSchimke%26aufirst%3DR.%2BT.%26aulast%3DSimoni%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520transport%2520by%2520the%2520multidrug%2520resistance%2520pump%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D5731%26epage%3D5734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">de Jong, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slootstra, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeijers, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puijk, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kool, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broxterman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloen, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span> </span><span class="NLM_article-title">Peptide transport by the multidrug resistance protein MRP1</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2552</span><span class="NLM_x">–</span> <span class="NLM_lpage">2557</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2552-2557&author=M.+C.+de+Jongauthor=J.+W.+Slootstraauthor=G.+L.+Schefferauthor=A.+B.+Schroeijersauthor=W.+C.+Puijkauthor=R.+Dinkelbergauthor=M.+Koolauthor=H.+J.+Broxtermanauthor=R.+H.+Meloenauthor=R.+J.+Scheper&title=Peptide+transport+by+the+multidrug+resistance+protein+MRP1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJong%26aufirst%3DM.%2BC.%26aulast%3DSlootstra%26aufirst%3DJ.%2BW.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DSchroeijers%26aufirst%3DA.%2BB.%26aulast%3DPuijk%26aufirst%3DW.%2BC.%26aulast%3DDinkelberg%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DBroxterman%26aufirst%3DH.%2BJ.%26aulast%3DMeloen%26aufirst%3DR.%2BH.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26atitle%3DPeptide%2520transport%2520by%2520the%2520multidrug%2520resistance%2520protein%2520MRP1%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2552%26epage%3D2557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Minderman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Loughlin, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span> </span><span class="NLM_article-title">Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1007%2Fs00280-006-0367-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17096161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFSkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=245-255&author=H.+Mindermanauthor=Y.+F.+Zhouauthor=K.+L.+O%E2%80%99Loughlinauthor=M.+R.+Baer&title=Bortezomib+activity+and+in+vitro+interactions+with+anthracyclines+and+cytarabine+in+acute+myeloid+leukemia+cells+are+independent+of+multidrug+resistance+mechanisms+and+p53+status"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status</span></div><div class="casAuthors">Minderman, Hans; Zhou, Yunfei; O'Loughlin, Kieran L.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The proteasome inhibitor bortezomib may be effective in combination with cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of targeting aberrantly activated NF-κB in AML stem cells.  We tested whether bortezomib cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells.  We also tested whether bortezomib interactions with cytarabine and anthracyclines are affected by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest.  Bortezomib sensitivity of cell lines overexpressing P-glycoprotein, multidrug resistance protein-1, breast cancer resistance protein and lung resistance protein was studied in the presence and absence of established modulators of these transport proteins.  Drug interactions during simultaneous and sequential exposure to bortezomib and anthracyclines or cytarabine in diverse ratios were evaluated by isobologram and combination index analyses in AML cell lines with wild type and inactive p53 and were correlated with cell cycle perturbations induced by bortezomib.  Of the MDR mechanisms studied, only P-glycoprotein conferred resistance to bortezomib, and resistance was only twofold.  Interactions between bortezomib and anthracyclines and cytarabine changed from antagonistic to additive or synergistic with increasing drug activity levels and were not affected by p53 status.  MDR proteins and p53 do not affect bortezomib cytotoxicity or in vitro interactions with anthracyclines or cytarabine, but these interactions are concn.-dependent, and this concn.-dependency should be considered in the design of combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokBnJbYEVXxbVg90H21EOLACvtfcHk0lis-GsXZw6Q0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFSkt7w%253D&md5=196970b8eea1d8bfef56b1ace3b5439f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0367-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0367-6%26sid%3Dliteratum%253Aachs%26aulast%3DMinderman%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%2BF.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BL.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DBortezomib%2520activity%2520and%2520in%2520vitro%2520interactions%2520with%2520anthracyclines%2520and%2520cytarabine%2520in%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520independent%2520of%2520multidrug%2520resistance%2520mechanisms%2520and%2520p53%2520status%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Verbrugge, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkmans, B. A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Uyl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oerlemans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Heijden, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gruijl, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span> </span><span class="NLM_article-title">Inactivating <i>PSMB5</i> mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+C.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+Van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0lgj-akd20ZQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%2BC.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DVan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Politou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karadimitris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terpos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotsianidis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahemtulla, A.</span><span> </span><span class="NLM_article-title">No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.leukres.2005.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16081156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSiu7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=240-241&author=M.+Politouauthor=A.+Karadimitrisauthor=E.+Terposauthor=I.+Kotsianidisauthor=J.+F.+Apperleyauthor=A.+Rahemtulla&title=No+evidence+of+mutations+of+the+PSMB5+%28beta-5+subunit+of+proteasome%29+in+a+case+of+myeloma+with+clinical+resistance+to+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib</span></div><div class="casAuthors">Politou, Marianna; Karadimitris, Anastasios; Terpos, Evangelos; Kotsianidis, Ioannis; Apperley, Jane F.; Rahemtulla, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-241</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bortezomib is a target-tailored drug for the treatment of refractory/relapsed multiple myeloma.  A 65-yr-old female patient suffering from multiple myeloma developed rapid clin. resistance to bortezomib after initial response.  The initial prompt response and the rapid relapse while on treatment suggested that treatment with bortezomib might be assocd. with the selection of a preexisting, clin. aggressive myeloma clone.  To det. whether the underlying mol. mechanism may include abrogation of bortezomib binding to the beta-5 subunit of the proteasome (i.e., the direct target of bortezomib), acquired mutations in the PSMB5 gene were screened.  No mutations were detected in the gene that was amplified by PCR and sequenced either directly or following cloning.  These results indicate that clin. resistance to bortezomib is not due to mutations of the beta-5 subunit of the proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfGFJr0ySz2bVg90H21EOLACvtfcHk0lgj-akd20ZQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSiu7bE&md5=fa4383dccdba4809d5432385f465311b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2005.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2005.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DPolitou%26aufirst%3DM.%26aulast%3DKaradimitris%26aufirst%3DA.%26aulast%3DTerpos%26aufirst%3DE.%26aulast%3DKotsianidis%26aufirst%3DI.%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DRahemtulla%26aufirst%3DA.%26atitle%3DNo%2520evidence%2520of%2520mutations%2520of%2520the%2520PSMB5%2520%2528beta-5%2520subunit%2520of%2520proteasome%2529%2520in%2520a%2520case%2520of%2520myeloma%2520with%2520clinical%2520resistance%2520to%2520bortezomib%26jtitle%3DLeuk.%2520Res.%26date%3D2006%26volume%3D30%26spage%3D240%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonavida, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J. R.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1111%2Fj.1365-2141.2009.08008.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19958357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFeqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=569-581&author=E.+Sanchezauthor=M.+J.+Liauthor=J.+A.+Steinbergauthor=C.+Wangauthor=J.+Shenauthor=B.+Bonavidaauthor=Z.+W.+Liauthor=H.+M.+Chenauthor=J.+R.+Berenson&title=The+proteasome+inhibitor+CEP-18770+enhances+the+anti-myeloma+activity+of+bortezomib+and+melphalan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan</span></div><div class="casAuthors">Sanchez, Eric; Li, Mingjie; Steinberg, Jeffrey A.; Wang, Cathy; Shen, Jing; Bonavida, Benjamin; Li, Zhi-Wei; Chen, Haiming; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-581</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The anti-multiple myeloma (MM) efficacy of bortezomib has led to the development of other proteasome inhibitors (PI), including CEP-18770 which has shown anti-MM effects in preclin. studies.  However, the efficacy of orally (PO) or i.v. administered CEP-18770 in multiple MM models and in combination with conventional anti-MM therapies has not been evaluated.  Herein, we show that CEP-18770 combined with melphalan or bortezomib induces synergistic inhibition of MM cell viability in vitro.  In MM xenograft models, the addn. of CEP-18770 i.v. to melphalan completely prevented the growth of both melphalan-sensitive and melphalan-resistant tumors.  The combination of CEP-18770 i.v. and bortezomib induced complete regression of bortezomib-sensitive tumors and markedly delayed progression of bortezomib-resistant tumors compared to treatment with either agent alone.  Single agent CEP-18770 PO also showed marked anti-MM effects in these xenograft models.  These studies provide strong preclin. rationale for further development of this novel PI in the treatment of MM as a monotherapy as well as combined with either melphalan or bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6B3jA7lTFFrVg90H21EOLACvtfcHk0lg5WFsRmiaQcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFeqt7w%253D&md5=8c6473468e9face749957b5f449c3f10</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2009.08008.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2009.08008.x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DM.%2BJ.%26aulast%3DSteinberg%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DBonavida%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%2BM.%26aulast%3DBerenson%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520proteasome%2520inhibitor%2520CEP-18770%2520enhances%2520the%2520anti-myeloma%2520activity%2520of%2520bortezomib%2520and%2520melphalan%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D148%26spage%3D569%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Kuhn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strader, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Leeuwen, F. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span> </span><span class="NLM_article-title">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin–proteasome pathway, against preclinical models of multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3281</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3281-3290&author=D.+J.+Kuhnauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=J.+S.+Straderauthor=K.+D.+Shenkauthor=C.+M.+Sunauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=F.+W.+B.+van+Leeuwenauthor=A.+A.+Chanan-Khanauthor=R.+Z.+Orlowski&title=Potent+activity+of+carfilzomib%2C+a+novel%2C+irreversible+inhibitor+of+the+ubiquitin%E2%80%93proteasome+pathway%2C+against+preclinical+models+of+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DStrader%26aufirst%3DJ.%2BS.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%2BB.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DPotent%2520activity%2520of%2520carfilzomib%252C%2520a%2520novel%252C%2520irreversible%2520inhibitor%2520of%2520the%2520ubiquitin%25E2%2580%2593proteasome%2520pathway%252C%2520against%2520preclinical%2520models%2520of%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3281%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciccarelli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4906</span><span class="NLM_x">–</span> <span class="NLM_lpage">4915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4906-4915&author=D.+Chauhanauthor=A.+V.+Singhauthor=M.+Aujayauthor=C.+J.+Kirkauthor=M.+Bandiauthor=B.+Ciccarelliauthor=N.+Rajeauthor=P.+Richardsonauthor=K.+C.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+ONX+0912+triggers+in+vitro+and+in+vivo+cytotoxicity+in+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%2BV.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DCiccarelli%26aufirst%3DB.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520ONX%25200912%2520triggers%2520in%2520vitro%2520and%2520in%2520vivo%2520cytotoxicity%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4906%26epage%3D4915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velankar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.ccr.2005.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16286248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=407-419&author=D.+Chauhanauthor=L.+Catleyauthor=G.+Liauthor=K.+Podarauthor=T.+Hideshimaauthor=M.+Velankarauthor=C.+Mitsiadesauthor=N.+Mitsiadesauthor=H.+Yasuiauthor=A.+Letaiauthor=H.+Ovaaauthor=C.+Berkersauthor=B.+Nicholsonauthor=T.-H.+Chaoauthor=S.+T.+C.+Neuteboomauthor=P.+Richardsonauthor=M.+A.+Palladinoauthor=K.+C.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+induces+apoptosis+in+multiple+myeloma+cells+with+mechanisms+distinct+from+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span></div><div class="casAuthors">Chauhan, Dharminder; Catley, Laurence; Li, Guilan; Podar, Klaus; Hideshima, Teru; Velankar, Mugdha; Mitsiades, Constantine; Mitsiades, Nicolas; Yasui, Hiroshi; Letai, Anthony; Ovaa, Huib; Berkers, Celia; Nicholson, Benjamin; Chao, Ta-Hsiang; Neuteboom, Saskia T. C.; Richardson, Paul; Palladino, Michael A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however, prolonged treatment is assocd. with toxicity and development of drug resistance.  Here, the authors show that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  NPI-0052 is distinct from bortezomib in its chem. structure, effects on proteasome activities, mechanisms of action, and toxicity profile against normal cells.  Moreover, NPI-0052 is orally bioactive.  In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence.  Combining NPI-0052 and bortezomib induces synergistic anti-MM activity.  Our study therefore provides the rationale for clin. protocols evaluating NPI-0052, alone and together with bortezomib, to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaYeiXJugULVg90H21EOLACvtfcHk0lhMGRrgj46PJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF&md5=7bce23ea2891fe8863835c589294b213</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DVelankar%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DT.-H.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520with%2520mechanisms%2520distinct%2520from%2520bortezomib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D407%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Gao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hietaranta, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saluja, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steer, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, M.</span><span> </span><span class="NLM_article-title">Inhibition of ubiquitin–proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=439-448&author=Y.+H.+Gaoauthor=S.+Leckerauthor=M.+J.+Postauthor=A.+J.+Hietarantaauthor=J.+Liauthor=R.+Volkauthor=M.+Liauthor=K.+Satoauthor=A.+K.+Salujaauthor=M.+L.+Steerauthor=A.+L.+Goldbergauthor=M.+Simons&title=Inhibition+of+ubiquitin%E2%80%93proteasome+pathway-mediated+I%CE%BAB%CE%B1+degradation+by+a+naturally+occurring+antibacterial+peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%2BH.%26aulast%3DLecker%26aufirst%3DS.%26aulast%3DPost%26aufirst%3DM.%2BJ.%26aulast%3DHietaranta%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DVolk%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DSaluja%26aufirst%3DA.%2BK.%26aulast%3DSteer%26aufirst%3DM.%2BL.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DSimons%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520ubiquitin%25E2%2580%2593proteasome%2520pathway-mediated%2520I%25CE%25BAB%25CE%25B1%2520degradation%2520by%2520a%2520naturally%2520occurring%2520antibacterial%2520peptide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3D439%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aird, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampton, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, M.</span><span> </span><span class="NLM_article-title">PR39, a peptide regulator of angiogenesis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2F71527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=10613823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1WlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=49-55&author=J.+Liauthor=M.+Postauthor=R.+Volkauthor=Y.+Gaoauthor=M.+Liauthor=C.+Metaisauthor=K.+Satoauthor=J.+Tsaiauthor=W.+Airdauthor=R.+D.+Rosenbergauthor=T.+G.+Hamptonauthor=J.+Liauthor=F.+Sellkeauthor=P.+Carmelietauthor=M.+Simons&title=PR39%2C+a+peptide+regulator+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">PR39, a peptide regulator of angiogenesis</span></div><div class="casAuthors">Li, Jian; Post, Mark; Volk, Rudiger; Gao, Youhe; Li, Min; Metais, Caroline; Sato, Kaori; Tsai, Jo; Aird, William; Rosenberg, Robert D.; Hampton, Thomas G.; Li, Jianyi; Sellke, Frank; Carmeliet, Peter; Simons, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-55</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Although tissue injury and inflammation are considered essential for the induction of angiogenesis, the mol. controls of this cascade are mostly unknown.  Here we show that a macrophage-derived peptide, PR39, inhibited the ubiquitin-proteasome-dependent degrdn. of hypoxia-inducible factor-1α protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice.  For the latter, coronary flow studies demonstrated that PR39-induced angiogenesis resulted in the prodn. of functional blood vessels.  These findings show that PR39 and related compds. can be used as potent inductors of angiogenesis, and that selective inhibition of hypoxia-inducible factor-1α degrdn. may underlie the mechanism of inflammation-induced angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmNGIiFzRNQ7Vg90H21EOLACvtfcHk0lh4td1VzCCNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1WlsA%253D%253D&md5=832cbec47bef0ca645f59de00d2639df</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2F71527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F71527%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DM.%26aulast%3DVolk%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMetais%26aufirst%3DC.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DAird%26aufirst%3DW.%26aulast%3DRosenberg%26aufirst%3DR.%2BD.%26aulast%3DHampton%26aufirst%3DT.%2BG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSellke%26aufirst%3DF.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DSimons%26aufirst%3DM.%26atitle%3DPR39%252C%2520a%2520peptide%2520regulator%2520of%2520angiogenesis%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Sprangers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span> </span><span class="NLM_article-title">TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6727</span><span class="NLM_x">–</span> <span class="NLM_lpage">6734</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi8005913" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=6727-6734&author=R.+Sprangersauthor=X.+M.+Liauthor=X.+L.+Maoauthor=J.+L.+Rubinsteinauthor=A.+D.+Schimmerauthor=L.+E.+Kay&title=TROSY-based+NMR+evidence+for+a+novel+class+of+20S+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fbi8005913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8005913%26sid%3Dliteratum%253Aachs%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKay%26aufirst%3DL.%2BE.%26atitle%3DTROSY-based%2520NMR%2520evidence%2520for%2520a%2520novel%2520class%2520of%252020S%2520proteasome%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D6727%26epage%3D6734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprangers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbrugge, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adomat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Religa, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">Effect of noncompetitive proteasome inhibition on bortezomib resistance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1093%2Fjnci%2Fdjq198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20505154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1069-1082&author=X.+M.+Liauthor=T.+E.+Woodauthor=R.+Sprangersauthor=G.+Jansenauthor=N.+E.+Frankeauthor=X.+L.+Maoauthor=X.+M.+Wangauthor=Y.+Zhangauthor=S.+E.+Verbruggeauthor=H.+Adomatauthor=Z.+H.+Liauthor=S.+Trudelauthor=C.+Chenauthor=T.+L.+Religaauthor=N.+Jamalauthor=H.+Messnerauthor=J.+Cloosauthor=D.+R.+Roseauthor=A.+Navonauthor=E.+Gunsauthor=R.+A.+Bateyauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Effect+of+noncompetitive+proteasome+inhibition+on+bortezomib+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance</span></div><div class="casAuthors">Li, Xiaoming; Wood, Tabitha E.; Sprangers, Remco; Jansen, Gerrit; Franke, Niels E.; Mao, Xinliang; Wang, Xiaoming; Zhang, Yi; Verbrugge, Sue Ellen; Adomat, Hans; Li, Zhi Hua; Trudel, Suzanne; Chen, Christine; Religa, Tomasz L.; Jamal, Nazir; Messner, Hans; Cloos, Jacqueline; Rose, David R.; Navon, Ami; Guns, Emma; Batey, Robert A.; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1069-1082</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Bortezomib and the other proteasome inhibitors that are currently under clin. investigation bind to the catalytic sites of proteasomes and are competitive inhibitors.  We hypothesized that proteasome inhibitors that act through a noncompetitive mechanism might overcome some forms of bortezomib resistance.  Methods: 5-amino-8-hydroxyquinoline (5AHQ) was identified through a screen of a 27-compd. chem. library based on the quinoline pharmacophore to identify proteasome inhibitors.  Inhibition of proteasome activity by 5AHQ was tested by measuring 7-amino-4-methylcoumarin (AMC) release from the proteasome substrate Suc-LLVY-AMC in intact human and mouse leukemia and myeloma cells and in tumor cell protein exts.  Cytotoxicity was assessed in 5AHQ-treated cell lines and primary cells from myeloma and leukemia patients using AlamarBlue fluorescence and MTS assays, trypan blue staining, and annexin V staining. 5AHQ-proteasome interaction was assessed by NMR. 5AHQ efficacy was evaluated in three leukemia xenograft mouse models (9-10 mice per group per model).  All statistical tests were two-sided.  Results 5AHQ inhibited the proteasome when added to cell exts. and intact cells (the mean concn. inhibiting 50% [IC50] of AMC release in intact cells ranged from 0.57 to 5.03 μM), induced cell death in intact cells from leukemia and myeloma cell lines (mean IC50 values for cell growth ranged from 0.94 to 3.85 μM), and preferentially induced cell death in primary myeloma and leukemia cells compared with normal hematopoietic cells.  5AHQ was equally cytotoxic to human myelomonocytic THP1 cells and to THP1/BTZ500 cells, which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of their overexpression and mutation of the bortezomib-binding β5 proteasome subunit (mean IC50 for cell death in the absence of bortezomib, wild-type THP1: 3.7 μM, 95% confidence interval = 3.4 to 4.0 μM; THP1/BTZ500: 6.6 μM, 95% confidence interval = 5.9 to 7.5 μM).  5AHQ interacted with the α subunits of the 20S proteasome at noncatalytic sites.  Orally administered 5AHQ inhibited tumor growth in all three mouse models of leukemia without overt toxicity (eg, OCI-AML2 model, median tumor wt. [interquartile range], 5AHQ vs control: 95.7 mg [61.4-163.5 mg] vs 247.2 mg [189.4-296.2 mg], P = .002).  Conclusions: 5AHQ is a noncompetitive proteasome inhibitor that is cytotoxic to myeloma and leukemia cells in vitro and inhibits xenograft tumor growth in vivo. 5AHQ can overcome some forms of bortezomib resistance in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4TcOS6iYs7Vg90H21EOLACvtfcHk0lh4td1VzCCNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D&md5=45a19957639165d2673f2dc72a0387a4</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjq198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjq198%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAdomat%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DJamal%26aufirst%3DN.%26aulast%3DMessner%26aufirst%3DH.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DD.%2BR.%26aulast%3DNavon%26aufirst%3DA.%26aulast%3DGuns%26aufirst%3DE.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DEffect%2520of%2520noncompetitive%2520proteasome%2520inhibition%2520on%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2010%26volume%3D102%26spage%3D1069%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Edelmann, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases</span> <span class="citation_source-journal">Expert Rev. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">e35</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=e35&author=M.+J.+Edelmannauthor=B.+Nicholsonauthor=B.+M.+Kessler&title=Pharmacological+targets+in+the+ubiquitin+system+offer+new+ways+of+treating+cancer%2C+neurodegenerative+disorders+and+infectious+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdelmann%26aufirst%3DM.%2BJ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DPharmacological%2520targets%2520in%2520the%2520ubiquitin%2520system%2520offer%2520new%2520ways%2520of%2520treating%2520cancer%252C%2520neurodegenerative%2520disorders%2520and%2520infectious%2520diseases%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3De35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>, version <span class="NLM_edition">1.5.0.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 57 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wenhu Zhan, Joseph Visone, Tierra Ouellette, Jacob C. Harris, Rong Wang, Hao Zhang, Pradeep K. Singh, John Ginn, George Sukenick, Tzu-Tshin Wong, Judith I. Okoro, Ryan M. Scales, Patrick K. Tumwebaze, Philip J. Rosenthal, Björn F. C. Kafsack, Roland A. Cooper, Peter T. Meinke, Laura A. Kirkman, <span class="NLM_string-name hlFld-ContribAuthor">Gang Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6137-6145. <a href="https://doi.org/10.1021/acs.jmedchem.9b00363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00363%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DImprovement%252Bof%252BAsparagine%252BEthylenediamines%252Bas%252BAnti-malarial%252BPlasmodium-Selective%252BProteasome%252BInhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D20062019%26date%3D09062019%26volume%3D62%26issue%3D13%26spage%3D6137%26epage%3D6145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Darci J.  Trader</span>, <span class="hlFld-ContribAuthor ">Scott  Simanski</span>, and <span class="hlFld-ContribAuthor ">Thomas  Kodadek</span>  . </span><span class="cited-content_cbyCitation_article-title">A Reversible and Highly Selective Inhibitor of the Proteasomal Ubiquitin Receptor Rpn13 Is Toxic to Multiple Myeloma Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (19)
                                     , 6312-6319. <a href="https://doi.org/10.1021/jacs.5b02069" title="DOI URL">https://doi.org/10.1021/jacs.5b02069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b02069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b02069%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BReversible%252Band%252BHighly%252BSelective%252BInhibitor%252Bof%252Bthe%252BProteasomal%252BUbiquitin%252BReceptor%252BRpn13%252BIs%252BToxic%252Bto%252BMultiple%252BMyeloma%252BCells%26aulast%3DTrader%26aufirst%3DDarci%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D25022015%26date%3D08052015%26date%3D20052015%26date%3D27042015%26volume%3D137%26issue%3D19%26spage%3D6312%26epage%3D6319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph  Scholz</span>, <span class="hlFld-ContribAuthor ">Sabine  Knorr</span>, <span class="hlFld-ContribAuthor ">Kay  Hamacher</span>, and <span class="hlFld-ContribAuthor ">Boris  Schmidt</span>  . </span><span class="cited-content_cbyCitation_article-title">DOCKTITE—A Highly Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening in the Molecular Operating Environment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (2)
                                     , 398-406. <a href="https://doi.org/10.1021/ci500681r" title="DOI URL">https://doi.org/10.1021/ci500681r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500681r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500681r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDOCKTITE%2525E2%252580%252594A%252BHighly%252BVersatile%252BStep-by-Step%252BWorkflow%252Bfor%252BCovalent%252BDocking%252Band%252BVirtual%252BScreening%252Bin%252Bthe%252BMolecular%252BOperating%252BEnvironment%26aulast%3DScholz%26aufirst%3DChristoph%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D12112014%26date%3D16012015%26date%3D23022015%26date%3D26122014%26volume%3D55%26issue%3D2%26spage%3D398%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melanie A.  Priestman</span>, <span class="hlFld-ContribAuthor ">Qunzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Finith E.  Jernigan</span>, <span class="hlFld-ContribAuthor ">Ruma  Chowdhury</span>, <span class="hlFld-ContribAuthor ">Marion  Schmidt</span>, and <span class="hlFld-ContribAuthor ">David S.  Lawrence</span>  . </span><span class="cited-content_cbyCitation_article-title">Multicolor Monitoring of the Proteasome’s Catalytic Signature. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2015,</strong> <em>10 </em>
                                    (2)
                                     , 433-440. <a href="https://doi.org/10.1021/cb5007322" title="DOI URL">https://doi.org/10.1021/cb5007322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb5007322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb5007322%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DMulticolor%252BMonitoring%252Bof%252Bthe%252BProteasome%2525E2%252580%252599s%252BCatalytic%252BSignature%26aulast%3DPriestman%26aufirst%3DMelanie%2BA.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D12092014%26date%3D24102014%26date%3D07112014%26date%3D20022015%26date%3D27102014%26volume%3D10%26issue%3D2%26spage%3D433%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabrina  Touchet</span>, <span class="hlFld-ContribAuthor ">Aurélie  Macé</span>, <span class="hlFld-ContribAuthor ">Thierry  Roisnel</span>, <span class="hlFld-ContribAuthor ">François  Carreaux</span>, <span class="hlFld-ContribAuthor ">Alexandre  Bouillon</span>, and <span class="hlFld-ContribAuthor ">Bertrand  Carboni</span>  . </span><span class="cited-content_cbyCitation_article-title">[3,3]-Sigmatropic Rearrangement of Boronated Allylcyanates: A New Route to α-Aminoboronate Derivatives and Trisubstituted Tetrahydrofurans. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2013,</strong> <em>15 </em>
                                    (11)
                                     , 2712-2715. <a href="https://doi.org/10.1021/ol401016x" title="DOI URL">https://doi.org/10.1021/ol401016x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol401016x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol401016x%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D%25255B3%25252C3%25255D-Sigmatropic%252BRearrangement%252Bof%252BBoronated%252BAllylcyanates%25253A%252BA%252BNew%252BRoute%252Bto%252B%2525CE%2525B1-Aminoboronate%252BDerivatives%252Band%252BTrisubstituted%252BTetrahydrofurans%26aulast%3DTouchet%26aufirst%3DSabrina%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D12042013%26date%3D21052013%26date%3D07062013%26volume%3D15%26issue%3D11%26spage%3D2712%26epage%3D2715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Margot S.F.  Roeten</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Zinia J.  Kwidama</span>, <span class="hlFld-ContribAuthor ">Giovanna  ter Huizen</span>, <span class="hlFld-ContribAuthor ">Wouter H.  Segerink</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan J.L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 665. <a href="https://doi.org/10.3390/cells10030665" title="DOI URL">https://doi.org/10.3390/cells10030665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10030665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10030665%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DPre-Clinical%252BEvaluation%252Bof%252Bthe%252BProteasome%252BInhibitor%252BIxazomib%252Bagainst%252BBortezomib-Resistant%252BLeukemia%252BCells%252Band%252BPrimary%252BAcute%252BLeukemia%252BCells%26aulast%3DRoeten%26aufirst%3DMargot%2BS.F.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick  Roth</span>, <span class="hlFld-ContribAuthor ">Warren P.  Mason</span>, <span class="hlFld-ContribAuthor ">Paul G.  Richardson</span>, <span class="hlFld-ContribAuthor ">Michael  Weller</span>. </span><span class="cited-content_cbyCitation_article-title">Proteasome inhibition for the treatment of glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (10)
                                     , 1133-1141. <a href="https://doi.org/10.1080/13543784.2020.1803827" title="DOI URL">https://doi.org/10.1080/13543784.2020.1803827</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1803827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1803827%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DProteasome%252Binhibition%252Bfor%252Bthe%252Btreatment%252Bof%252Bglioblastoma%26aulast%3DRoth%26aufirst%3DPatrick%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D10%26spage%3D1133%26epage%3D1141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parthasaradhireddy  Tanguturi</span>, <span class="hlFld-ContribAuthor ">Kye-Seong  Kim</span>, <span class="hlFld-ContribAuthor ">Suresh  Ramakrishna</span>. </span><span class="cited-content_cbyCitation_article-title">The role of deubiquitinating enzymes in cancer drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2020,</strong> <em>85 </em>
                                    (4)
                                     , 627-639. <a href="https://doi.org/10.1007/s00280-020-04046-8" title="DOI URL">https://doi.org/10.1007/s00280-020-04046-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-020-04046-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-020-04046-8%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DThe%252Brole%252Bof%252Bdeubiquitinating%252Benzymes%252Bin%252Bcancer%252Bdrug%252Bresistance%26aulast%3DTanguturi%26aufirst%3DParthasaradhireddy%26date%3D2020%26date%3D2020%26volume%3D85%26issue%3D4%26spage%3D627%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silpa  Narayanan</span>, <span class="hlFld-ContribAuthor ">Chao-Yun  Cai</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Hui-Qin  Guo</span>, <span class="hlFld-ContribAuthor ">Qingbin  Cui</span>, <span class="hlFld-ContribAuthor ">Liuya  Wei</span>, <span class="hlFld-ContribAuthor ">Juan-Juan  Huang</span>, <span class="hlFld-ContribAuthor ">Charles R.  Ashby</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2020,</strong> <em>48 </em>, 100663. <a href="https://doi.org/10.1016/j.drup.2019.100663" title="DOI URL">https://doi.org/10.1016/j.drup.2019.100663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2019.100663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2019.100663%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DTargeting%252Bthe%252Bubiquitin-proteasome%252Bpathway%252Bto%252Bovercome%252Banti-cancer%252Bdrug%252Bresistance%26aulast%3DNarayanan%26aufirst%3DSilpa%26date%3D2020%26volume%3D48%26spage%3D100663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guedes</span>, <span class="hlFld-ContribAuthor ">Aniceto</span>, <span class="hlFld-ContribAuthor ">Andrade</span>, <span class="hlFld-ContribAuthor ">Salvador</span>, <span class="hlFld-ContribAuthor ">Guedes</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (21)
                                     , 5326. <a href="https://doi.org/10.3390/ijms20215326" title="DOI URL">https://doi.org/10.3390/ijms20215326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20215326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20215326%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DChemical%252BPatterns%252Bof%252BProteasome%252BInhibitors%25253A%252BLessons%252BLearned%252Bfrom%252BTwo%252BDecades%252Bof%252BDrug%252BDesign%26aulast%3DGuedes%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D21%26spage%3D5326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arjan  Mofers</span>, <span class="hlFld-ContribAuthor ">Paola  Perego</span>, <span class="hlFld-ContribAuthor ">Karthik  Selvaraju</span>, <span class="hlFld-ContribAuthor ">Laura  Gatti</span>, <span class="hlFld-ContribAuthor ">Joachim  Gullbo</span>, <span class="hlFld-ContribAuthor ">Stig  Linder</span>, <span class="hlFld-ContribAuthor ">Padraig  D'Arcy</span>, . </span><span class="cited-content_cbyCitation_article-title">Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2019,</strong> <em>14 </em>
                                    (10)
                                     , e0223807. <a href="https://doi.org/10.1371/journal.pone.0223807" title="DOI URL">https://doi.org/10.1371/journal.pone.0223807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0223807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0223807%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DAnalysis%252Bof%252Bdeterminants%252Bfor%252Bin%252Bvitro%252Bresistance%252Bto%252Bthe%252Bsmall%252Bmolecule%252Bdeubiquitinase%252Binhibitor%252Bb-AP15%26aulast%3DMofers%26aufirst%3DArjan%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3De0223807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexey V.  Morozov</span>, <span class="hlFld-ContribAuthor ">Vadim L.  Karpov</span>. </span><span class="cited-content_cbyCitation_article-title">Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00761" title="DOI URL">https://doi.org/10.3389/fonc.2019.00761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00761%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DProteasomes%252Band%252BSeveral%252BAspects%252Bof%252BTheir%252BHeterogeneity%252BRelevant%252Bto%252BCancer%26aulast%3DMorozov%26aufirst%3DAlexey%2BV.%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellis C.  O’Neill</span>, <span class="hlFld-ContribAuthor ">Michelle  Schorn</span>, <span class="hlFld-ContribAuthor ">Charles B.  Larson</span>, <span class="hlFld-ContribAuthor ">Natalie  Millán-Aguiñaga</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted antibiotic discovery through biosynthesis-associated resistance determinants: target directed genome mining. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Microbiology</span><span> <strong>2019,</strong> <em>45 </em>
                                    (3)
                                     , 255-277. <a href="https://doi.org/10.1080/1040841X.2019.1590307" title="DOI URL">https://doi.org/10.1080/1040841X.2019.1590307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1040841X.2019.1590307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1040841X.2019.1590307%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Microbiology%26atitle%3DTargeted%252Bantibiotic%252Bdiscovery%252Bthrough%252Bbiosynthesis-associated%252Bresistance%252Bdeterminants%25253A%252Btarget%252Bdirected%252Bgenome%252Bmining%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DEllis%2BC.%26date%3D2019%26date%3D2019%26volume%3D45%26issue%3D3%26spage%3D255%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wai Kwan  Tang</span>, <span class="hlFld-ContribAuthor ">Taivan  Odzorig</span>, <span class="hlFld-ContribAuthor ">Whitney  Jin</span>, <span class="hlFld-ContribAuthor ">Di  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2019,</strong> <em>95 </em>
                                    (3)
                                     , 286-293. <a href="https://doi.org/10.1124/mol.118.114256" title="DOI URL">https://doi.org/10.1124/mol.118.114256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/mol.118.114256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmol.118.114256%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DStructural%252BBasis%252Bof%252Bp97%252BInhibition%252Bby%252Bthe%252BSite-Selective%252BAnticancer%252BCompound%252BCB-5083%26aulast%3DTang%26aufirst%3DWai%2BKwan%26date%3D2019%26date%3D2018%26volume%3D95%26issue%3D3%26spage%3D286%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saumitra  Sengupta</span>, <span class="hlFld-ContribAuthor ">Goverdhan  Mehta</span>. </span><span class="cited-content_cbyCitation_article-title">Non-peptidic natural products as ubiquitin-proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (7)
                                     , 817-853. <a href="https://doi.org/10.1016/j.tet.2018.12.012" title="DOI URL">https://doi.org/10.1016/j.tet.2018.12.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.12.012%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DNon-peptidic%252Bnatural%252Bproducts%252Bas%252Bubiquitin-proteasome%252Binhibitors%26aulast%3DSengupta%26aufirst%3DSaumitra%26date%3D2019%26volume%3D75%26issue%3D7%26spage%3D817%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Longhui  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 109-124. <a href="https://doi.org/10.1016/B978-0-12-816435-8.00008-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-816435-8.00008-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816435-8.00008-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816435-8.00008-0%26sid%3Dliteratum%253Aachs%26atitle%3DBruton%252527s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitors%252Bas%252BSensitizing%252BAgents%252Bfor%252BCancer%252BChemotherapy%26aulast%3DZhang%26aufirst%3DHui%26date%3D2019%26spage%3D109%26epage%3D124%26pub%3DElsevier%26atitle%3DProtein%252BKinase%252BInhibitors%252Bas%252BSensitizing%252BAgents%252Bfor%252BChemotherapy%26date%3D2019%26volume%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjie  Zhang</span>, <span class="hlFld-ContribAuthor ">Heyuan  Bai</span>, <span class="hlFld-ContribAuthor ">Liqiang  Han</span>, <span class="hlFld-ContribAuthor ">Han  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Xu</span>, <span class="hlFld-ContribAuthor ">Jingrong  Cui</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Zemei  Ge</span>, <span class="hlFld-ContribAuthor ">Runtao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (14)
                                     , 2459-2464. <a href="https://doi.org/10.1016/j.bmcl.2018.06.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bcurcumin%252Bderivatives%252Bmodified%252Bwith%252B%2525CE%2525B1-amino%252Bboronic%252Bacid%252Bas%252Bproteasome%252Binhibitors%26aulast%3DZhang%26aufirst%3DWenjie%26date%3D2018%26volume%3D28%26issue%3D14%26spage%3D2459%26epage%3D2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji Eun  Park</span>, <span class="hlFld-ContribAuthor ">Zachary  Miller</span>, <span class="hlFld-ContribAuthor ">Yearin  Jun</span>, <span class="hlFld-ContribAuthor ">Wooin  Lee</span>, <span class="hlFld-ContribAuthor ">Kyung Bo  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Next-generation proteasome inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Translational Research</span><span> <strong>2018,</strong> <em>198 </em>, 1-16. <a href="https://doi.org/10.1016/j.trsl.2018.03.002" title="DOI URL">https://doi.org/10.1016/j.trsl.2018.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trsl.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trsl.2018.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Research%26atitle%3DNext-generation%252Bproteasome%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DPark%26aufirst%3DJi%2BEun%26date%3D2018%26volume%3D198%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ali  Dehghanifard</span>, <span class="hlFld-ContribAuthor ">Saeid  Kaviani</span>, <span class="hlFld-ContribAuthor ">Saeid  Abroun</span>, <span class="hlFld-ContribAuthor ">Mahshad  Mehdizadeh</span>, <span class="hlFld-ContribAuthor ">Sajedeh  Saiedi</span>, <span class="hlFld-ContribAuthor ">Amirhosein  Maali</span>, <span class="hlFld-ContribAuthor ">Sasan  Ghaffari</span>, <span class="hlFld-ContribAuthor ">Mehdi  Azad</span>. </span><span class="cited-content_cbyCitation_article-title">Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lymphoma Myeloma and Leukemia</span><span> <strong>2018,</strong> <em>18 </em>
                                    (5)
                                     , 311-320. <a href="https://doi.org/10.1016/j.clml.2018.03.007" title="DOI URL">https://doi.org/10.1016/j.clml.2018.03.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clml.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clml.2018.03.007%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lymphoma%2520Myeloma%2520and%2520Leukemia%26atitle%3DVarious%252BSignaling%252BPathways%252Bin%252BMultiple%252BMyeloma%252BCells%252Band%252BEffects%252Bof%252BTreatment%252Bon%252BThese%252BPathways%26aulast%3DDehghanifard%26aufirst%3DAli%26date%3D2018%26volume%3D18%26issue%3D5%26spage%3D311%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emilia  Scalzulli</span>, <span class="hlFld-ContribAuthor ">Sara  Grammatico</span>, <span class="hlFld-ContribAuthor ">Federico  Vozella</span>, <span class="hlFld-ContribAuthor ">Maria Teresa  Petrucci</span>. </span><span class="cited-content_cbyCitation_article-title">Proteasome inhibitors for the treatment of multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2018,</strong> <em>19 </em>
                                    (4)
                                     , 375-386. <a href="https://doi.org/10.1080/14656566.2018.1441287" title="DOI URL">https://doi.org/10.1080/14656566.2018.1441287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1441287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1441287%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DProteasome%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bmultiple%252Bmyeloma%26aulast%3DScalzulli%26aufirst%3DEmilia%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D4%26spage%3D375%26epage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>, <span class="hlFld-ContribAuthor ">Margot SF  Roeten</span>, <span class="hlFld-ContribAuthor ">Niels E  Franke</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan JL  Kaspers</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>. </span><span class="cited-content_cbyCitation_article-title">(Immuno)proteasomes as therapeutic target in acute leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancer and Metastasis Reviews</span><span> <strong>2017,</strong> <em>36 </em>
                                    (4)
                                     , 599-615. <a href="https://doi.org/10.1007/s10555-017-9699-4" title="DOI URL">https://doi.org/10.1007/s10555-017-9699-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10555-017-9699-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10555-017-9699-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520and%2520Metastasis%2520Reviews%26atitle%3D%252528Immuno%252529proteasomes%252Bas%252Btherapeutic%252Btarget%252Bin%252Bacute%252Bleukemia%26aulast%3DCloos%26aufirst%3DJacqueline%26date%3D2017%26date%3D2017%26volume%3D36%26issue%3D4%26spage%3D599%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Domenico  Franco</span>, <span class="hlFld-ContribAuthor ">Sebastiano  Trusso</span>, <span class="hlFld-ContribAuthor ">Enza  Fazio</span>, <span class="hlFld-ContribAuthor ">Alessandro  Allegra</span>, <span class="hlFld-ContribAuthor ">Caterina  Musolino</span>, <span class="hlFld-ContribAuthor ">Antonio  Speciale</span>, <span class="hlFld-ContribAuthor ">Francesco  Cimino</span>, <span class="hlFld-ContribAuthor ">Antonella  Saija</span>, <span class="hlFld-ContribAuthor ">Fortunato  Neri</span>, <span class="hlFld-ContribAuthor ">Marco S.  Nicolò</span>, <span class="hlFld-ContribAuthor ">Salvatore P.P.  Guglielmino</span>. </span><span class="cited-content_cbyCitation_article-title">Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2017,</strong> <em>187 </em>, 15-22. <a href="https://doi.org/10.1016/j.saa.2017.06.020" title="DOI URL">https://doi.org/10.1016/j.saa.2017.06.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2017.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2017.06.020%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DRaman%252Bspectroscopy%252Bdifferentiates%252Bbetween%252Bsensitive%252Band%252Bresistant%252Bmultiple%252Bmyeloma%252Bcell%252Blines%26aulast%3DFranco%26aufirst%3DDomenico%26date%3D2017%26volume%3D187%26spage%3D15%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong Min  Lee</span>, <span class="hlFld-ContribAuthor ">In Young  Kim</span>, <span class="hlFld-ContribAuthor ">Min Ji  Seo</span>, <span class="hlFld-ContribAuthor ">Mi Ri  Kwon</span>, <span class="hlFld-ContribAuthor ">Kyeong Sook  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. </span><span class="cited-content_cbyCitation_journal-name">Experimental & Molecular Medicine</span><span> <strong>2017,</strong> <em>49 </em>
                                    (8)
                                     , e365-e365. <a href="https://doi.org/10.1038/emm.2017.112" title="DOI URL">https://doi.org/10.1038/emm.2017.112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/emm.2017.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Femm.2017.112%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520%2526%2520Molecular%2520Medicine%26atitle%3DNutlin-3%252Benhances%252Bthe%252Bbortezomib%252Bsensitivity%252Bof%252Bp53-defective%252Bcancer%252Bcells%252Bby%252Binducing%252Bparaptosis%26aulast%3DLee%26aufirst%3DDong%2BMin%26date%3D2017%26date%3D2017%26volume%3D49%26issue%3D8%26spage%3De365%26epage%3De365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix  Wolf</span>, <span class="hlFld-ContribAuthor ">Leonard  Kaysser</span>. </span><span class="cited-content_cbyCitation_article-title">Genombasierte Suche nach Protease-Inhibitoren aus bakteriellen Quellen. </span><span class="cited-content_cbyCitation_journal-name">BIOspektrum</span><span> <strong>2017,</strong> <em>23 </em>
                                    (1)
                                     , 41-45. <a href="https://doi.org/10.1007/s12268-017-0765-9" title="DOI URL">https://doi.org/10.1007/s12268-017-0765-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12268-017-0765-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12268-017-0765-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBIOspektrum%26atitle%3DGenombasierte%252BSuche%252Bnach%252BProtease-Inhibitoren%252Baus%252Bbakteriellen%252BQuellen%26aulast%3DWolf%26aufirst%3DFelix%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D1%26spage%3D41%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Tsvetkov</span>, <span class="hlFld-ContribAuthor ">Ethan  Sokol</span>, <span class="hlFld-ContribAuthor ">Dexter  Jin</span>, <span class="hlFld-ContribAuthor ">Zarina  Brune</span>, <span class="hlFld-ContribAuthor ">Prathapan  Thiru</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Ghandi</span>, <span class="hlFld-ContribAuthor ">Levi A.  Garraway</span>, <span class="hlFld-ContribAuthor ">Piyush B.  Gupta</span>, <span class="hlFld-ContribAuthor ">Sandro  Santagata</span>, <span class="hlFld-ContribAuthor ">Luke  Whitesell</span>, <span class="hlFld-ContribAuthor ">Susan  Lindquist</span>. </span><span class="cited-content_cbyCitation_article-title">Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2017,</strong> <em>114 </em>
                                    (2)
                                     , 382-387. <a href="https://doi.org/10.1073/pnas.1619067114" title="DOI URL">https://doi.org/10.1073/pnas.1619067114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1619067114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1619067114%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DSuppression%252Bof%252B19S%252Bproteasome%252Bsubunits%252Bmarks%252Bemergence%252Bof%252Ban%252Baltered%252Bcell%252Bstate%252Bin%252Bdiverse%252Bcancers%26aulast%3DTsvetkov%26aufirst%3DPeter%26date%3D2017%26date%3D2016%26volume%3D114%26issue%3D2%26spage%3D382%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Elisa  Pasqua</span>, <span class="hlFld-ContribAuthor ">B.  Wilding</span>, <span class="hlFld-ContribAuthor ">M.D.  Cheeseman</span>, <span class="hlFld-ContribAuthor ">K.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 202-280. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12395-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12395-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12395-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12395-9%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BProtein%252BSynthesis%25252C%252BFolding%25252C%252Band%252BDegradation%252BPathways%252Bin%252BCancer%26aulast%3DPasqua%26aufirst%3DA%2BElisa%26date%3D2017%26spage%3D202%26epage%3D280%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryam  Delforoush</span>, <span class="hlFld-ContribAuthor ">Mattias  Berglund</span>, <span class="hlFld-ContribAuthor ">Per-Henrik  Edqvist</span>, <span class="hlFld-ContribAuthor ">Christer  Sundström</span>, <span class="hlFld-ContribAuthor ">Joachim  Gullbo</span>, <span class="hlFld-ContribAuthor ">Gunilla  Enblad</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Haematology</span><span> <strong>2017,</strong> <em>98 </em>
                                    (1)
                                     , 52-56. <a href="https://doi.org/10.1111/ejh.12784" title="DOI URL">https://doi.org/10.1111/ejh.12784</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ejh.12784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fejh.12784%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Haematology%26atitle%3DExpression%252Bof%252Bpossible%252Btargets%252Bfor%252Bnew%252Bproteasome%252Binhibitors%252Bin%252Bdiffuse%252Blarge%252BB-cell%252Blymphoma%26aulast%3DDelforoush%26aufirst%3DMaryam%26date%3D2017%26date%3D2016%26volume%3D98%26issue%3D1%26spage%3D52%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niels E.  Franke</span>, <span class="hlFld-ContribAuthor ">Gertjan L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Floortje L.  Kessler</span>, <span class="hlFld-ContribAuthor ">Pino J.  Poddighe</span>, <span class="hlFld-ContribAuthor ">Jeroen  Kole</span>, <span class="hlFld-ContribAuthor ">Serge J.  Smeets</span>, <span class="hlFld-ContribAuthor ">Bauke  Ylstra</span>, <span class="hlFld-ContribAuthor ">Chonglei  Bi</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Terzah M.  Horton</span>, <span class="hlFld-ContribAuthor ">Rene X.  Menezes</span>, <span class="hlFld-ContribAuthor ">Renée J.P.  Musters</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (46)
                                     , 74779-74796. <a href="https://doi.org/10.18632/oncotarget.11340" title="DOI URL">https://doi.org/10.18632/oncotarget.11340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.11340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.11340%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DExocytosis%252Bof%252Bpolyubiquitinated%252Bproteins%252Bin%252Bbortezomib-resistant%252Bleukemia%252Bcells%25253A%252Ba%252Brole%252Bfor%252BMARCKS%252Bin%252Bacquired%252Bresistance%252Bto%252Bproteasome%252Binhibitors%26aulast%3DFranke%26aufirst%3DNiels%2BE.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D46%26spage%3D74779%26epage%3D74796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandre  Rouette</span>, <span class="hlFld-ContribAuthor ">Assya  Trofimov</span>, <span class="hlFld-ContribAuthor ">David  Haberl</span>, <span class="hlFld-ContribAuthor ">Geneviève  Boucher</span>, <span class="hlFld-ContribAuthor ">Vincent-Philippe  Lavallée</span>, <span class="hlFld-ContribAuthor ">Giovanni  D’Angelo</span>, <span class="hlFld-ContribAuthor ">Josée  Hébert</span>, <span class="hlFld-ContribAuthor ">Guy  Sauvageau</span>, <span class="hlFld-ContribAuthor ">Sébastien  Lemieux</span>, <span class="hlFld-ContribAuthor ">Claude  Perreault</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of immunoproteasome genes is regulated by cell-intrinsic and –extrinsic factors in human cancers. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep34019" title="DOI URL">https://doi.org/10.1038/srep34019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep34019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep34019%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DExpression%252Bof%252Bimmunoproteasome%252Bgenes%252Bis%252Bregulated%252Bby%252Bcell-intrinsic%252Band%252B%2525E2%252580%252593extrinsic%252Bfactors%252Bin%252Bhuman%252Bcancers%26aulast%3DRouette%26aufirst%3DAlexandre%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nancy  Levin</span>, <span class="hlFld-ContribAuthor ">Andrew  Spencer</span>, <span class="hlFld-ContribAuthor ">Simon J.  Harrison</span>, <span class="hlFld-ContribAuthor ">Dharminder  Chauhan</span>, <span class="hlFld-ContribAuthor ">Francis J.  Burrows</span>, <span class="hlFld-ContribAuthor ">Kenneth C.  Anderson</span>, <span class="hlFld-ContribAuthor ">Steven D.  Reich</span>, <span class="hlFld-ContribAuthor ">Paul G.  Richardson</span>, <span class="hlFld-ContribAuthor ">Mohit  Trikha</span>. </span><span class="cited-content_cbyCitation_article-title">Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Haematology</span><span> <strong>2016,</strong> <em>174 </em>
                                    (5)
                                     , 711-720. <a href="https://doi.org/10.1111/bjh.14113" title="DOI URL">https://doi.org/10.1111/bjh.14113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bjh.14113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbjh.14113%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Haematology%26atitle%3DMarizomib%252Birreversibly%252Binhibits%252Bproteasome%252Bto%252Bovercome%252Bcompensatory%252Bhyperactivation%252Bin%252Bmultiple%252Bmyeloma%252Band%252Bsolid%252Btumour%252Bpatients%26aulast%3DLevin%26aufirst%3DNancy%26date%3D2016%26date%3D2016%26volume%3D174%26issue%3D5%26spage%3D711%26epage%3D720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veronica  Ferrucci</span>, <span class="hlFld-ContribAuthor ">Iolanda  Boffa</span>, <span class="hlFld-ContribAuthor ">Gina  De Masi</span>, <span class="hlFld-ContribAuthor ">Massimo  Zollo</span>. </span><span class="cited-content_cbyCitation_article-title">Natural compounds for pediatric cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2016,</strong> <em>389 </em>
                                    (2)
                                     , 131-149. <a href="https://doi.org/10.1007/s00210-015-1191-5" title="DOI URL">https://doi.org/10.1007/s00210-015-1191-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-015-1191-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-015-1191-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DNatural%252Bcompounds%252Bfor%252Bpediatric%252Bcancer%252Btreatment%26aulast%3DFerrucci%26aufirst%3DVeronica%26date%3D2016%26date%3D2015%26volume%3D389%26issue%3D2%26spage%3D131%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Tsvetkov</span>, <span class="hlFld-ContribAuthor ">Marc L  Mendillo</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhao</span>, <span class="hlFld-ContribAuthor ">Jan E  Carette</span>, <span class="hlFld-ContribAuthor ">Parker H  Merrill</span>, <span class="hlFld-ContribAuthor ">Domagoj  Cikes</span>, <span class="hlFld-ContribAuthor ">Malini  Varadarajan</span>, <span class="hlFld-ContribAuthor ">Ferdy R  van Diemen</span>, <span class="hlFld-ContribAuthor ">Josef M  Penninger</span>, <span class="hlFld-ContribAuthor ">Alfred L  Goldberg</span>, <span class="hlFld-ContribAuthor ">Thijn R  Brummelkamp</span>, <span class="hlFld-ContribAuthor ">Sandro  Santagata</span>, <span class="hlFld-ContribAuthor ">Susan  Lindquist</span>. </span><span class="cited-content_cbyCitation_article-title">Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2015,</strong> <em>4 </em><a href="https://doi.org/10.7554/eLife.08467" title="DOI URL">https://doi.org/10.7554/eLife.08467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.08467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.08467%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DCompromising%252Bthe%252B19S%252Bproteasome%252Bcomplex%252Bprotects%252Bcells%252Bfrom%252Breduced%252Bflux%252Bthrough%252Bthe%252Bproteasome%26aulast%3DTsvetkov%26aufirst%3DPeter%26date%3D2015%26date%3D2015%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shardule P.  Shah</span>, <span class="hlFld-ContribAuthor ">Sagar  Lonial</span>, <span class="hlFld-ContribAuthor ">Lawrence H.  Boise</span>. </span><span class="cited-content_cbyCitation_article-title">When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2015,</strong> <em>13 </em>
                                    (8)
                                     , 1163-1173. <a href="https://doi.org/10.1158/1541-7786.MCR-15-0135" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-15-0135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-15-0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-15-0135%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DWhen%252BCancer%252BFights%252BBack%25253A%252BMultiple%252BMyeloma%25252C%252BProteasome%252BInhibition%25252C%252Band%252Bthe%252BHeat-Shock%252BResponse%26aulast%3DShah%26aufirst%3DShardule%2BP.%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D8%26spage%3D1163%26epage%3D1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karthik  Selvaraju</span>, <span class="hlFld-ContribAuthor ">Magdalena  Mazurkiewicz</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Joachim  Gullbo</span>, <span class="hlFld-ContribAuthor ">Stig  Linder</span>, <span class="hlFld-ContribAuthor ">Pádraig  D’Arcy</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2015,</strong> <em>21-22 </em>, 20-29. <a href="https://doi.org/10.1016/j.drup.2015.06.001" title="DOI URL">https://doi.org/10.1016/j.drup.2015.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2015.06.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DInhibition%252Bof%252Bproteasome%252Bdeubiquitinase%252Bactivity%25253A%252Ba%252Bstrategy%252Bto%252Bovercome%252Bresistance%252Bto%252Bconventional%252Bproteasome%252Binhibitors%25253F%26aulast%3DSelvaraju%26aufirst%3DKarthik%26date%3D2015%26volume%3D21-22%26spage%3D20%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junya  Kuroda</span>, <span class="hlFld-ContribAuthor ">Shinsuke  Mizutani</span>, <span class="hlFld-ContribAuthor ">Yuji  Shimura</span>, <span class="hlFld-ContribAuthor ">Saori  Maegawa</span>, <span class="hlFld-ContribAuthor ">Hisao  Nagoshi</span>, <span class="hlFld-ContribAuthor ">Yoshiaki  Chinen</span>, <span class="hlFld-ContribAuthor ">Shotaro  Tatekawa</span>, <span class="hlFld-ContribAuthor ">Taku  Tsukamoto</span>, <span class="hlFld-ContribAuthor ">Yoshimi  Mizuno</span>, <span class="hlFld-ContribAuthor ">Mio  Yamamoto-Sugitani</span>, <span class="hlFld-ContribAuthor ">Tsutomu  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Yosuke  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Shigeo  Horiike</span>, <span class="hlFld-ContribAuthor ">Masafumi  Taniwaki</span>. </span><span class="cited-content_cbyCitation_article-title">Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy. </span><span class="cited-content_cbyCitation_journal-name">Annals of Hematology</span><span> <strong>2015,</strong> <em>94 </em>
                                    (4)
                                     , 687-689. <a href="https://doi.org/10.1007/s00277-014-2214-x" title="DOI URL">https://doi.org/10.1007/s00277-014-2214-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00277-014-2214-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00277-014-2214-x%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Hematology%26atitle%3DIntravenous%252Bbortezomib%252Bfor%252Bmultiple%252Bmyeloma%252Bthat%252Bhas%252Bprogressed%252Bafter%252Bsubcutaneous%252Bbortezomib%252Btherapy%26aulast%3DKuroda%26aufirst%3DJunya%26date%3D2015%26date%3D2014%26volume%3D94%26issue%3D4%26spage%3D687%26epage%3D689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva M.  Huber</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Heinemeyer</span>, <span class="hlFld-ContribAuthor ">Michael  Groll</span>. </span><span class="cited-content_cbyCitation_article-title">Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2015,</strong> <em>23 </em>
                                    (2)
                                     , 407-417. <a href="https://doi.org/10.1016/j.str.2014.11.019" title="DOI URL">https://doi.org/10.1016/j.str.2014.11.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2014.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2014.11.019%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DBortezomib-Resistant%252BMutant%252BProteasomes%25253A%252BStructural%252Band%252BBiochemical%252BEvaluation%252Bwith%252BCarfilzomib%252Band%252BONX%252B0914%26aulast%3DHuber%26aufirst%3DEva%25C2%25A0M.%26date%3D2015%26volume%3D23%26issue%3D2%26spage%3D407%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minal  Surati</span>, <span class="hlFld-ContribAuthor ">Kelly  Valla</span>, <span class="hlFld-ContribAuthor ">Katherine Sanvidge  Shah</span>, <span class="hlFld-ContribAuthor ">Elyse Hall  Panjic</span>, <span class="hlFld-ContribAuthor ">Sagar  Lonial</span>. </span><span class="cited-content_cbyCitation_article-title">Panobinostat for the treatment of multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Orphan Drugs</span><span> <strong>2015,</strong> <em>3 </em>
                                    (2)
                                     , 229-238. <a href="https://doi.org/10.1517/21678707.2015.999665" title="DOI URL">https://doi.org/10.1517/21678707.2015.999665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/21678707.2015.999665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F21678707.2015.999665%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Orphan%2520Drugs%26atitle%3DPanobinostat%252Bfor%252Bthe%252Btreatment%252Bof%252Bmultiple%252Bmyeloma%26aulast%3DSurati%26aufirst%3DMinal%26date%3D2015%26date%3D2015%26volume%3D3%26issue%3D2%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel E  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Endocrine-Related Cancer</span><span> <strong>2015,</strong> <em>22 </em>
                                    (1)
                                     , T1-T17. <a href="https://doi.org/10.1530/ERC-14-0005" title="DOI URL">https://doi.org/10.1530/ERC-14-0005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/ERC-14-0005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FERC-14-0005%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine-Related%2520Cancer%26atitle%3DThe%252Bubiquitin%2525E2%252580%252593proteasome%252Bsystem%25253A%252Bopportunities%252Bfor%252Btherapeutic%252Bintervention%252Bin%252Bsolid%252Btumors%26aulast%3DJohnson%26aufirst%3DDaniel%2BE%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3DT1%26epage%3DT17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan J.L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular basis of resistance to proteasome inhibitors in hematological malignancies. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2015,</strong> <em>18 </em>, 18-35. <a href="https://doi.org/10.1016/j.drup.2014.12.001" title="DOI URL">https://doi.org/10.1016/j.drup.2014.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2014.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DMolecular%252Bbasis%252Bof%252Bresistance%252Bto%252Bproteasome%252Binhibitors%252Bin%252Bhematological%252Bmalignancies%26aulast%3DNiewerth%26aufirst%3DDenise%26date%3D2015%26volume%3D18%26spage%3D18%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sue  Verbrugge</span>, <span class="hlFld-ContribAuthor ">Rik J  Scheper</span>, <span class="hlFld-ContribAuthor ">Willem F  Lems</span>, <span class="hlFld-ContribAuthor ">Tanja D  de Gruijl</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>. </span><span class="cited-content_cbyCitation_article-title">Proteasome inhibitors as experimental therapeutics of autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">Arthritis Research & Therapy</span><span> <strong>2015,</strong> <em>17 </em>
                                    (1)
                                     , 17. <a href="https://doi.org/10.1186/s13075-015-0529-1" title="DOI URL">https://doi.org/10.1186/s13075-015-0529-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13075-015-0529-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13075-015-0529-1%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26atitle%3DProteasome%252Binhibitors%252Bas%252Bexperimental%252Btherapeutics%252Bof%252Bautoimmune%252Bdiseases%26aulast%3DVerbrugge%26aufirst%3DSue%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillem  Paniagua Soriano</span>, <span class="hlFld-ContribAuthor ">Gerjan  De Bruin</span>, <span class="hlFld-ContribAuthor ">Herman S.  Overkleeft</span>, <span class="hlFld-ContribAuthor ">Bogdan I.  Florea</span>. </span><span class="cited-content_cbyCitation_article-title">Toward Understanding Induction of Oxidative Stress and Apoptosis by Proteasome Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants & Redox Signaling</span><span> <strong>2014,</strong> <em>21 </em>
                                    (17)
                                     , 2419-2443. <a href="https://doi.org/10.1089/ars.2013.5794" title="DOI URL">https://doi.org/10.1089/ars.2013.5794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/ars.2013.5794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fars.2013.5794%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%2520%2526%2520Redox%2520Signaling%26atitle%3DToward%252BUnderstanding%252BInduction%252Bof%252BOxidative%252BStress%252Band%252BApoptosis%252Bby%252BProteasome%252BInhibitors%26aulast%3DPaniagua%2BSoriano%26aufirst%3DGuillem%26date%3D2014%26volume%3D21%26issue%3D17%26spage%3D2419%26epage%3D2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda F  Baker</span>, <span class="hlFld-ContribAuthor ">Neale T  Hanke</span>, <span class="hlFld-ContribAuthor ">Barbara J  Sands</span>, <span class="hlFld-ContribAuthor ">Liliana  Carbajal</span>, <span class="hlFld-ContribAuthor ">Janet L  Anderl</span>, <span class="hlFld-ContribAuthor ">Linda L  Garland</span>. </span><span class="cited-content_cbyCitation_article-title">Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2014,</strong> <em>33 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-014-0111-8" title="DOI URL">https://doi.org/10.1186/s13046-014-0111-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-014-0111-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-014-0111-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DCarfilzomib%252Bdemonstrates%252Bbroad%252Banti-tumor%252Bactivity%252Bin%252Bpre-clinical%252Bnon-small%252Bcell%252Band%252Bsmall%252Bcell%252Blung%252Bcancer%252Bmodels%26aulast%3DBaker%26aufirst%3DAmanda%2BF%26date%3D2014%26date%3D2014%26volume%3D33%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia V.  Andreu-Vieyra</span>, <span class="hlFld-ContribAuthor ">James R.  Berenson</span>. </span><span class="cited-content_cbyCitation_article-title">The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Hematology</span><span> <strong>2014,</strong> <em>5 </em>
                                    (6)
                                     , 197-210. <a href="https://doi.org/10.1177/2040620714552614" title="DOI URL">https://doi.org/10.1177/2040620714552614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2040620714552614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2040620714552614%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Hematology%26atitle%3DThe%252Bpotential%252Bof%252Bpanobinostat%252Bas%252Ba%252Btreatment%252Boption%252Bin%252Bpatients%252Bwith%252Brelapsed%252Band%252Brefractory%252Bmultiple%252Bmyeloma%26aulast%3DAndreu-Vieyra%26aufirst%3DClaudia%2BV.%26date%3D2014%26date%3D2014%26volume%3D5%26issue%3D6%26spage%3D197%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zdeněk  Škrott</span>, <span class="hlFld-ContribAuthor ">Boris  Cvek</span>. </span><span class="cited-content_cbyCitation_article-title">Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2014,</strong> <em>92 </em>
                                    (2)
                                     , 61-70. <a href="https://doi.org/10.1016/j.critrevonc.2014.05.003" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2014.05.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2014.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2014.05.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DLinking%252Bthe%252Bactivity%252Bof%252Bbortezomib%252Bin%252Bmultiple%252Bmyeloma%252Band%252Bautoimmune%252Bdiseases%26aulast%3D%25C5%25A0krott%26aufirst%3DZden%25C4%259Bk%26date%3D2014%26volume%3D92%26issue%3D2%26spage%3D61%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Andreu-Vieyra</span>, <span class="hlFld-ContribAuthor ">James R  Berenson</span>. </span><span class="cited-content_cbyCitation_article-title">Carfilzomib in multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Biological Therapy</span><span> <strong>2014,</strong> <em>14 </em>
                                    (11)
                                     , 1685-1699. <a href="https://doi.org/10.1517/14712598.2014.953050" title="DOI URL">https://doi.org/10.1517/14712598.2014.953050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14712598.2014.953050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14712598.2014.953050%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Biological%2520Therapy%26atitle%3DCarfilzomib%252Bin%252Bmultiple%252Bmyeloma%26aulast%3DAndreu-Vieyra%26aufirst%3DClaudia%26date%3D2014%26date%3D2014%26volume%3D14%26issue%3D11%26spage%3D1685%26epage%3D1699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui-xia  Zeng</span>, <span class="hlFld-ContribAuthor ">Yi-Bo  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Fan</span>, <span class="hlFld-ContribAuthor ">Ge-Li  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Biology International</span><span> <strong>2014,</strong> <em>38 </em>
                                    (10)
                                     , 1221-1226. <a href="https://doi.org/10.1002/cbin.10311" title="DOI URL">https://doi.org/10.1002/cbin.10311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbin.10311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbin.10311%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Biology%2520International%26atitle%3Dp62%25252FSQSTM1%252Bis%252Binvolved%252Bin%252Bcaspase-8%252Bassociated%252Bcell%252Bdeath%252Binduced%252Bby%252Bproteasome%252Binhibitor%252BMG132%252Bin%252BU87MG%252Bcells%26aulast%3DZeng%26aufirst%3DRui-xia%26date%3D2014%26date%3D2014%26volume%3D38%26issue%3D10%26spage%3D1221%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Micale</span>, <span class="hlFld-ContribAuthor ">Kety  Scarbaci</span>, <span class="hlFld-ContribAuthor ">Valeria  Troiano</span>, <span class="hlFld-ContribAuthor ">Roberta  Ettari</span>, <span class="hlFld-ContribAuthor ">Silvana  Grasso</span>, <span class="hlFld-ContribAuthor ">Maria  Zappalà</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-Based Proteasome Inhibitors in Anticancer Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2014,</strong> <em>34 </em>
                                    (5)
                                     , 1001-1069. <a href="https://doi.org/10.1002/med.21312" title="DOI URL">https://doi.org/10.1002/med.21312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21312%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DPeptide-Based%252BProteasome%252BInhibitors%252Bin%252BAnticancer%252BDrug%252BDesign%26aulast%3DMicale%26aufirst%3DNicola%26date%3D2014%26date%3D2014%26volume%3D34%26issue%3D5%26spage%3D1001%26epage%3D1069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zang</span>, <span class="hlFld-ContribAuthor ">Christopher J  Kirk</span>, <span class="hlFld-ContribAuthor ">Daniel E  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Biology & Therapy</span><span> <strong>2014,</strong> <em>15 </em>
                                    (9)
                                     , 1142-1152. <a href="https://doi.org/10.4161/cbt.29452" title="DOI URL">https://doi.org/10.4161/cbt.29452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4161/cbt.29452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4161%2Fcbt.29452%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biology%2520%2526%2520Therapy%26atitle%3DCarfilzomib%252Band%252Boprozomib%252Bsynergize%252Bwith%252Bhistone%252Bdeacetylase%252Binhibitors%252Bin%252Bhead%252Band%252Bneck%252Bsquamous%252Bcell%252Bcarcinoma%252Bmodels%252Bof%252Bacquired%252Bresistance%252Bto%252Bproteasome%252Binhibitors%26aulast%3DZang%26aufirst%3DYan%26date%3D2014%26date%3D2014%26volume%3D15%26issue%3D9%26spage%3D1142%26epage%3D1152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Lesley F. V.  Riethoff</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Kale</span>, <span class="hlFld-ContribAuthor ">Bradley S.  Moore</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Janet L.  Anderl</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan J. L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Antileukemic Activity and Mechanism of Drug Resistance to the Marine
              Salinispora tropica
              Proteasome Inhibitor Salinosporamide A (Marizomib). </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2014,</strong> <em>86 </em>
                                    (1)
                                     , 12-19. <a href="https://doi.org/10.1124/mol.114.092114" title="DOI URL">https://doi.org/10.1124/mol.114.092114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/mol.114.092114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmol.114.092114%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DAntileukemic%252BActivity%252Band%252BMechanism%252Bof%252BDrug%252BResistance%252Bto%252Bthe%252BMarine%252BSalinispora%252Btropica%252BProteasome%252BInhibitor%252BSalinosporamide%252BA%252B%252528Marizomib%252529%26aulast%3DNiewerth%26aufirst%3DDenise%26date%3D2014%26date%3D2014%26volume%3D86%26issue%3D1%26spage%3D12%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Tessa C.  Hendrickx</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Kirk</span>, <span class="hlFld-ContribAuthor ">Janet L.  Anderl</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan J.L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2014,</strong> <em>89 </em>
                                    (1)
                                     , 43-51. <a href="https://doi.org/10.1016/j.bcp.2014.02.005" title="DOI URL">https://doi.org/10.1016/j.bcp.2014.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2014.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DAnti-leukemic%252Bactivity%252Band%252Bmechanisms%252Bunderlying%252Bresistance%252Bto%252Bthe%252Bnovel%252Bimmunoproteasome%252Binhibitor%252BPR-924%26aulast%3DNiewerth%26aufirst%3DDenise%26date%3D2014%26volume%3D89%26issue%3D1%26spage%3D43%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Yan  Pei</span>, <span class="hlFld-ContribAuthor ">Yun  Dai</span>, <span class="hlFld-ContribAuthor ">Jessica  Felthousen</span>, <span class="hlFld-ContribAuthor ">Shuang  Chen</span>, <span class="hlFld-ContribAuthor ">Yukie  Takabatake</span>, <span class="hlFld-ContribAuthor ">Liang  Zhou</span>, <span class="hlFld-ContribAuthor ">Leena E.  Youssefian</span>, <span class="hlFld-ContribAuthor ">Michael W.  Sanderson</span>, <span class="hlFld-ContribAuthor ">Wesley W.  Bodie</span>, <span class="hlFld-ContribAuthor ">Lora B.  Kramer</span>, <span class="hlFld-ContribAuthor ">Robert Z.  Orlowski</span>, <span class="hlFld-ContribAuthor ">Steven  Grant</span>, . </span><span class="cited-content_cbyCitation_article-title">Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (3)
                                     , e89064. <a href="https://doi.org/10.1371/journal.pone.0089064" title="DOI URL">https://doi.org/10.1371/journal.pone.0089064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0089064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0089064%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DCircumvention%252Bof%252BMcl-1-Dependent%252BDrug%252BResistance%252Bby%252BSimultaneous%252BChk1%252Band%252BMEK1%25252F2%252BInhibition%252Bin%252BHuman%252BMultiple%252BMyeloma%252BCells%26aulast%3DPei%26aufirst%3DXin-Yan%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D3%26spage%3De89064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hans C.  Lee</span>, <span class="hlFld-ContribAuthor ">Robert Z.  Orlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 81-98. <a href="https://doi.org/10.1007/978-3-319-06752-0_3" title="DOI URL">https://doi.org/10.1007/978-3-319-06752-0_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-06752-0_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-06752-0_3%26sid%3Dliteratum%253Aachs%26atitle%3DOvercoming%252BBortezomib%252BResistance%25253A%252BA%252BReview%252Bof%252Bthe%252BSecond-Generation%252BProteasome%252BInhibitor%252BCarfilzomib%252Bin%252Bthe%252BTreatment%252Bof%252BMultiple%252BMyeloma%26aulast%3DLee%26aufirst%3DHans%2BC.%26date%3D2014%26date%3D2014%26spage%3D81%26epage%3D98%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DResistance%252Bto%252BProteasome%252BInhibitors%252Bin%252BCancer%26aulast%3DDou%26aufirst%3DQ.%2BPing%26date%3D2014%26volume%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>, <span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 181-204. <a href="https://doi.org/10.1007/978-3-319-06752-0_7" title="DOI URL">https://doi.org/10.1007/978-3-319-06752-0_7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-06752-0_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-06752-0_7%26sid%3Dliteratum%253Aachs%26atitle%3DPreclinical%252BStudies%252Bon%252Bthe%252BMolecular%252BBasis%252Bof%252BBortezomib%252BResistance%252Band%252BModalities%252Bto%252BOvercome%252BResistance%252Bin%252BHematological%252BMalignancies%26aulast%3DCloos%26aufirst%3DJacqueline%26date%3D2014%26date%3D2014%26spage%3D181%26epage%3D204%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DResistance%252Bto%252BProteasome%252BInhibitors%252Bin%252BCancer%26aulast%3DDou%26aufirst%3DQ.%2BPing%26date%3D2014%26volume%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Gertjan JL  Kaspers</span>, <span class="hlFld-ContribAuthor ">Yehuda G  Assaraf</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Christopher J  Kirk</span>, <span class="hlFld-ContribAuthor ">Janet  Anderl</span>, <span class="hlFld-ContribAuthor ">Jonathan L  Blank</span>, <span class="hlFld-ContribAuthor ">Peter M  van de Ven</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2014,</strong> <em>7 </em>
                                    (1)
                                     , 7. <a href="https://doi.org/10.1186/1756-8722-7-7" title="DOI URL">https://doi.org/10.1186/1756-8722-7-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1756-8722-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1756-8722-7-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DInterferon-%2525CE%2525B3-induced%252Bupregulation%252Bof%252Bimmunoproteasome%252Bsubunit%252Bassembly%252Bovercomes%252Bbortezomib%252Bresistance%252Bin%252Bhuman%252Bhematological%252Bcell%252Blines%26aulast%3DNiewerth%26aufirst%3DDenise%26date%3D2014%26volume%3D7%26issue%3D1%26spage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatiana N.  Moiseeva</span>, <span class="hlFld-ContribAuthor ">Andrew  Bottrill</span>, <span class="hlFld-ContribAuthor ">Gerry  Melino</span>, <span class="hlFld-ContribAuthor ">Nickolai A.  Barlev</span>. </span><span class="cited-content_cbyCitation_article-title">DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2013,</strong> <em>4 </em>
                                    (9)
                                     , 1338-1348. <a href="https://doi.org/10.18632/oncotarget.1060" title="DOI URL">https://doi.org/10.18632/oncotarget.1060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.1060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.1060%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDNA%252Bdamage-induced%252Bubiquitylation%252Bof%252Bproteasome%252Bcontrols%252Bits%252Bproteolytic%252Bactivity%26aulast%3DMoiseeva%26aufirst%3DTatiana%2BN.%26date%3D2013%26date%3D2013%26volume%3D4%26issue%3D9%26spage%3D1338%26epage%3D1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy D.  Marshall</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Picchione</span>, <span class="hlFld-ContribAuthor ">Ramon I. Klein  Geltink</span>, <span class="hlFld-ContribAuthor ">Gerard C.  Grosveld</span>. </span><span class="cited-content_cbyCitation_article-title">PAX3-FOXO1 Induces Up-Regulation of Noxa Sensitizing Alveolar Rhabdomyosarcoma Cells to Apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2013,</strong> <em>15 </em>
                                    (7)
                                     , 738-IN15. <a href="https://doi.org/10.1593/neo.121888" title="DOI URL">https://doi.org/10.1593/neo.121888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1593/neo.121888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1593%2Fneo.121888%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DPAX3-FOXO1%252BInduces%252BUp-Regulation%252Bof%252BNoxa%252BSensitizing%252BAlveolar%252BRhabdomyosarcoma%252BCells%252Bto%252BApoptosis%26aulast%3DMarshall%26aufirst%3DAmy%2BD.%26date%3D2013%26volume%3D15%26issue%3D7%26spage%3D738%26epage%3DIN15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise  Niewerth</span>, <span class="hlFld-ContribAuthor ">Ilse  Dingjan</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Gertjan  Kaspers</span>. </span><span class="cited-content_cbyCitation_article-title">Proteasome inhibitors in acute leukemia. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2013,</strong> <em>13 </em>
                                    (3)
                                     , 327-337. <a href="https://doi.org/10.1586/era.13.4" title="DOI URL">https://doi.org/10.1586/era.13.4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/era.13.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2Fera.13.4%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DProteasome%252Binhibitors%252Bin%252Bacute%252Bleukemia%26aulast%3DNiewerth%26aufirst%3DDenise%26date%3D2013%26date%3D2014%26volume%3D13%26issue%3D3%26spage%3D327%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0005.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ubiquitin–proteasome system. Polyubiquitination of cellular proteins by the cascade of E1, E2, and E3 enzymes assigns substrate proteins for 26S proteasomal degradation. Poly-Ub proteins are recognized and unfolded by the 19S regulatory particle and fed into the proteolytic 20S core particle for destruction by the three catalytically active subunits, β5, β2, and β1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of selected proteasome inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/medium/jm-2012-00434z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Substrate binding analysis of <b>1</b> and the β5-subunit of the <i>Saccharomyces cerevisiae</i> 20S proteasome. (a) Dashed lines represent H-bonding with the distance shown in Å. Mutations observed at Ala49, Ala50, and Thr21 may disrupt H-bonding and decrease PI binding. Reproduced in part from <i>Structure</i> (<a href="http://www.sciencedirect.com/science/journal/09692126" class="extLink">http://www.sciencedirect.com/science/journal/09692126</a>), Vol. 14, Groll, M., Berkers, C. R., Ploegh, H. L., and Ovaa, H., “Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome”, pp 451–456, Copyright 2006, with permission from Elsevier.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (b) Crystal structure of the S1 binding pocket with <b>1</b> bound. Image was created using PDB file <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16">2F16</a>, and chain K was rendered in PyMol.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-23/jm300434z/production/images/large/jm-2012-00434z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300434z&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Murata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yashiroda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of proteasome assembly</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fnrm2630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19165213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=104-115&author=S.+Murataauthor=H.+Yashirodaauthor=K.+Tanaka&title=Molecular+mechanisms+of+proteasome+assembly"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of proteasome assembly</span></div><div class="casAuthors">Murata, Shigeo; Yashiroda, Hideki; Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 26S proteasome is a highly conserved protein degrdn. machine that consists of the 20S proteasome and 19S regulatory particles, which include 14 and 19 different polypeptides, resp.  How the proteasome components are assembled is a fundamental question towards understanding the process of protein degrdn. and its functions in diverse biol. processes.  Several proteasome-dedicated chaperones are involved in the efficient and correct assembly of the 20S proteasome.  These chaperones help the initiation and progression of the assembly process by transiently assocg. with proteasome precursors.  By contrast, little is known about the assembly of the 19S regulatory particles, but several hints have emerged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh7BlzwswLvLVg90H21EOLACvtfcHk0ljKBy-IlIMGHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVChtQ%253D%253D&md5=acfc193c4fb9d0fefa21b43d9cc611b3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2630%26sid%3Dliteratum%253Aachs%26aulast%3DMurata%26aufirst%3DS.%26aulast%3DYashiroda%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520proteasome%2520assembly%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D104%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Borissenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groll, M.</span><span> </span><span class="NLM_article-title">20S proteasome and its inhibitors: crystallographic knowledge for drug development</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&author=L.+Borissenkoauthor=M.+Groll&title=20S+proteasome+and+its+inhibitors%3A+crystallographic+knowledge+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520proteasome%2520and%2520its%2520inhibitors%253A%2520crystallographic%2520knowledge%2520for%2520drug%2520development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D687%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Genin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboud-Ravaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, J.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.2174%2F156802610790725515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20166955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1ent7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=232-256&author=E.+Geninauthor=M.+Reboud-Ravauxauthor=J.+Vidal&title=Proteasome+inhibitors%3A+recent+advances+and+new+perspectives+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry</span></div><div class="casAuthors">Genin, E.; Reboud-Ravaux, M.; Vidal, J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-256</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The search for proteasome inhibitors began fifteen years ago.  These inhibitors proved to be powerful tools for investigating many important cellular processes regulated by the ubiquitin-proteasome pathway.  Targeting the proteasome pathway can also lead to new treatments for disorders like cancer, muscular dystrophies, inflammation and immune diseases.  This is already true for cancer; the FDA approved bortezomib, a potent proteasome inhibitor, for treating multiple myeloma in 2003, and mantle cell lymphoma in 2006.  The chem. structures identified in some of the early proteasome inhibitors have led to the development of new anti-cancer drugs (CEP-18770, Carfilzomib, NPI-0052).  All these mols. are covalent bonding inhibitors that react with the catalytic Thr1-Oγ of the three types of active site.  This review covers recent developments in medicinal chem. of natural and synthetic proteasome inhibitors.  Advances in non-covalent inhibitors that have no reactive group will be highlighted as they should minimize side-effects.  New structures and new modes of action have been recently identified that open the door to new drug candidates for treating a range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv2fNL-WAY3LVg90H21EOLACvtfcHk0lhw7fbv9sUIFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1ent7Y%253D&md5=ef6b9b743b0c4f4981ad9138beceb90d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802610790725515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790725515%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DE.%26aulast%3DReboud-Ravaux%26aufirst%3DM.%26aulast%3DVidal%26aufirst%3DJ.%26atitle%3DProteasome%2520inhibitors%253A%2520recent%2520advances%2520and%2520new%2520perspectives%2520in%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D232%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Nencioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunebach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballestrero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brossart, P.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: antitumor effects and beyond</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=30-36&author=A.+Nencioniauthor=F.+Grunebachauthor=F.+Patroneauthor=A.+Ballestreroauthor=P.+Brossart&title=Proteasome+inhibitors%3A+antitumor+effects+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNencioni%26aufirst%3DA.%26aulast%3DGrunebach%26aufirst%3DF.%26aulast%3DPatrone%26aufirst%3DF.%26aulast%3DBallestrero%26aufirst%3DA.%26aulast%3DBrossart%26aufirst%3DP.%26atitle%3DProteasome%2520inhibitors%253A%2520antitumor%2520effects%2520and%2520beyond%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D30%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Woodle, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloway, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brailey, P.</span><span> </span><span class="NLM_article-title">Proteasome inhibitor therapy for antibody-mediated rejection</span> <span class="citation_source-journal">Pediatr. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1111%2Fj.1399-3046.2011.01543.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21884344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GmtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=548-556&author=E.+S.+Woodleauthor=R.+C.+Walshauthor=R.+R.+Allowayauthor=A.+Girnitaauthor=P.+Brailey&title=Proteasome+inhibitor+therapy+for+antibody-mediated+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitor therapy for antibody-mediated rejection</span></div><div class="casAuthors">Woodle, E. S.; Walsh, R. C.; Alloway, R. R.; Girnita, A.; Brailey, P.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Transplantation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>CODEN:
                <span class="NLM_cas:coden">PETRF6</span>;
        ISSN:<span class="NLM_cas:issn">1397-3142</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  AMR is being recognized with increasing efficiency, but continues to present a significant threat to renal allograft survival.  Traditional therapies for AMR (IVIG, plasmapheresis, rituximab, and antilymphocyte prepns.) in general have provided inconsistent results and do not deplete the source of antibody prodn., viz., the mature plasma cell.  Recently, the first plasma cell-targeted therapy in humans has been developed using bortezomib (a first in class PI) for AMR treatment in kidney transplant recipients.  Initial experience with bortezomib involved treatment of refractory AMR.  Subsequently, the efficacy of bortezomib in primary therapy for AMR was demonstrated.  In a multicenter collaborative effort, the initial results with bortezomib in AMR have been confirmed and expanded to pediatric and adult heart transplant recipients.  More recently, results from a prospective, staged desensitization trial has shown that bortezomib alone can substantially reduce anti-HLA antibody levels.  These results demonstrate the significant potential of proteasome inhibition in addressing humoral barriers.  However, the major advantage of proteasome inhibition lies in the numerous potential strategies for achieving synergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXj42bdoxjbVg90H21EOLACvtfcHk0lhw7fbv9sUIFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GmtrrE&md5=d8e97c39d8bc3826ea2174a740e25d88</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3046.2011.01543.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3046.2011.01543.x%26sid%3Dliteratum%253Aachs%26aulast%3DWoodle%26aufirst%3DE.%2BS.%26aulast%3DWalsh%26aufirst%3DR.%2BC.%26aulast%3DAlloway%26aufirst%3DR.%2BR.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DBrailey%26aufirst%3DP.%26atitle%3DProteasome%2520inhibitor%2520therapy%2520for%2520antibody-mediated%2520rejection%26jtitle%3DPediatr.%2520Transplant.%26date%3D2011%26volume%3D15%26spage%3D548%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kisselev, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Linden, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H. S.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors: an expanding army attacking a unique target</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.chembiol.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22284358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=99-115&author=A.+F.+Kisselevauthor=W.+A.+van+der+Lindenauthor=H.+S.+Overkleeft&title=Proteasome+inhibitors%3A+an+expanding+army+attacking+a+unique+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitors: An Expanding Army Attacking a Unique Target</span></div><div class="casAuthors">Kisselev, Alexei F.; van der Linden, Wouter A.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention.  The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles.  The 20S core contains three types of active sites.  Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades.  One, bortezomib, is used clin. for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection.  Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers.  Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives.  In addn., inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc-6qcZILhrVg90H21EOLACvtfcHk0lhw7fbv9sUIFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D&md5=a4eca9d710b209d5455c2eaa58dfd0bc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520inhibitors%253A%2520an%2520expanding%2520army%2520attacking%2520a%2520unique%2520target%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D99%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Cheriyath, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, M. A.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors</span> <span class="citation_source-journal">Drugs R&D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.2165%2F00126839-200708010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17249845" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1-12&author=V.+Cheriyathauthor=B.+S.+Jacobsauthor=M.+A.+Hussein&title=Proteasome+inhibitors+in+the+clinical+setting%3A+benefits+and+strategies+to+overcome+multiple+myeloma+resistance+to+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F00126839-200708010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200708010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCheriyath%26aufirst%3DV.%26aulast%3DJacobs%26aufirst%3DB.%2BS.%26aulast%3DHussein%26aufirst%3DM.%2BA.%26atitle%3DProteasome%2520inhibitors%2520in%2520the%2520clinical%2520setting%253A%2520benefits%2520and%2520strategies%2520to%2520overcome%2520multiple%2520myeloma%2520resistance%2520to%2520proteasome%2520inhibitors%26jtitle%3DDrugs%2520R%2526D%26date%3D2007%26volume%3D8%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, D. J.</span><span> </span><span class="NLM_article-title">Proteasome inhibitors in cancer therapy: lessons from the first decade</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F1078-0432.CCR-07-2218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18347166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1649-1657&author=R.+Z.+Orlowskiauthor=D.+J.+Kuhn&title=Proteasome+inhibitors+in+cancer+therapy%3A+lessons+from+the+first+decade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors in cancer therapy: lessons from the first decade</span></div><div class="casAuthors">Orlowski, Robert Z.; Kuhn, Deborah J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis.  First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells.  They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clin. efficacy and toxicity, and some of their limitations in the form of resistance pathways.  Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a std. of care.  Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases.  This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCNIRIVHoPx7Vg90H21EOLACvtfcHk0lgbYJQmW3Zc1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejt74%253D&md5=f1639611d273422351658c10b4d8e9ad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2218%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26atitle%3DProteasome%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520lessons%2520from%2520the%2520first%2520decade%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">McConkey, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span> </span><span class="NLM_article-title">Mechanisms of proteasome inhibitor action and resistance in cancer</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.drup.2008.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18818117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2ku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=164-179&author=D.+J.+McConkeyauthor=K.+Zhu&title=Mechanisms+of+proteasome+inhibitor+action+and+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of proteasome inhibitor action and resistance in cancer</span></div><div class="casAuthors">McConkey, David J.; Zhu, Keyi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">164-179</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors (PIs), such as bortezomib, carfilzomib or NPI-0052, have excellent clin. activity in patients with multiple myeloma and mantle cell lymphoma, and they are currently being evaluated in combination with other agents in patients with solid tumors.  Although they exert broad effects on cancer cells, their ability to (1) stabilize pro-apoptotic members of the BCL-2 family, (2) inhibit the two major pathways leading to NFκB activation, and (3) cause the build-up of misfolded proteins appear to be particularly important.  In addn., PIs may disrupt tumor-stromal interactions that drive NFκB activation and angiogenesis and in such a way sensitize cancer cells to other agents.  Still, drug resistance ultimately emerges in all tumors that initially respond to PIs.  This review provides an overview of the current thinking about how PIs may kill cancer cells exemplified for pancreatic cancer and the possible mechanisms involved in resistance to PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRdveVSdECeLVg90H21EOLACvtfcHk0lgbYJQmW3Zc1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2ku7fJ&md5=ec7aec08dd2fb4837a9819117e67601a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2008.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2008.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DMcConkey%26aufirst%3DD.%2BJ.%26aulast%3DZhu%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520proteasome%2520inhibitor%2520action%2520and%2520resistance%2520in%2520cancer%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2008%26volume%3D11%26spage%3D164%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Naujokat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, S.</span><span> </span><span class="NLM_article-title">Role and function of the 26S proteasome in proliferation and apoptosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">965</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=965-980&author=C.+Naujokatauthor=S.+Hoffmann&title=Role+and+function+of+the+26S+proteasome+in+proliferation+and+apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaujokat%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DS.%26atitle%3DRole%2520and%2520function%2520of%2520the%252026S%2520proteasome%2520in%2520proliferation%2520and%2520apoptosis%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D965%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fuchs, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berges, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opelz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naujokat, C.</span><span> </span><span class="NLM_article-title">Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=270-283&author=D.+Fuchsauthor=C.+Bergesauthor=G.+Opelzauthor=V.+Danielauthor=C.+Naujokat&title=Increased+expression+and+altered+subunit+composition+of+proteasomes+induced+by+continuous+proteasome+inhibition+establish+apoptosis+resistance+and+hyperproliferation+of+Burkitt+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuchs%26aufirst%3DD.%26aulast%3DBerges%26aufirst%3DC.%26aulast%3DOpelz%26aufirst%3DG.%26aulast%3DDaniel%26aufirst%3DV.%26aulast%3DNaujokat%26aufirst%3DC.%26atitle%3DIncreased%2520expression%2520and%2520altered%2520subunit%2520composition%2520of%2520proteasomes%2520induced%2520by%2520continuous%2520proteasome%2520inhibition%2520establish%2520apoptosis%2520resistance%2520and%2520hyperproliferation%2520of%2520Burkitt%2520lymphoma%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D103%26spage%3D270%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Oerlemans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zantwijk, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debipersad, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojtekova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijden, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ylstra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkmans, B. A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span> </span><span class="NLM_article-title">Molecular basis of bortezomib resistance: proteasome subunit β5 (<i>PSMB5</i>) gene mutation and overexpression of PSMB5 protein</span> <span class="citation_source-journal">Blood.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span><span class="NLM_x">–</span> <span class="NLM_lpage">2499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=2489-2499&author=R.+Oerlemansauthor=N.+E.+Frankeauthor=Y.+G.+Assarafauthor=J.+Cloosauthor=I.+van+Zantwijkauthor=C.+R.+Berkersauthor=G.+L.+Schefferauthor=K.+Debipersadauthor=K.+Vojtekovaauthor=C.+Lemosauthor=J.+W.+van+der+Heijdenauthor=B.+Ylstraauthor=G.+J.+Petersauthor=G.+L.+Kaspersauthor=B.+A.+C.+Dijkmansauthor=R.+J.+Scheperauthor=G.+Jansen&title=Molecular+basis+of+bortezomib+resistance%3A+proteasome+subunit+%CE%B25+%28PSMB5%29+gene+mutation+and+overexpression+of+PSMB5+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2BZantwijk%26aufirst%3DI.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DDebipersad%26aufirst%3DK.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3DLemos%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3DYlstra%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DKaspers%26aufirst%3DG.%2BL.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%2BC.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DMolecular%2520basis%2520of%2520bortezomib%2520resistance%253A%2520proteasome%2520subunit%2520%25CE%25B25%2520%2528PSMB5%2529%2520gene%2520mutation%2520and%2520overexpression%2520of%2520PSMB5%2520protein%26jtitle%3DBlood.%26date%3D2008%26volume%3D112%26spage%3D2489%26epage%3D2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lü, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. M.</span><span> </span><span class="NLM_article-title">Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1124%2Fjpet.108.138131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18502982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=423-431&author=S.+Q.+L%C3%BCauthor=J.+M.+Yangauthor=X.+M.+Songauthor=S.+L.+Gongauthor=H.+Zhouauthor=L.+P.+Guoauthor=N.+X.+Songauthor=X.+C.+Baoauthor=P.+P.+Chenauthor=J.+M.+Wang&title=Point+mutation+of+the+proteasome+%CE%B25+subunit+gene+is+an+important+mechanism+of+bortezomib+resistance+in+bortezomib-selected+variants+of+Jurkat+T+cell+lymphoblastic+lymphoma%2Fleukemia+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line</span></div><div class="casAuthors">Lu, Shuqing; Yang, Jianmin; Song, Xianmin; Gong, Shenglan; Zhou, Hong; Guo, Lieping; Song, Ningxia; Bao, Xiaochen; Chen, Pingping; Wang, Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T lymphoblastic lymphoma/leukemia cell lines, designated the JurkatBs, from the parental Jurkat line via repeated drug selection.  There were no significant differences in the growth curves or colony formation between the JurkatB cells and parental Jurkat cells.  The effects of bortezomib on cytotoxicity, cell cycle arrest, and induction of apoptosis were decreased in JurkatB cells compared with parental Jurkat cells.  A mutation in the proteasome β5 subunit (PSMB5) gene (G322A), which encodes an amino acid change from Ala to Thr at polypeptide position 108, was detected by sequencing full-length cDNA clones and direct polymerase chain reaction products of the PSMB5 gene.  Bortezomib caused less inhibition of chymotrypsin-like activity in resistant cells.  When the G322A mutant PSMB5 was retrovirally introduced into parental Jurkat cells, it conferred bortezomib resistance to these cells, resulting in decreased cytotoxicity, apoptosis, and inhibition of chymotrypsin-like activity.  The predicted structure of A108T-mutated PSMB5 shows a conformational change that suggests decreased affinity to bortezomib.  In short, the G322A mutation of the PSMB5 gene is a novel mechanism for bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn09QDIJWXl7Vg90H21EOLACvtfcHk0lho2rX4un0ESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVWqsr8%253D&md5=922a0fd3626c460deb44e821f6807dde</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.138131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.138131%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%2BQ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DSong%26aufirst%3DX.%2BM.%26aulast%3DGong%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%2BP.%26aulast%3DSong%26aufirst%3DN.%2BX.%26aulast%3DBao%26aufirst%3DX.%2BC.%26aulast%3DChen%26aufirst%3DP.%2BP.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26atitle%3DPoint%2520mutation%2520of%2520the%2520proteasome%2520%25CE%25B25%2520subunit%2520gene%2520is%2520an%2520important%2520mechanism%2520of%2520bortezomib%2520resistance%2520in%2520bortezomib-selected%2520variants%2520of%2520Jurkat%2520T%2520cell%2520lymphoblastic%2520lymphoma%252Fleukemia%2520line%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D423%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Lü, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. M.</span><span> </span><span class="NLM_article-title">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.exphem.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19426847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A280%3ADC%252BD1MvjtVCitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=831-837&author=S.+Q.+L%C3%BCauthor=J.+M.+Yangauthor=Z.+L.+Chenauthor=S.+L.+Gongauthor=H.+Zhouauthor=X.+Q.+Xuauthor=J.+M.+Wang&title=Different+mutants+of+PSMB5+confer+varying+bortezomib+resistance+in+T+lymphoblastic+lymphoma%2Fleukemia+cells+derived+from+the+Jurkat+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</span></div><div class="casAuthors">Lu Shuqing; Yang Jianmin; Chen Zhilong; Gong Shenglan; Zhou Hong; Xu Xiaoqian; Wang Jianmin</div><div class="citationInfo"><span class="NLM_cas:title">Experimental hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">831-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To investigate the relationship between bortezomib resistance and mutations in the proteasome beta5 subunit (PSMB5) gene.  MATERIALS AND METHODS:  Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection.  Mutations were detected by sequencing the complementary DNA of the PSMB5 gene.  Mutated clones were selected by limited dilution and cultured without bortezomib.  Messenger RNA expression levels of PSMB5 in these mutated clones were measured by quantitative reverse transcription polymerase chain reaction.  The degree of resistance was determined by cytotoxicity at various bortezomib concentrations.  The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin.  RESULTS:  In addition to the previously reported PSMB5 G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones containing these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained.  After being cultured without bortezomib for >2 months, no significant difference in PSMB5 messenger RNA levels was detected between these JurkatB cells and parental Jurkat cells.  JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, respectively, to bortezomib compared to Jurkat cells.  There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells.  The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between.  CONCLUSION:  Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSno336RtLX5O98rul4nhSdfW6udTcc2eb4CG6taDPwjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvjtVCitg%253D%253D&md5=6f79014204a2fcce65e26e640bb006a4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DS.%2BQ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DZ.%2BL.%26aulast%3DGong%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%2BQ.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26atitle%3DDifferent%2520mutants%2520of%2520PSMB5%2520confer%2520varying%2520bortezomib%2520resistance%2520in%2520T%2520lymphoblastic%2520lymphoma%252Fleukemia%2520cells%2520derived%2520from%2520the%2520Jurkat%2520cell%2520line%26jtitle%3DExp.%2520Hematol.%26date%3D2009%26volume%3D37%26spage%3D831%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Rückrich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdoes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalbacher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driessen, C.</span><span> </span><span class="NLM_article-title">Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1098-1105&author=T.+R%C3%BCckrichauthor=M.+Krausauthor=J.+Gogelauthor=A.+Beckauthor=H.+Ovaaauthor=M.+Verdoesauthor=H.+S.+Overkleeftauthor=H.+Kalbacherauthor=C.+Driessen&title=Characterization+of+the+ubiquitin%E2%80%93proteasome+system+in+bortezomib-adapted+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCckrich%26aufirst%3DT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DKalbacher%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520the%2520ubiquitin%25E2%2580%2593proteasome%2520system%2520in%2520bortezomib-adapted%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1098%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Bortezomib-resistant myeloma cell lines: a role for mutated <i>PSMB5</i> in preventing the accumulation of unfolded proteins and fatal ER stress</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1506-1512&author=M.+Riauthor=S.+Iidaauthor=T.+Nakashimaauthor=H.+Miyazakiauthor=F.+Moriauthor=A.+Itoauthor=A.+Inagakiauthor=S.+Kusumotoauthor=T.+Ishidaauthor=H.+Komatsuauthor=Y.+Shiotsuauthor=R.+Ueda&title=Bortezomib-resistant+myeloma+cell+lines%3A+a+role+for+mutated+PSMB5+in+preventing+the+accumulation+of+unfolded+proteins+and+fatal+ER+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRi%26aufirst%3DM.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DF.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DInagaki%26aufirst%3DA.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DBortezomib-resistant%2520myeloma%2520cell%2520lines%253A%2520a%2520role%2520for%2520mutated%2520PSMB5%2520in%2520preventing%2520the%2520accumulation%2520of%2520unfolded%2520proteins%2520and%2520fatal%2520ER%2520stress%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1506%26epage%3D1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Pérez-Galán, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mora-Jensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weniger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzatti, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stennett, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavachari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetler-Stevenson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittaluga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maric, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunleavy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestner, A.</span><span> </span><span class="NLM_article-title">Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=542-552&author=P.+P%C3%A9rez-Gal%C3%A1nauthor=H.+Mora-Jensenauthor=M.+A.+Wenigerauthor=A.+L.+Shafferauthor=E.+G.+Rizzattiauthor=C.+M.+Chapmanauthor=C.+C.+Moauthor=L.+S.+Stennettauthor=C.+Raderauthor=P.+C.+Liuauthor=N.+Raghavachariauthor=M.+Stetler-Stevensonauthor=C.+Yuanauthor=S.+Pittalugaauthor=I.+Maricauthor=K.+M.+Dunleavyauthor=W.+H.+Wilsonauthor=L.+M.+Staudtauthor=A.+Wiestner&title=Bortezomib+resistance+in+mantle+cell+lymphoma+is+associated+with+plasmacytic+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Gal%25C3%25A1n%26aufirst%3DP.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DWeniger%26aufirst%3DM.%2BA.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRizzatti%26aufirst%3DE.%2BG.%26aulast%3DChapman%26aufirst%3DC.%2BM.%26aulast%3DMo%26aufirst%3DC.%2BC.%26aulast%3DStennett%26aufirst%3DL.%2BS.%26aulast%3DRader%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%2BC.%26aulast%3DRaghavachari%26aufirst%3DN.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DDunleavy%26aufirst%3DK.%2BM.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DBortezomib%2520resistance%2520in%2520mantle%2520cell%2520lymphoma%2520is%2520associated%2520with%2520plasmacytic%2520differentiation%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D542%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewerth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Meerloo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojtekova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zantwijk, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweegman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geerke, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span> </span><span class="NLM_article-title">Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=757-768&author=N.+E.+Frankeauthor=D.+Niewerthauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=K.+Vojtekovaauthor=C.+H.+van+Zantwijkauthor=S.+Zweegmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=D.+P.+Geerkeauthor=A.+D.+Schimmerauthor=G.+J.+L.+Kaspersauthor=G.+Jansenauthor=J.+Cloos&title=Impaired+bortezomib+binding+to+mutant+%CE%B25+subunit+of+the+proteasome+is+the+underlying+basis+for+bortezomib+resistance+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3Dvan%2BZantwijk%26aufirst%3DC.%2BH.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGeerke%26aufirst%3DD.%2BP.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DImpaired%2520bortezomib%2520binding%2520to%2520mutant%2520%25CE%25B25%2520subunit%2520of%2520the%2520proteasome%2520is%2520the%2520underlying%2520basis%2520for%2520bortezomib%2520resistance%2520in%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2011%26volume%3D26%26spage%3D757%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Suzuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arastu-Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsagel, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of bortezomib resistant adenocarcinoma cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e27996&author=E.+Suzukiauthor=S.+Demoauthor=E.+Deuauthor=J.+Keatsauthor=S.+Arastu-Kapurauthor=P.+L.+Bergsagelauthor=M.+K.+Bennettauthor=C.+J.+Kirk&title=Molecular+mechanisms+of+bortezomib+resistant+adenocarcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DDeu%26aufirst%3DE.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520mechanisms%2520of%2520bortezomib%2520resistant%2520adenocarcinoma%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De27996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">de Wilt, L. H. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Meerloo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruyt, F. A. E.</span><span> </span><span class="NLM_article-title">Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=207-217&author=L.+H.+A.+M.+de+Wiltauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=J.+Cloosauthor=A.+D.+Schimmerauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=F.+A.+E.+Kruyt&title=Proteasome-based+mechanisms+of+intrinsic+and+acquired+bortezomib+resistance+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWilt%26aufirst%3DL.%2BH.%2BA.%2BM.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DKruyt%26aufirst%3DF.%2BA.%2BE.%26atitle%3DProteasome-based%2520mechanisms%2520of%2520intrinsic%2520and%2520acquired%2520bortezomib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D207%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Balsas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan-Malo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.leukres.2011.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21978467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=212-218&author=P.+Balsasauthor=P.+Galan-Maloauthor=I.+Marzoauthor=J.+Naval&title=Bortezomib+resistance+in+a+myeloma+cell+line+is+associated+to+PSM%CE%B25+overexpression+and+polyploidy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy</span></div><div class="casAuthors">Balsas, Patricia; Galan-Malo, Patricia; Marzo, Isabel; Naval, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-218</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM), though a no. of patients show resistance to this drug.  To study the cellular basis of this resistance we have generated a MM cell line displaying enhanced (5-6-fold) resistance to bortezomib by serial cultivation of RPMI 8226 cells with increasing concns. of this drug.  Bortezomib-resistant cells (8226/7B) became bigger in size than parental cells and nearly doubled the amt. of DNA per cell, evolving from hypotriploidy to near-tetraploidy. 8226/7B displayed lowered Noxa accumulation and reduced caspase-3 activation in response to bortezomib.  Resistant 8226/7B cells overexpressed the PSMβ5 proteasome subunit, the mol. target of bortezomib, both at the mRNA and protein level.  No mutations were detected in the PSMβ5 gene.  Bortezomib-resistant cells were roughly as sensitive as parental cells to other chemotherapeutic drugs, including doxorubicin, melphalan, vincristine, BMS-214662 and BMS-345541.  8226/7B cells showed partial and high cross-resistance to the proteasome inhibitors epoxomicin and MG-132, resp.  Co-treatment with the histone deacetylase inhibitor trichostatin A (TSA) potentiated bortezomib-induced apoptosis in parental RPMI 8226 cells but did not revert bortezomib resistance in 8226/7B cells.  Therefore, treatment of bortezomib-refractory myeloma with drugs targeting mol. structures other than proteasome seems to be the more suitable therapeutic strategy to overcome bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4fMGrGcs_rVg90H21EOLACvtfcHk0lglabaO43rnLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVemtw%253D%253D&md5=efa85279e50aa27c59a1876d90640462</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2011.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2011.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DBalsas%26aufirst%3DP.%26aulast%3DGalan-Malo%26aufirst%3DP.%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DBortezomib%2520resistance%2520in%2520a%2520myeloma%2520cell%2520line%2520is%2520associated%2520to%2520PSM%25CE%25B25%2520overexpression%2520and%2520polyploidy%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D212%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Finley, D.</span><span> </span><span class="NLM_article-title">Recognition and processing of ubiquitin-protein conjugates by the proteasome</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1146%2Fannurev.biochem.78.081507.101607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19489727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=477-513&author=D.+Finley&title=Recognition+and+processing+of+ubiquitin-protein+conjugates+by+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition and processing of ubiquitin-protein conjugates by the proteasome</span></div><div class="casAuthors">Finley, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">477-513</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The proteasome is an intricate mol. machine, which serves to degrade proteins following their conjugation to ubiquitin.  Substrates dock onto the proteasome at its 19-subunit regulatory particle via a diverse set of ubiquitin receptors and are then translocated into an internal chamber within the 28-subunit proteolytic core particle (CP), where they are hydrolyzed.  The substrate is threaded into the CP through a narrow gated channel, and thus translocation requires unfolding of the substrate.  Six distinct ATPases in the regulatory particle appear to form a ring complex and to drive unfolding as well as translocation.  ATP-dependent, degrdn.-coupled deubiquitination of the substrate is required both for efficient substrate degrdn. and for preventing the degrdn. of the ubiquitin tag.  However, the proteasome also contains deubiquitinating enzymes (DUBs) that can remove ubiquitin before substrate degrdn. initiates, thus allowing some substrates to dissoc. from the proteasome and escape degrdn.  Here, the authors examine the key elements of this mol. machine and how they cooperate in the processing of proteolytic substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiMN2MjjcyS7Vg90H21EOLACvtfcHk0lgir6sjhGZc3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Ghurw%253D&md5=a8d286d88577011670470b65d304e808</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.78.081507.101607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.78.081507.101607%26sid%3Dliteratum%253Aachs%26aulast%3DFinley%26aufirst%3DD.%26atitle%3DRecognition%2520and%2520processing%2520of%2520ubiquitin-protein%2520conjugates%2520by%2520the%2520proteasome%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2009%26volume%3D78%26spage%3D477%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Xu, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclean, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skrtic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavareh, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketela, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2251-2259&author=G.+W.+Xuauthor=M.+Aliauthor=T.+E.+Woodauthor=D.+Wongauthor=N.+Macleanauthor=X.+M.+Wangauthor=M.+Grondaauthor=M.+Skrticauthor=X.+M.+Liauthor=R.+Hurrenauthor=X.+L.+Maoauthor=M.+Venkatesanauthor=R.+B.+Zavarehauthor=T.+Ketelaauthor=J.+C.+Reedauthor=D.+Roseauthor=J.+Moffatauthor=R.+A.+Bateyauthor=S.+Dhe-Paganonauthor=A.+D.+Schimmer&title=The+ubiquitin-activating+enzyme+E1+as+a+therapeutic+target+for+the+treatment+of+leukemia+and+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DSkrtic%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DZavareh%26aufirst%3DR.%2BB.%26aulast%3DKetela%26aufirst%3DT.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DRose%26aufirst%3DD.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DThe%2520ubiquitin-activating%2520enzyme%2520E1%2520as%2520a%2520therapeutic%2520target%2520for%2520the%2520treatment%2520of%2520leukemia%2520and%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2251%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hochstrasser, M.</span><span> </span><span class="NLM_article-title">Origin and function of ubiquitin-like proteins</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">458</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fnature07958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19325621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Klsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=422-429&author=M.+Hochstrasser&title=Origin+and+function+of+ubiquitin-like+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and function of ubiquitin-like proteins</span></div><div class="casAuthors">Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7237</span>),
    <span class="NLM_cas:pages">422-429</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Eukaryotic proteins can be modified through attachment to various small mols. and proteins.  One such modification is conjugation to ubiquitin and ubiquitin-like proteins (UBLs), which controls an enormous range of physiol. processes.  Bound UBLs mainly regulate the interactions of proteins with other macromols., e.g., binding to the proteasome or recruitment to chromatin.  The various UBL systems use related enzymes to attach specific UBLs to proteins (or other mols.), and most of these attachments are transient.  There is increasing evidence suggesting that such UBL-protein modification evolved from prokaryotic sulfurtransferase systems or related enzymes.  Moreover, proteins similar to UBL-conjugating enzymes and UBL-deconjugating enzymes seem to have already been widespread at the time of the last common ancestor (LCA) of eukaryotes, suggesting that UBL-protein conjugation did not 1st evolve in eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaZQ06CJ5q7Vg90H21EOLACvtfcHk0lgir6sjhGZc3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Klsbg%253D&md5=da78b38ccb5d49faaac5acf75119ddb4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature07958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07958%26sid%3Dliteratum%253Aachs%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DOrigin%2520and%2520function%2520of%2520ubiquitin-like%2520proteins%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D422%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bochtler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstetter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span> </span><span class="NLM_article-title">Molecular machines for protein degradation</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1002%2Fcbic.200400313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=15678420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=222-256&author=M.+Grollauthor=M.+Bochtlerauthor=H.+Brandstetterauthor=T.+Clausenauthor=R.+Huber&title=Molecular+machines+for+protein+degradation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular machines for protein degradation</span></div><div class="casAuthors">Groll, Michael; Bochtler, Matthias; Brandstetter, Hans; Clausen, Tim; Huber, Robert</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-256</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  One of the most precisely regulated processes in living cells is intracellular protein degrdn.  The main component of the degrdn. machinery is the 20S proteasome present in both eukaryotes and prokaryotes.  In addn., there exist other proteasome-related protein-degrdn. machineries, like HslVU protease in eubacteria.  Peptides generated by proteasomes and related systems can be used by the cell, e.g., for antigen presentation.  However, most of the peptides must be degraded to single amino acids, which are further used in cell metab. and for the synthesis of new proteins.  Tricorn protease and its interacting factors work downstream of the proteasome and process the peptides into amino acids.  Here, the authors summarize the current state of knowledge about protein-degrdn. systems, focusing in particular on the 20S proteasome, HslVU protease, tricorn protease and its interacting factors, and DegP protease.  The structural information about these protein complexes opens new possibilities for identifying, characterizing, and elucidating the mode of action of natural and synthetic inhibitors, which affects their function.  Some of these compds. may find therapeutic applications in contemporary medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFH-O3dirM-bVg90H21EOLACvtfcHk0liYEcsT5dQhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVKhtbs%253D&md5=04ca944e381d6ed59067c9286df1bd56</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400313%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBochtler%26aufirst%3DM.%26aulast%3DBrandstetter%26aufirst%3DH.%26aulast%3DClausen%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DR.%26atitle%3DMolecular%2520machines%2520for%2520protein%2520degradation%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D222%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Darwin, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, C. F.</span><span> </span><span class="NLM_article-title">The proteasome of <i>Mycobacterium tuberculosis</i> is required for resistance to nitric oxide</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1966</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1126%2Fscience.1091176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=14671303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ams7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=1963-1966&author=K.+H.+Darwinauthor=S.+Ehrtauthor=J.+C.+Gutierrez-Ramosauthor=N.+Weichauthor=C.+F.+Nathan&title=The+proteasome+of+Mycobacterium+tuberculosis+is+required+for+resistance+to+nitric+oxide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide</span></div><div class="casAuthors">Darwin, K. Heran; Ehrt, Sabine; Gutierrez-Ramos, Jose-Carlos; Weich, Nadine; Nathan, Carl F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5652</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The prodn. of nitric oxide and other reactive nitrogen intermediates (RNI) by macrophages helps to control infection by Mycobacterium tuberculosis (Mtb).  However, the protection is imperfect and infection persists.  To identify genes that Mtb requires to resist RNI, the authors screened 10,100 Mtb transposon mutants for hypersusceptibility to acidified nitrite.  They found 12 mutants with insertions in seven genes representing six pathways, including the repair of DNA (uvrB) and the synthesis of a flavin cofactor (fbiC).  Five mutants had insertions in proteasome-assocd. genes.  An Mtb mutant deficient in a presumptive proteasomal ATPase was attenuated in mice, and exposure to proteasomal protease inhibitors markedly sensitized wild-type Mtb to RNI.  Thus, the mycobacterial proteasome serves as a defense against oxidative or nitrosative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejml3OLRZJLVg90H21EOLACvtfcHk0liYEcsT5dQhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ams7c%253D&md5=0fa331331948788703fc2a3a87c78e68</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.1091176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1091176%26sid%3Dliteratum%253Aachs%26aulast%3DDarwin%26aufirst%3DK.%2BH.%26aulast%3DEhrt%26aufirst%3DS.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26aulast%3DWeich%26aufirst%3DN.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26atitle%3DThe%2520proteasome%2520of%2520Mycobacterium%2520tuberculosis%2520is%2520required%2520for%2520resistance%2520to%2520nitric%2520oxide%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D1963%26epage%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Imajoh-Ohmi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, H.</span><span> </span><span class="NLM_article-title">Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">217</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=1995&pages=1070-1077&author=S.+Imajoh-Ohmiauthor=T.+Kawaguchiauthor=S.+Sugiyamaauthor=K.+Tanakaauthor=S.+Omuraauthor=H.+Kikuchi&title=Lactacystin%2C+a+specific+inhibitor+of+the+proteasome%2C+induces+apoptosis+in+human+monoblast+U937+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImajoh-Ohmi%26aufirst%3DS.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DLactacystin%252C%2520a%2520specific%2520inhibitor%2520of%2520the%2520proteasome%252C%2520induces%2520apoptosis%2520in%2520human%2520monoblast%2520U937%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D217%26spage%3D1070%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Delic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masdehors, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosset, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binet, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdelenat, H.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fbjc.1998.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=9569046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADyaK1cXisVKhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1998&pages=1103-1107&author=J.+Delicauthor=P.+Masdehorsauthor=S.+Omuraauthor=J.+M.+Cossetauthor=J.+Dumontauthor=J.+L.+Binetauthor=H.+Magdelenat&title=The+proteasome+inhibitor+lactacystin+induces+apoptosis+and+sensitizes+chemo-+and+radioresistant+human+chronic+lymphocytic+leukaemia+lymphocytes+to+TNF-%CE%B1-initiated+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-α-initiated apoptosis</span></div><div class="casAuthors">Delic, J.; Masdehors, P.; Omura, S.; Cosset, J. -M.; Dumont, J.; Binet, J. -L.; Magdelenat, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1103-1107</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">Apoptosis can be triggered by cytotoxic agents and radiation currently used in cancer treatment.  However, the apoptotic response appears to vary between cell types (normal or transformed) and between types of malignancy.  Thus, irradn. induces apoptosis in normal human lymphocytes but not in lymphocytes derived from a subset of chronic lymphocytic leukemia (CLL).  Moreover, in this subset, spontaneous apoptosis is inhibited by irradn.  Why irradn. does not allow the initiation of the apoptotic death pathway could be explained, at least in part, and in agreement with recent findings on exptl. models, by the activation of the transcriptional factor NF-κB, which is able to inhibit apoptotic cell response.  Low doses (at which no effect is obsd. with normal human lymphocytes) of the highly specific proteasome inhibitor lactacystin are sufficient to trigger apoptosis in these malignant cells.  Proteasome inhibition by lactacystin prevents the nuclear translocation of both p50 and p65 NF-κB subunits and sensitizes these cells to apoptosis by tumor necrosis factor (TNF)-α treatment.  As this subset of CLL is totally resistant to any treatment, proteasome inhibition by lactacystin provides a new therapeutic approach to be explored, considering the sensitivity of malignant CLL-derived lymphocytes to be quite different from that of normal human lymphocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3COCNaHCirVg90H21EOLACvtfcHk0liYEcsT5dQhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVKhs74%253D&md5=5430d590d55a0ebadda258c6a953f5d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.183%26sid%3Dliteratum%253Aachs%26aulast%3DDelic%26aufirst%3DJ.%26aulast%3DMasdehors%26aufirst%3DP.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DCosset%26aufirst%3DJ.%2BM.%26aulast%3DDumont%26aufirst%3DJ.%26aulast%3DBinet%26aufirst%3DJ.%2BL.%26aulast%3DMagdelenat%26aufirst%3DH.%26atitle%3DThe%2520proteasome%2520inhibitor%2520lactacystin%2520induces%2520apoptosis%2520and%2520sensitizes%2520chemo-%2520and%2520radioresistant%2520human%2520chronic%2520lymphocytic%2520leukaemia%2520lymphocytes%2520to%2520TNF-%25CE%25B1-initiated%2520apoptosis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D77%26spage%3D1103%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eswara, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafond-Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, C. V.</span><span> </span><span class="NLM_article-title">Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4342-4348&author=R.+Z.+Orlowskiauthor=J.+R.+Eswaraauthor=A.+Lafond-Walkerauthor=M.+R.+Greverauthor=M.+Orlowskiauthor=C.+V.+Dang&title=Tumor+growth+inhibition+induced+in+a+murine+model+of+human+Burkitt%E2%80%99s+lymphoma+by+a+proteasome+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DEswara%26aufirst%3DJ.%2BR.%26aulast%3DLafond-Walker%26aufirst%3DA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DTumor%2520growth%2520inhibition%2520induced%2520in%2520a%2520murine%2520model%2520of%2520human%2520Burkitt%25E2%2580%2599s%2520lymphoma%2520by%2520a%2520proteasome%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4342%26epage%3D4348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F1535-7163.MCT-11-0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22072815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2034-2042&author=T.+Hideshimaauthor=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Mechanism+of+action+of+proteasome+inhibitors+and+deacetylase+inhibitors+and+the+biological+basis+of+synergy+in+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span></div><div class="casAuthors">Hideshima, Teru; Richardson, Paul G.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2034-2042</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Novel agents, including the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade.  Despite these advances, many patients relapse or do not benefit from the currently available therapies; thus, multiple myeloma remains an incurable disease.  Deacetylase inhibitors (DACi), including panobinostat and vorinostat, have recently emerged as novel agents being evaluated in the treatment of multiple myeloma.  Deacetylases are a group of enzymes with effects on various intracellular proteins, including histones, transcription factors, and mol. chaperones.  Although DACi inhibit cell growth and induce apoptosis in multiple myeloma cells as a single agent, synergistic activity has been obsd. when they were used in combination with bortezomib.  The mechanistic basis of synergy is multifactorial and includes disruption of protein degrdn. and inhibition of the interaction of multiple myeloma cells with the tumor microenvironment.  This review summarizes recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma and examines the biol. basis of their synergistic effects.  Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clin. trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma.  Mol Cancer Ther; 10(11); 2034-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTic1RyTJsbVg90H21EOLACvtfcHk0lj3CxH95xgDWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ&md5=741285acef164545c3388037dc42f73f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0433%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMechanism%2520of%2520action%2520of%2520proteasome%2520inhibitors%2520and%2520deacetylase%2520inhibitors%2520and%2520the%2520biological%2520basis%2520of%2520synergy%2520in%2520multiple%2520myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2034%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Masdehors, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merle-Beral, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdelenat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delic, J.</span><span> </span><span class="NLM_article-title">Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=269-274&author=P.+Masdehorsauthor=H.+Merle-Beralauthor=K.+Maloumauthor=S.+Omuraauthor=H.+Magdelenatauthor=J.+Delic&title=Deregulation+of+the+ubiquitin+system+and+p53+proteolysis+modify+the+apoptotic+response+in+B-CLL+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasdehors%26aufirst%3DP.%26aulast%3DMerle-Beral%26aufirst%3DH.%26aulast%3DMaloum%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DMagdelenat%26aufirst%3DH.%26aulast%3DDelic%26aufirst%3DJ.%26atitle%3DDeregulation%2520of%2520the%2520ubiquitin%2520system%2520and%2520p53%2520proteolysis%2520modify%2520the%2520apoptotic%2520response%2520in%2520B-CLL%2520lymphocytes%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D269%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pengo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calbi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenci, S.</span><span> </span><span class="NLM_article-title">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3040</span><span class="NLM_x">–</span> <span class="NLM_lpage">3049</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1182%2Fblood-2008-08-172734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19164601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3040-3049&author=G.+Bianchiauthor=L.+Olivaauthor=P.+Cascioauthor=N.+Pengoauthor=F.+Fontanaauthor=F.+Cerrutiauthor=A.+Orsiauthor=E.+Pasqualettoauthor=A.+Mezghraniauthor=V.+Calbiauthor=G.+Palladiniauthor=N.+Giulianiauthor=K.+C.+Andersonauthor=R.+Sitiaauthor=S.+Cenci&title=The+proteasome+load+versus+capacity+balance+determines+apoptotic+sensitivity+of+multiple+myeloma+cells+to+proteasome+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition</span></div><div class="casAuthors">Bianchi, Giada; Oliva, Laura; Cascio, Paolo; Pengo, Niccolo; Fontana, Francesca; Cerruti, Fulvia; Orsi, Andrea; Pasqualetto, Elena; Mezghrani, Alexandre; Calbi, Valeria; Palladini, Giovanni; Giuliani, Nicola; Anderson, Kenneth C.; Sitia, Roberto; Cenci, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the mechanisms of action and bases of individual susceptibility remain unclear.  Recent work linked PI sensitivity to protein synthesis and proteasome activity, raising the question whether different levels of proteasome expression and workload underlie PI sensitivity in MM cells (MMCs).  Exploiting human MM lines characterized by differential PI sensitivity, we report that highly sensitive MMCs express lower proteasome levels and higher proteasomal workload than relatively PI-resistant MMCs, resulting in the accumulation of polyubiquitinated proteins at the expense of free ubiquitin (proteasome stress).  Manipulating proteasome expression or workload alters apoptotic sensitivity to PI, demonstrating a cause-effect relationship between proteasome stress and apoptotic responses in MMCs.  Intracellular immunostaining in primary, patient-derived MMCs reveals that polyubiquitinated proteins hallmark neoplastic plasma cells, in pos. correlation with Ig content, both intra- and interpatient.  Moreover, overall proteasome activity of primary MMCs inversely correlates with apoptotic sensitivity to PI.  Altogether, our data indicate that the balance between proteasome workload and degradative capacity represents a crit. determinant of apoptotic sensitivity of MMCs to PI, potentially providing a framework for identifying indicators of responsiveness and designing novel combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZB8ZrWDyLbVg90H21EOLACvtfcHk0lj3CxH95xgDWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWntrs%253D&md5=dd9f98f07f06ba2d312a54228d96ceef</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-08-172734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-08-172734%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DPengo%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DF.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCalbi%26aufirst%3DV.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCenci%26aufirst%3DS.%26atitle%3DThe%2520proteasome%2520load%2520versus%2520capacity%2520balance%2520determines%2520apoptotic%2520sensitivity%2520of%2520multiple%2520myeloma%2520cells%2520to%2520proteasome%2520inhibition%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3040%26epage%3D3049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Cenci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelouard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masciarelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattioli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagliavacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span> </span><span class="NLM_article-title">Progressively impaired proteasomal capacity during terminal plasma cell differentiation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1104</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1104-1113&author=S.+Cenciauthor=A.+Mezghraniauthor=P.+Cascioauthor=G.+Bianchiauthor=F.+Cerrutiauthor=A.+Fraauthor=H.+Lelouardauthor=S.+Masciarelliauthor=L.+Mattioliauthor=L.+Olivaauthor=A.+Orsiauthor=E.+Pasqualettoauthor=P.+Pierreauthor=E.+Ruffatoauthor=L.+Tagliavaccaauthor=R.+Sitia&title=Progressively+impaired+proteasomal+capacity+during+terminal+plasma+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DP.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DFra%26aufirst%3DA.%26aulast%3DLelouard%26aufirst%3DH.%26aulast%3DMasciarelli%26aufirst%3DS.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DOrsi%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DRuffato%26aufirst%3DE.%26aulast%3DTagliavacca%26aufirst%3DL.%26aulast%3DSitia%26aufirst%3DR.%26atitle%3DProgressively%2520impaired%2520proteasomal%2520capacity%2520during%2520terminal%2520plasma%2520cell%2520differentiation%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1104%26epage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Moore, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eustáquio, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, R. P.</span><span> </span><span class="NLM_article-title">Advances in and applications of proteasome inhibitors</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.cbpa.2008.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=18656549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=434-440&author=B.+S.+Mooreauthor=A.+S.+Eust%C3%A1quioauthor=R.+P.+McGlinchey&title=Advances+in+and+applications+of+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in and applications of proteasome inhibitors</span></div><div class="casAuthors">Moore, Bradley S.; Eustaquio, Alessandra S.; McGlinchey, Ryan P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-440</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the recent US Food and Drug Administration approval of bortezomib (Velcade) for the treatment of relapsed multiple myeloma, the proteasome has emerged as a new therapeutic target with diverse pathol.  Drug discovery programs in academia and the pharmaceutical industry have developed a range of low nanomolar synthetic and natural inhibitors of the 20S proteasome core particle that have entered human clin. trials as significant anticancer and antiinflammatory leads.  Moreover, proteasome inhibitors continue to serve as valuable research tools in cellular biol. through the elucidation of important biol. processes assocd. with the ubiquitin-proteasome pathway of protein degrdn.  This review will highlight recent advances in the development and application of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOuBSm-tslrVg90H21EOLACvtfcHk0lj0aRsys1I89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsrvE&md5=1b47064214a39584a0dc4ecca8a254d3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DB.%2BS.%26aulast%3DEust%25C3%25A1quio%26aufirst%3DA.%2BS.%26aulast%3DMcGlinchey%26aufirst%3DR.%2BP.%26atitle%3DAdvances%2520in%2520and%2520applications%2520of%2520proteasome%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D434%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogyo, M.</span><span> </span><span class="NLM_article-title">Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2FS1074-5521%2802%2900144-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=12031672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVWis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=655-662&author=M.+Grollauthor=T.+Nazifauthor=R.+Huberauthor=M.+Bogyo&title=Probing+structural+determinants+distal+to+the+site+of+hydrolysis+that+control+substrate+specificity+of+the+20S+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Probing Structural Determinants Distal to the Site of Hydrolysis that Control Substrate Specificity of the 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Nazif, Tamim; Huber, Robert; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The 20S proteasome is a large multicomponent protease complex.  Relatively little is known about the mechanisms that control substrate specificity of its multiple active sites.  We present here the crystal structure at 2.95 A resoln. of a β2-selective inhibitor (MB1) bound to the yeast 20S proteasome core particle (CP).  This structure is compared to the structure of the CP bound to a general inhibitor (MB2) that covalently modified all three (β1, β2, β5) catalytic subunits.  These two inhibitors differ only in their P3 and P4 residues, thereby highlighting binding interactions distal to the active site threonine that control abs. substrate specificity of the complex.  Comparisons of the CP-bound structures of MB1, MB2, and the natural products epoxomicin and TMC-95A also provide information regarding general binding modes for several classes of proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFy2YLpjvm-LVg90H21EOLACvtfcHk0lj0aRsys1I89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVWis70%253D&md5=4ef255415612e227382546e12eb521b7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2802%2900144-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252802%252900144-8%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DNazif%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DProbing%2520structural%2520determinants%2520distal%2520to%2520the%2520site%2520of%2520hydrolysis%2520that%2520control%2520substrate%2520specificity%2520of%2520the%252020S%2520proteasome%26jtitle%3DChem.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P. E.</span><span> </span><span class="NLM_article-title">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.drudis.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20116451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=243-249&author=L.+R.+Dickauthor=P.+E.+Fleming&title=Building+on+bortezomib%3A+second-generation+proteasome+inhibitors+as+anti-cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span></div><div class="casAuthors">Dick, Lawrence R.; Fleming, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the proteasome (a highly abundant enzymic complex responsible for intracellular protein turnover) is an effective anti-cancer therapeutic approach, as demonstrated by the first-in-class agent bortezomib.  Various new proteasome inhibitors are now in development, including peptide boronic acid analogs MLN9708 and CEP-18770, peptide epoxyketones carfilzomib and PR-047, and NPI-0052, a β-lactone compd.  All are potent inhibitors of proteasome activity in vitro but show differences in enzyme binding kinetics, which might affect their pharmacol. and result in different efficacy and safety profiles.  Here, we review the second-generation proteasome inhibitors and assess the potential pharmacol. impact of their different chem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuklkNi02WRbVg90H21EOLACvtfcHk0lj0aRsys1I89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D&md5=6a6ceeb81601f467ea56debc9f607738</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DFleming%26aufirst%3DP.%2BE.%26atitle%3DBuilding%2520on%2520bortezomib%253A%2520second-generation%2520proteasome%2520inhibitors%2520as%2520anti-cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D243%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ruschak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slassi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">Novel proteasome inhibitors to overcome bortezomib resistance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1093%2Fjnci%2Fdjr160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21606441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2011&pages=1007-1017&author=A.+M.+Ruschakauthor=M.+Slassiauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Novel+proteasome+inhibitors+to+overcome+bortezomib+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Proteasome Inhibitors to Overcome Bortezomib Resistance</span></div><div class="casAuthors">Ruschak, Amy M.; Slassi, Malik; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1007-1017</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins and thereby regulates protein levels within the cell.  Given this important role in maintaining cellular homeostasis, it is perhaps somewhat surprising that proteasome inhibitors have a therapeutic window.  Proteasome inhibitors have demonstrated clin. efficacy in the treatment of multiple myeloma and mantle cell lymphoma and are under evaluation for the treatment of other malignancies.  Bortezomib is the first and only Food and Drug Administration-approved proteasome inhibitor that inhibits this enzyme complex in a reversible fashion.  Although bortezomib improves clin. outcomes when used as a single agent, most patients do not respond to this drug and those who do respond almost uniformly relapse.  As such, efforts are underway to develop proteasome inhibitors that act through mechanisms distinct from that of bortezomib.  Specifically, inhibitors that bind the active site of the proteasome and inhibit the complex irreversibly have been developed and are in advanced clin. trials.  Inhibitors that act on sites of the proteasome outside of the catalytic center have also been identified and are in preclin. development.  In this review, we discuss the structure and function of the proteasome.  We then focus on the mol. biol., chem., and the preclin. and clin. efficacy of novel proteasome inhibitors as strategies to inhibit this target and overcome some forms of bortezomib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWeUjDj5ezAbVg90H21EOLACvtfcHk0ljNrJMSvck6UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKqsrs%253D&md5=52b263bbfd39bf18a543a382610c762f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr160%26sid%3Dliteratum%253Aachs%26aulast%3DRuschak%26aufirst%3DA.%2BM.%26aulast%3DSlassi%26aufirst%3DM.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DNovel%2520proteasome%2520inhibitors%2520to%2520overcome%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D103%26spage%3D1007%26epage%3D1017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pylypenko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosicki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karamanesht, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leleu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grishunina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masliak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robak, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shubina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnulf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deraedt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span> </span><span class="NLM_article-title">Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2FS1470-2045%2811%2970081-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=21507715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A280%3ADC%252BC3MvnvVWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=431-440&author=P.+Moreauauthor=H.+Pylypenkoauthor=S.+Grosickiauthor=I.+Karamaneshtauthor=X.+Leleuauthor=M.+Grishuninaauthor=G.+Rekhtmanauthor=Z.+Masliakauthor=T.+Robakauthor=A.+Shubinaauthor=B.+Arnulfauthor=M.+Kropffauthor=J.+Cavetauthor=D.+L.+Esseltineauthor=H.+B.+Fengauthor=S.+Girgisauthor=H.+van+de+Veldeauthor=W.+Deraedtauthor=J.+L.+Harousseau&title=Subcutaneous+versus+intravenous+administration+of+bortezomib+in+patients+with+relapsed+multiple+myeloma%3A+a+randomised%2C+phase+3%2C+non-inferiority+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study</span></div><div class="casAuthors">Moreau Philippe; Pylypenko Halyna; Grosicki Sebastian; Karamanesht Ievgenii; Leleu Xavier; Grishunina Maria; Rekhtman Grigoriy; Masliak Zvenyslava; Robak Tadeusz; Shubina Anna; Arnulf Bertrand; Kropff Martin; Cavet James; Esseltine Dixie-Lee; Feng Huaibao; Girgis Suzette; van de Velde Helgi; Deraedt William; Harousseau Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative.  We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma.  METHODS:  This randomised, phase 3 study was undertaken at 53 centres in ten countries in Europe, Asia, and South America.  Patients aged 18 years and older with relapsed multiple myeloma after one to three previous lines of therapy were randomly assigned to receive up to eight 21-day cycles of bortezomib 1·3 mg/m(2), on days 1, 4, 8, and 11, by subcutaneous injection or intravenous infusion.  Randomisation was by an interactive voice response system based on a computer-generated randomisation schedule, stratified by number of previous lines and disease stage.  Patients and treating physicians were not masked to treatment allocation.  The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in all patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug (response-evaluable population).  Non-inferiority was defined as retaining 60% of the intravenous treatment effect.  This study is registered with ClinicalTrials.gov, number NCT00722566, and is ongoing for long-term follow-up.  FINDINGS:  222 patients were randomly assigned to receive subcutaneous (n=148) or intravenous (n=74) bortezomib.  The response-evaluable population consisted of 145 patients in the subcutaneous group and 73 in the intravenous group.  Patients received a median of eight cycles (range one to ten) in both groups.  ORR after four cycles was 42% in both groups (61 patients in subcutaneous group and 31 in intravenous group; ORR difference -0·4%, 95% CI -14·3 to 13·5), showing non-inferiority (p=0·002).  After a median follow-up of 11·8 months (IQR 7·9-16·8) in the subcutaneous group and 12·0 months (8·1-15·6) in the intravenous group, there were no significant differences in time to progression (median 10·4 months, 95% CI 8·5-11·7, vs 9·4 months, 7·6-10·6; p=0·387) and 1-year overall survival (72·6%, 95% CI 63·1-80·0, vs 76·7%, 64·1-85·4; p=0·504) with subcutaneous versus intravenous bortezomib.  Grade 3 or worse adverse events were reported in 84 (57%) patients in the subcutaneous group versus 52 (70%) in the intravenous group; the most common were thrombocytopenia (19 [13%] vs 14 [19%]), neutropenia (26 [18%] vs 13 [18%]), and anaemia (18 [12%] vs six [8%]).  Peripheral neuropathy of any grade (56 [38%] vs 39 [53%]; p=0·044), grade 2 or worse (35 [24%] vs 30 [41%]; p=0·012), and grade 3 or worse (nine [6%] vs 12 [16%]; p=0·026) was significantly less common with subcutaneous than with intravenous administration.  Subcutaneous administration was locally well tolerated.  INTERPRETATION:  Subcutaneous bortezomib offers non-inferior efficacy to standard intravenous administration, with an improved safety profile.  FUNDING:  Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMW7KnkpVTZkbxh97K6Vt6fW6udTcc2eb638QZSqYq_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvnvVWqtw%253D%253D&md5=032dbef9cc436c2b6c4716af52d0b34d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970081-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970081-X%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DPylypenko%26aufirst%3DH.%26aulast%3DGrosicki%26aufirst%3DS.%26aulast%3DKaramanesht%26aufirst%3DI.%26aulast%3DLeleu%26aufirst%3DX.%26aulast%3DGrishunina%26aufirst%3DM.%26aulast%3DRekhtman%26aufirst%3DG.%26aulast%3DMasliak%26aufirst%3DZ.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DShubina%26aufirst%3DA.%26aulast%3DArnulf%26aufirst%3DB.%26aulast%3DKropff%26aufirst%3DM.%26aulast%3DCavet%26aufirst%3DJ.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DH.%2BB.%26aulast%3DGirgis%26aufirst%3DS.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DDeraedt%26aufirst%3DW.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26atitle%3DSubcutaneous%2520versus%2520intravenous%2520administration%2520of%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%253A%2520a%2520randomised%252C%2520phase%25203%252C%2520non-inferiority%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D431%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kupperman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannerman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzzese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfredi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolen, J.</span><span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+C.+Leeauthor=Y.+Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0ljNrJMSvck6UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DCao%26aufirst%3DY.%2BY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagno, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coscia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massaia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allievi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescalli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Giovine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Feudis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strepponi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferracini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussolati, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camussi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernareggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2765</span><span class="NLM_x">–</span> <span class="NLM_lpage">2775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2765-2775&author=R.+Pivaauthor=B.+Ruggeriauthor=M.+Williamsauthor=G.+Costaauthor=I.+Tamagnoauthor=D.+Ferreroauthor=V.+Giaiauthor=M.+Cosciaauthor=S.+Peolaauthor=M.+Massaiaauthor=G.+Pezzoniauthor=C.+Allieviauthor=N.+Pescalliauthor=M.+Cassinauthor=S.+di+Giovineauthor=P.+Nicoliauthor=P.+de+Feudisauthor=I.+Strepponiauthor=I.+Roatoauthor=R.+Ferraciniauthor=B.+Bussolatiauthor=G.+Camussiauthor=S.+Jones-Bolinauthor=K.+Hunterauthor=H.+Zhaoauthor=A.+Neriauthor=A.+Palumboauthor=C.+Berkersauthor=H.+Ovaaauthor=A.+Bernareggiauthor=G.+Inghirami&title=CEP-18770%3A+a+novel%2C+orally+active+proteasome+inhibitor+with+a+tumor-selective+pharmacologic+profile+competitive+with+bortezomib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DTamagno%26aufirst%3DI.%26aulast%3DFerrero%26aufirst%3DD.%26aulast%3DGiai%26aufirst%3DV.%26aulast%3DCoscia%26aufirst%3DM.%26aulast%3DPeola%26aufirst%3DS.%26aulast%3DMassaia%26aufirst%3DM.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DPescalli%26aufirst%3DN.%26aulast%3DCassin%26aufirst%3DM.%26aulast%3Ddi%2BGiovine%26aufirst%3DS.%26aulast%3DNicoli%26aufirst%3DP.%26aulast%3Dde%2BFeudis%26aufirst%3DP.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRoato%26aufirst%3DI.%26aulast%3DFerracini%26aufirst%3DR.%26aulast%3DBussolati%26aufirst%3DB.%26aulast%3DCamussi%26aufirst%3DG.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DNeri%26aufirst%3DA.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DCEP-18770%253A%2520a%2520novel%252C%2520orally%2520active%2520proteasome%2520inhibitor%2520with%2520a%2520tumor-selective%2520pharmacologic%2520profile%2520competitive%2520with%2520bortezomib%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2765%26epage%3D2775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallone, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineaux, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span> </span><span class="NLM_article-title">Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6383</span><span class="NLM_x">–</span> <span class="NLM_lpage">6391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+activity+of+PR-171%2C+a+novel+irreversible+inhibitor+of+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0lj8W9YPaZIftw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520PR-171%252C%2520a%2520novel%2520irreversible%2520inhibitor%2520of%2520the%2520proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6383%26epage%3D6391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Zhou, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchamuel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwonek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. F.</span><span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.+J.+Zhouauthor=M.+A.+Aujayauthor=M.+K.+Bennettauthor=M.+Dajeeauthor=S.+D.+Demoauthor=Y.+Fangauthor=M.+N.+Hoauthor=J.+Jiangauthor=C.+J.+Kirkauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+D.+Shenkauthor=J.+Shieldsauthor=P.+J.+Shwonekauthor=T.+Stantonauthor=C.+C.+M.+Sunauthor=C.+Sylvainauthor=T.+M.+Wooauthor=J.+F.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0livW_9s7MxyxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%2BC.%2BM.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Roccaro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Runnels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">4051</span><span class="NLM_x">–</span> <span class="NLM_lpage">4060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1182%2Fblood-2009-09-243402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20110419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4051-4060&author=A.+M.+Roccaroauthor=A.+Saccoauthor=M.+Aujayauthor=H.+T.+Ngoauthor=A.+K.+Azabauthor=F.+Azabauthor=P.+Quangauthor=P.+Maisoauthor=J.+Runnelsauthor=K.+C.+Andersonauthor=S.+Demoauthor=I.+M.+Ghobrial&title=Selective+inhibition+of+chymotrypsin-like+activity+of+the+immunoproteasome+and+constitutive+proteasome+in+Waldenstrom+macroglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span></div><div class="casAuthors">Roccaro, Aldo M.; Sacco, Antonio; Aujay, Monette; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Demo, Susan; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4051-4060</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clin. trials.  Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects.  Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematol. tumors.  We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S.  Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor κB (NF-κB) inhibition, caspase cleavage, and initiation of the unfolded protein response.  Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells.  These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBDkasuJTbVg90H21EOLACvtfcHk0livW_9s7MxyxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D&md5=6a1bdb8c763db89328adc15bc4a29f6f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243402%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DH.%2BT.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DRunnels%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520chymotrypsin-like%2520activity%2520of%2520the%2520immunoproteasome%2520and%2520constitutive%2520proteasome%2520in%2520Waldenstrom%2520macroglobulinemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4051%26epage%3D4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Meng, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, B. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elofsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, C. M.</span><span> </span><span class="NLM_article-title">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">10403</span><span class="NLM_x">–</span> <span class="NLM_lpage">10408</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1073%2Fpnas.96.18.10403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=10468620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10403-10408&author=L.+H.+Mengauthor=R.+Mohanauthor=B.+H.+B.+Kwokauthor=M.+Elofssonauthor=N.+Sinauthor=C.+M.+Crews&title=Epoxomicin%2C+a+potent+and+selective+proteasome+inhibitor%2C+exhibits+in+vivo+antiinflammatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span></div><div class="casAuthors">Meng, Lihao; Mohan, Royce; Kwok, Benjamin H. B.; Elofsson, Mikael; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10403-10408</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The proteasome (multicatalytic protease) regulates cellular processes as diverse as cell cycle progression and NF-κB activation.  The potent antitumor natural product epoxomicin specifically targets the proteasome.  Using biotinylated epoxomicin as a mol. probe showed that epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome.  Enzymic analyses with purified bovine erythrocyte proteasome revealed that epoxomicin potently inhibited primarily the chymotrypsin-like activity.  The trypsin-like and peptidyl-glutamyl peptide hydrolyzing catalytic activities were also inhibited at 100- and 1000-fold slower rates, resp.  In contrast to peptide aldehyde proteasome inhibitors, epoxomicin did not inhibit the nonproteasomal proteases, such as trypsin, chymotrypsin, papain, calpain, and cathepsin B, at concns. up to 50 μM.  Epoxomicin was a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS.  Epoxomicin also effectively inhibited the NF-κB activation in vitro and potently blocked the in vivo inflammation in the murine ear edema assay.  The results define epoxomicin as a novel proteasome inhibitor that may be useful in exploring the role of proteasome in various in vivo and in vitro systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXsPAKuQJ_LVg90H21EOLACvtfcHk0livW_9s7MxyxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D&md5=df0b5cdcccf546d60dc4e01d885d554b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10403%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKwok%26aufirst%3DB.%2BH.%2BB.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEpoxomicin%252C%2520a%2520potent%2520and%2520selective%2520proteasome%2520inhibitor%252C%2520exhibits%2520in%2520vivo%2520antiinflammatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D10403%26epage%3D10408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Gulder, T. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. S.</span><span> </span><span class="NLM_article-title">Salinosporamide natural products: potent 20S proteasome inhibitors as promising cancer chemotherapeutics</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">9346</span><span class="NLM_x">–</span> <span class="NLM_lpage">9367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1002%2Fanie.201000728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSls7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=9346-9367&author=T.+A.+M.+Gulderauthor=B.+S.+Moore&title=Salinosporamide+natural+products%3A+potent+20S+proteasome+inhibitors+as+promising+cancer+chemotherapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Salinosporamide Natural Products: Potent 20S Proteasome Inhibitors as Promising Cancer Chemotherapeutics</span></div><div class="casAuthors">Gulder, Tobias A. M.; Moore, Bradley S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">9346-9367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors are rapidly evolving as potent treatment options in cancer therapy.  One of the most promising drug candidates of this type is salinosporamide A from the bacterium Salinispora tropica.  This marine natural product possesses a complex, densely functionalized γ-lactam-β-lactone pharmacophore, which is responsible for its irreversible binding to its target, the β subunit of the 20S proteasome.  Salinosporamide A entered phase I clin. trials for the treatment of multiple myeloma only three years after its discovery.  The strong biol. activity and the challenging structure of this compd. have fueled intense academic and industrial research in recent years, which has led to the development of more than ten syntheses, the elucidation of its biosynthetic pathway, and the generation of promising structure-activity relationships and oncol. data.  Salinosporamide A thus serves as an intriguing example of the successful interplay of modern drug discovery and biomedical research, medicinal chem. and pharmacol., natural product synthesis and anal., as well as biosynthesis and bioengineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFXG8gnUHQLVg90H21EOLACvtfcHk0liwytUWF_p-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSls7zL&md5=f15906343033c261c03c2b1e750cdbfd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fanie.201000728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201000728%26sid%3Dliteratum%253Aachs%26aulast%3DGulder%26aufirst%3DT.%2BA.%2BM.%26aulast%3DMoore%26aufirst%3DB.%2BS.%26atitle%3DSalinosporamide%2520natural%2520products%253A%2520potent%252020S%2520proteasome%2520inhibitors%2520as%2520promising%2520cancer%2520chemotherapeutics%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D9346%26epage%3D9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlogie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkumar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srkalovic, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limentani, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkein, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A phase 2 study of bortezomib in relapsed, refractory myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1056%2FNEJMoa030288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=12826635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2609-2617&author=P.+G.+Richardsonauthor=B.+Barlogieauthor=J.+Berensonauthor=S.+Singhalauthor=S.+Jagannathauthor=D.+Irwinauthor=S.+V.+Rajkumarauthor=G.+Srkalovicauthor=M.+Alsinaauthor=R.+Alexanianauthor=D.+Siegelauthor=R.+Z.+Orlowskiauthor=D.+Kuterauthor=S.+A.+Limentaniauthor=S.+Leeauthor=T.+Hideshimaauthor=D.-L.+Esseltineauthor=M.+Kauffmanauthor=J.+Adamsauthor=D.+P.+Schenkeinauthor=K.+C.+Anderson&title=A+phase+2+study+of+bortezomib+in+relapsed%2C+refractory+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of bortezomib in relapsed, refractory myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Barlogie, Bart; Berenson, James; Singhal, Seema; Jagannath, Sundar; Irwin, David; Rajkumar, S. Vincent; Srkalovic, Gordan; Alsina, Melissa; Alexanian, Raymond; Siegel, David; Orlowski, Robert Z.; Kuter, David; Limentani, Steven A.; Lee, Stephanie; Hideshima, Teru; Esseltine, Dixie-Lee; Kauffman, Michael; Adams, Julian; Schenkein, David P.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2609-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclin. and phase 1 studies to have antimyeloma activity.  Methods: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently.  Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 wk, followed by 1 wk without treatment, for up to eight cycles (24 wk).  In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen.  The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee.  Results: Of 193 patients who could be evaluated, 92 % had been treated with three or more of the major classes of agents for myeloma, and in 91 %, the myeloma was refractory to the therapy received most recently.  The rate of response to bortezomib was 35 %, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation.  The median overall survival was 16 mo, with a median duration of response of 12 mo.  Grade 3 adverse events included thrombocytopenia (in 28 % of patients), fatigue (in 12 %), peripheral neuropathy (in 12 %), and neutropenia (in 11 %).  Grade 4 events occurred in 14 % of patients.  Conclusions: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvlvB12o1xbVg90H21EOLACvtfcHk0liwytUWF_p-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D&md5=7d7ef72077f270a421a538557b3bf9ca</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030288%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DBarlogie%26aufirst%3DB.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DRajkumar%26aufirst%3DS.%2BV.%26aulast%3DSrkalovic%26aufirst%3DG.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlexanian%26aufirst%3DR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DKuter%26aufirst%3DD.%26aulast%3DLimentani%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DEsseltine%26aufirst%3DD.-L.%26aulast%3DKauffman%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%2BP.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520phase%25202%2520study%2520of%2520bortezomib%2520in%2520relapsed%252C%2520refractory%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2609%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Shaughnessy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usmani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuck, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanamura, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaissie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waheed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlogie, B.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">3512</span><span class="NLM_x">–</span> <span class="NLM_lpage">3524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=3512-3524&author=J.+D.+Shaughnessyauthor=P.+Quauthor=S.+Usmaniauthor=C.+J.+Heuckauthor=Q.+Zhangauthor=Y.+Zhouauthor=E.+Tianauthor=I.+Hanamuraauthor=F.+van+Rheeauthor=E.+Anaissieauthor=J.+Epsteinauthor=B.+Nairauthor=O.+Stephensauthor=R.+Williamsauthor=S.+Waheedauthor=Y.+Alsayedauthor=J.+Crowleyauthor=B.+Barlogie&title=Pharmacogenomics+of+bortezomib+test-dosing+identifies+hyperexpression+of+proteasome+genes%2C+especially+PSMD4%2C+as+novel+high-risk+feature+in+myeloma+treated+with+total+therapy+3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaughnessy%26aufirst%3DJ.%2BD.%26aulast%3DQu%26aufirst%3DP.%26aulast%3DUsmani%26aufirst%3DS.%26aulast%3DHeuck%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DE.%26aulast%3DHanamura%26aufirst%3DI.%26aulast%3Dvan%2BRhee%26aufirst%3DF.%26aulast%3DAnaissie%26aufirst%3DE.%26aulast%3DEpstein%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DB.%26aulast%3DStephens%26aufirst%3DO.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DWaheed%26aufirst%3DS.%26aulast%3DAlsayed%26aufirst%3DY.%26aulast%3DCrowley%26aufirst%3DJ.%26aulast%3DBarlogie%26aufirst%3DB.%26atitle%3DPharmacogenomics%2520of%2520bortezomib%2520test-dosing%2520identifies%2520hyperexpression%2520of%2520proteasome%2520genes%252C%2520especially%2520PSMD4%252C%2520as%2520novel%2520high-risk%2520feature%2520in%2520myeloma%2520treated%2520with%2520total%2520therapy%25203%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D3512%26epage%3D3524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kraus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückrich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overkleeft, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driessen, C.</span><span> </span><span class="NLM_article-title">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2Fsj.leu.2404414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17024115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=84-92&author=M.+Krausauthor=T.+R%C3%BCckrichauthor=M.+Reichauthor=J.+Gogelauthor=A.+Beckauthor=W.+Kammerauthor=C.+R.+Berkersauthor=D.+Burgauthor=H.+Overkleeftauthor=H.+Ovaaauthor=C.+Driessen&title=Activity+patterns+of+proteasome+subunits+reflect+bortezomib+sensitivity+of+hematologic+malignancies+and+are+variable+in+primary+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span></div><div class="casAuthors">Kraus, M.; Rueckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasomal proteolysis relies on the activity of six catalytically active proteasomal subunits (β1, β2, β5, β1i, β2i and β5i).  Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells.  In primary leukemia samples, we obsd. remarkable variability in the amts. of active β1/1i-, β2/2i- and β5/5i-type of subunits, contrasting with their const. protein expression.  Bortezomib inhibited β5- and β1-type, but to a lesser extend β2-type of subunits in live primary cells in vitro and in vivo.  When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual β1/β5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells.  In a panel of cell lines from hematol. malignancies, the ratio between β2-type and (β1+β5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity.  We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematol. malignancies toward bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSfjpxWwrmrVg90H21EOLACvtfcHk0lhQJqigWwtpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL&md5=a7e3c1e5930d38f7359836967ee8c066</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404414%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DR%25C3%25BCckrich%26aufirst%3DT.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DKammer%26aufirst%3DW.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DActivity%2520patterns%2520of%2520proteasome%2520subunits%2520reflect%2520bortezomib%2520sensitivity%2520of%2520hematologic%2520malignancies%2520and%2520are%2520variable%2520in%2520primary%2520human%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D84%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+bortezomib+in+complex+with+the+yeast+20S+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lhQJqigWwtpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Kale, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. S.</span><span> </span><span class="NLM_article-title">Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1257</span><span class="NLM_x">–</span> <span class="NLM_lpage">1264</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb2002544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1257-1264&author=A.+J.+Kaleauthor=R.+P.+McGlincheyauthor=A.+Lechnerauthor=B.+S.+Moore&title=Bacterial+self-resistance+to+the+natural+proteasome+inhibitor+salinosporamide+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb2002544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb2002544%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DA.%2BJ.%26aulast%3DMcGlinchey%26aufirst%3DR.%2BP.%26aulast%3DLechner%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DB.%2BS.%26atitle%3DBacterial%2520self-resistance%2520to%2520the%2520natural%2520proteasome%2520inhibitor%2520salinosporamide%2520A%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D1257%26epage%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Sharma, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitelman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimke, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoni, R. D.</span><span> </span><span class="NLM_article-title">Peptide transport by the multidrug resistance pump</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">5731</span><span class="NLM_x">–</span> <span class="NLM_lpage">5734</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=5731-5734&author=R.+C.+Sharmaauthor=S.+Inoueauthor=J.+Roitelmanauthor=R.+T.+Schimkeauthor=R.+D.+Simoni&title=Peptide+transport+by+the+multidrug+resistance+pump"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%2BC.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DRoitelman%26aufirst%3DJ.%26aulast%3DSchimke%26aufirst%3DR.%2BT.%26aulast%3DSimoni%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520transport%2520by%2520the%2520multidrug%2520resistance%2520pump%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D5731%26epage%3D5734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">de Jong, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slootstra, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeijers, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puijk, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kool, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broxterman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloen, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span> </span><span class="NLM_article-title">Peptide transport by the multidrug resistance protein MRP1</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2552</span><span class="NLM_x">–</span> <span class="NLM_lpage">2557</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2552-2557&author=M.+C.+de+Jongauthor=J.+W.+Slootstraauthor=G.+L.+Schefferauthor=A.+B.+Schroeijersauthor=W.+C.+Puijkauthor=R.+Dinkelbergauthor=M.+Koolauthor=H.+J.+Broxtermanauthor=R.+H.+Meloenauthor=R.+J.+Scheper&title=Peptide+transport+by+the+multidrug+resistance+protein+MRP1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJong%26aufirst%3DM.%2BC.%26aulast%3DSlootstra%26aufirst%3DJ.%2BW.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DSchroeijers%26aufirst%3DA.%2BB.%26aulast%3DPuijk%26aufirst%3DW.%2BC.%26aulast%3DDinkelberg%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DBroxterman%26aufirst%3DH.%2BJ.%26aulast%3DMeloen%26aufirst%3DR.%2BH.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26atitle%3DPeptide%2520transport%2520by%2520the%2520multidrug%2520resistance%2520protein%2520MRP1%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2552%26epage%3D2557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Minderman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Loughlin, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span> </span><span class="NLM_article-title">Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1007%2Fs00280-006-0367-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=17096161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFSkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=245-255&author=H.+Mindermanauthor=Y.+F.+Zhouauthor=K.+L.+O%E2%80%99Loughlinauthor=M.+R.+Baer&title=Bortezomib+activity+and+in+vitro+interactions+with+anthracyclines+and+cytarabine+in+acute+myeloid+leukemia+cells+are+independent+of+multidrug+resistance+mechanisms+and+p53+status"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status</span></div><div class="casAuthors">Minderman, Hans; Zhou, Yunfei; O'Loughlin, Kieran L.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The proteasome inhibitor bortezomib may be effective in combination with cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of targeting aberrantly activated NF-κB in AML stem cells.  We tested whether bortezomib cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells.  We also tested whether bortezomib interactions with cytarabine and anthracyclines are affected by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest.  Bortezomib sensitivity of cell lines overexpressing P-glycoprotein, multidrug resistance protein-1, breast cancer resistance protein and lung resistance protein was studied in the presence and absence of established modulators of these transport proteins.  Drug interactions during simultaneous and sequential exposure to bortezomib and anthracyclines or cytarabine in diverse ratios were evaluated by isobologram and combination index analyses in AML cell lines with wild type and inactive p53 and were correlated with cell cycle perturbations induced by bortezomib.  Of the MDR mechanisms studied, only P-glycoprotein conferred resistance to bortezomib, and resistance was only twofold.  Interactions between bortezomib and anthracyclines and cytarabine changed from antagonistic to additive or synergistic with increasing drug activity levels and were not affected by p53 status.  MDR proteins and p53 do not affect bortezomib cytotoxicity or in vitro interactions with anthracyclines or cytarabine, but these interactions are concn.-dependent, and this concn.-dependency should be considered in the design of combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokBnJbYEVXxbVg90H21EOLACvtfcHk0liwnPrAeh4EBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFSkt7w%253D&md5=196970b8eea1d8bfef56b1ace3b5439f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0367-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0367-6%26sid%3Dliteratum%253Aachs%26aulast%3DMinderman%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%2BF.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BL.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DBortezomib%2520activity%2520and%2520in%2520vitro%2520interactions%2520with%2520anthracyclines%2520and%2520cytarabine%2520in%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520independent%2520of%2520multidrug%2520resistance%2520mechanisms%2520and%2520p53%2520status%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Verbrugge, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkmans, B. A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffer, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Uyl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oerlemans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Heijden, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gruijl, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheper, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span> </span><span class="NLM_article-title">Inactivating <i>PSMB5</i> mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+C.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+Van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0liwnPrAeh4EBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%2BC.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DVan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Politou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karadimitris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terpos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotsianidis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahemtulla, A.</span><span> </span><span class="NLM_article-title">No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.leukres.2005.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16081156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSiu7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=240-241&author=M.+Politouauthor=A.+Karadimitrisauthor=E.+Terposauthor=I.+Kotsianidisauthor=J.+F.+Apperleyauthor=A.+Rahemtulla&title=No+evidence+of+mutations+of+the+PSMB5+%28beta-5+subunit+of+proteasome%29+in+a+case+of+myeloma+with+clinical+resistance+to+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib</span></div><div class="casAuthors">Politou, Marianna; Karadimitris, Anastasios; Terpos, Evangelos; Kotsianidis, Ioannis; Apperley, Jane F.; Rahemtulla, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-241</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bortezomib is a target-tailored drug for the treatment of refractory/relapsed multiple myeloma.  A 65-yr-old female patient suffering from multiple myeloma developed rapid clin. resistance to bortezomib after initial response.  The initial prompt response and the rapid relapse while on treatment suggested that treatment with bortezomib might be assocd. with the selection of a preexisting, clin. aggressive myeloma clone.  To det. whether the underlying mol. mechanism may include abrogation of bortezomib binding to the beta-5 subunit of the proteasome (i.e., the direct target of bortezomib), acquired mutations in the PSMB5 gene were screened.  No mutations were detected in the gene that was amplified by PCR and sequenced either directly or following cloning.  These results indicate that clin. resistance to bortezomib is not due to mutations of the beta-5 subunit of the proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfGFJr0ySz2bVg90H21EOLACvtfcHk0liwnPrAeh4EBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSiu7bE&md5=fa4383dccdba4809d5432385f465311b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2005.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2005.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DPolitou%26aufirst%3DM.%26aulast%3DKaradimitris%26aufirst%3DA.%26aulast%3DTerpos%26aufirst%3DE.%26aulast%3DKotsianidis%26aufirst%3DI.%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DRahemtulla%26aufirst%3DA.%26atitle%3DNo%2520evidence%2520of%2520mutations%2520of%2520the%2520PSMB5%2520%2528beta-5%2520subunit%2520of%2520proteasome%2529%2520in%2520a%2520case%2520of%2520myeloma%2520with%2520clinical%2520resistance%2520to%2520bortezomib%26jtitle%3DLeuk.%2520Res.%26date%3D2006%26volume%3D30%26spage%3D240%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Sanchez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonavida, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenson, J. R.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1111%2Fj.1365-2141.2009.08008.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=19958357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFeqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=569-581&author=E.+Sanchezauthor=M.+J.+Liauthor=J.+A.+Steinbergauthor=C.+Wangauthor=J.+Shenauthor=B.+Bonavidaauthor=Z.+W.+Liauthor=H.+M.+Chenauthor=J.+R.+Berenson&title=The+proteasome+inhibitor+CEP-18770+enhances+the+anti-myeloma+activity+of+bortezomib+and+melphalan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan</span></div><div class="casAuthors">Sanchez, Eric; Li, Mingjie; Steinberg, Jeffrey A.; Wang, Cathy; Shen, Jing; Bonavida, Benjamin; Li, Zhi-Wei; Chen, Haiming; Berenson, James R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-581</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The anti-multiple myeloma (MM) efficacy of bortezomib has led to the development of other proteasome inhibitors (PI), including CEP-18770 which has shown anti-MM effects in preclin. studies.  However, the efficacy of orally (PO) or i.v. administered CEP-18770 in multiple MM models and in combination with conventional anti-MM therapies has not been evaluated.  Herein, we show that CEP-18770 combined with melphalan or bortezomib induces synergistic inhibition of MM cell viability in vitro.  In MM xenograft models, the addn. of CEP-18770 i.v. to melphalan completely prevented the growth of both melphalan-sensitive and melphalan-resistant tumors.  The combination of CEP-18770 i.v. and bortezomib induced complete regression of bortezomib-sensitive tumors and markedly delayed progression of bortezomib-resistant tumors compared to treatment with either agent alone.  Single agent CEP-18770 PO also showed marked anti-MM effects in these xenograft models.  These studies provide strong preclin. rationale for further development of this novel PI in the treatment of MM as a monotherapy as well as combined with either melphalan or bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6B3jA7lTFFrVg90H21EOLACvtfcHk0lhdEOLhoHuxqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFeqt7w%253D&md5=8c6473468e9face749957b5f449c3f10</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2009.08008.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2009.08008.x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DM.%2BJ.%26aulast%3DSteinberg%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DBonavida%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%2BM.%26aulast%3DBerenson%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520proteasome%2520inhibitor%2520CEP-18770%2520enhances%2520the%2520anti-myeloma%2520activity%2520of%2520bortezomib%2520and%2520melphalan%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D148%26spage%3D569%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Kuhn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strader, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Leeuwen, F. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span> </span><span class="NLM_article-title">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin–proteasome pathway, against preclinical models of multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3281</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3281-3290&author=D.+J.+Kuhnauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=J.+S.+Straderauthor=K.+D.+Shenkauthor=C.+M.+Sunauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=F.+W.+B.+van+Leeuwenauthor=A.+A.+Chanan-Khanauthor=R.+Z.+Orlowski&title=Potent+activity+of+carfilzomib%2C+a+novel%2C+irreversible+inhibitor+of+the+ubiquitin%E2%80%93proteasome+pathway%2C+against+preclinical+models+of+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DStrader%26aufirst%3DJ.%2BS.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%2BB.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DPotent%2520activity%2520of%2520carfilzomib%252C%2520a%2520novel%252C%2520irreversible%2520inhibitor%2520of%2520the%2520ubiquitin%25E2%2580%2593proteasome%2520pathway%252C%2520against%2520preclinical%2520models%2520of%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3281%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciccarelli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4906</span><span class="NLM_x">–</span> <span class="NLM_lpage">4915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4906-4915&author=D.+Chauhanauthor=A.+V.+Singhauthor=M.+Aujayauthor=C.+J.+Kirkauthor=M.+Bandiauthor=B.+Ciccarelliauthor=N.+Rajeauthor=P.+Richardsonauthor=K.+C.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+ONX+0912+triggers+in+vitro+and+in+vivo+cytotoxicity+in+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%2BV.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DCiccarelli%26aufirst%3DB.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520ONX%25200912%2520triggers%2520in%2520vitro%2520and%2520in%2520vivo%2520cytotoxicity%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4906%26epage%3D4915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velankar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1016%2Fj.ccr.2005.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=16286248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=407-419&author=D.+Chauhanauthor=L.+Catleyauthor=G.+Liauthor=K.+Podarauthor=T.+Hideshimaauthor=M.+Velankarauthor=C.+Mitsiadesauthor=N.+Mitsiadesauthor=H.+Yasuiauthor=A.+Letaiauthor=H.+Ovaaauthor=C.+Berkersauthor=B.+Nicholsonauthor=T.-H.+Chaoauthor=S.+T.+C.+Neuteboomauthor=P.+Richardsonauthor=M.+A.+Palladinoauthor=K.+C.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+induces+apoptosis+in+multiple+myeloma+cells+with+mechanisms+distinct+from+bortezomib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span></div><div class="casAuthors">Chauhan, Dharminder; Catley, Laurence; Li, Guilan; Podar, Klaus; Hideshima, Teru; Velankar, Mugdha; Mitsiades, Constantine; Mitsiades, Nicolas; Yasui, Hiroshi; Letai, Anthony; Ovaa, Huib; Berkers, Celia; Nicholson, Benjamin; Chao, Ta-Hsiang; Neuteboom, Saskia T. C.; Richardson, Paul; Palladino, Michael A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however, prolonged treatment is assocd. with toxicity and development of drug resistance.  Here, the authors show that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  NPI-0052 is distinct from bortezomib in its chem. structure, effects on proteasome activities, mechanisms of action, and toxicity profile against normal cells.  Moreover, NPI-0052 is orally bioactive.  In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence.  Combining NPI-0052 and bortezomib induces synergistic anti-MM activity.  Our study therefore provides the rationale for clin. protocols evaluating NPI-0052, alone and together with bortezomib, to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaYeiXJugULVg90H21EOLACvtfcHk0lhdEOLhoHuxqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF&md5=7bce23ea2891fe8863835c589294b213</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DVelankar%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DT.-H.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520with%2520mechanisms%2520distinct%2520from%2520bortezomib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D407%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Gao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hietaranta, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saluja, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steer, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, M.</span><span> </span><span class="NLM_article-title">Inhibition of ubiquitin–proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=439-448&author=Y.+H.+Gaoauthor=S.+Leckerauthor=M.+J.+Postauthor=A.+J.+Hietarantaauthor=J.+Liauthor=R.+Volkauthor=M.+Liauthor=K.+Satoauthor=A.+K.+Salujaauthor=M.+L.+Steerauthor=A.+L.+Goldbergauthor=M.+Simons&title=Inhibition+of+ubiquitin%E2%80%93proteasome+pathway-mediated+I%CE%BAB%CE%B1+degradation+by+a+naturally+occurring+antibacterial+peptide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%2BH.%26aulast%3DLecker%26aufirst%3DS.%26aulast%3DPost%26aufirst%3DM.%2BJ.%26aulast%3DHietaranta%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DVolk%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DSaluja%26aufirst%3DA.%2BK.%26aulast%3DSteer%26aufirst%3DM.%2BL.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DSimons%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520ubiquitin%25E2%2580%2593proteasome%2520pathway-mediated%2520I%25CE%25BAB%25CE%25B1%2520degradation%2520by%2520a%2520naturally%2520occurring%2520antibacterial%2520peptide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3D439%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aird, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampton, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, M.</span><span> </span><span class="NLM_article-title">PR39, a peptide regulator of angiogenesis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1038%2F71527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=10613823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1WlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=49-55&author=J.+Liauthor=M.+Postauthor=R.+Volkauthor=Y.+Gaoauthor=M.+Liauthor=C.+Metaisauthor=K.+Satoauthor=J.+Tsaiauthor=W.+Airdauthor=R.+D.+Rosenbergauthor=T.+G.+Hamptonauthor=J.+Liauthor=F.+Sellkeauthor=P.+Carmelietauthor=M.+Simons&title=PR39%2C+a+peptide+regulator+of+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">PR39, a peptide regulator of angiogenesis</span></div><div class="casAuthors">Li, Jian; Post, Mark; Volk, Rudiger; Gao, Youhe; Li, Min; Metais, Caroline; Sato, Kaori; Tsai, Jo; Aird, William; Rosenberg, Robert D.; Hampton, Thomas G.; Li, Jianyi; Sellke, Frank; Carmeliet, Peter; Simons, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-55</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Although tissue injury and inflammation are considered essential for the induction of angiogenesis, the mol. controls of this cascade are mostly unknown.  Here we show that a macrophage-derived peptide, PR39, inhibited the ubiquitin-proteasome-dependent degrdn. of hypoxia-inducible factor-1α protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice.  For the latter, coronary flow studies demonstrated that PR39-induced angiogenesis resulted in the prodn. of functional blood vessels.  These findings show that PR39 and related compds. can be used as potent inductors of angiogenesis, and that selective inhibition of hypoxia-inducible factor-1α degrdn. may underlie the mechanism of inflammation-induced angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmNGIiFzRNQ7Vg90H21EOLACvtfcHk0ljgYkHdKT1EdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1WlsA%253D%253D&md5=832cbec47bef0ca645f59de00d2639df</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2F71527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F71527%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DM.%26aulast%3DVolk%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMetais%26aufirst%3DC.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DAird%26aufirst%3DW.%26aulast%3DRosenberg%26aufirst%3DR.%2BD.%26aulast%3DHampton%26aufirst%3DT.%2BG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSellke%26aufirst%3DF.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DSimons%26aufirst%3DM.%26atitle%3DPR39%252C%2520a%2520peptide%2520regulator%2520of%2520angiogenesis%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Sprangers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span> </span><span class="NLM_article-title">TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6727</span><span class="NLM_x">–</span> <span class="NLM_lpage">6734</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi8005913" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=6727-6734&author=R.+Sprangersauthor=X.+M.+Liauthor=X.+L.+Maoauthor=J.+L.+Rubinsteinauthor=A.+D.+Schimmerauthor=L.+E.+Kay&title=TROSY-based+NMR+evidence+for+a+novel+class+of+20S+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fbi8005913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8005913%26sid%3Dliteratum%253Aachs%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKay%26aufirst%3DL.%2BE.%26atitle%3DTROSY-based%2520NMR%2520evidence%2520for%2520a%2520novel%2520class%2520of%252020S%2520proteasome%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D6727%26epage%3D6734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Li, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprangers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbrugge, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adomat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Religa, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimmer, A. D.</span><span> </span><span class="NLM_article-title">Effect of noncompetitive proteasome inhibition on bortezomib resistance</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm300434z&amp;key=10.1093%2Fjnci%2Fdjq198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm300434z&amp;key=20505154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm300434z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1069-1082&author=X.+M.+Liauthor=T.+E.+Woodauthor=R.+Sprangersauthor=G.+Jansenauthor=N.+E.+Frankeauthor=X.+L.+Maoauthor=X.+M.+Wangauthor=Y.+Zhangauthor=S.+E.+Verbruggeauthor=H.+Adomatauthor=Z.+H.+Liauthor=S.+Trudelauthor=C.+Chenauthor=T.+L.+Religaauthor=N.+Jamalauthor=H.+Messnerauthor=J.+Cloosauthor=D.+R.+Roseauthor=A.+Navonauthor=E.+Gunsauthor=R.+A.+Bateyauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Effect+of+noncompetitive+proteasome+inhibition+on+bortezomib+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance</span></div><div class="casAuthors">Li, Xiaoming; Wood, Tabitha E.; Sprangers, Remco; Jansen, Gerrit; Franke, Niels E.; Mao, Xinliang; Wang, Xiaoming; Zhang, Yi; Verbrugge, Sue Ellen; Adomat, Hans; Li, Zhi Hua; Trudel, Suzanne; Chen, Christine; Religa, Tomasz L.; Jamal, Nazir; Messner, Hans; Cloos, Jacqueline; Rose, David R.; Navon, Ami; Guns, Emma; Batey, Robert A.; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1069-1082</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Bortezomib and the other proteasome inhibitors that are currently under clin. investigation bind to the catalytic sites of proteasomes and are competitive inhibitors.  We hypothesized that proteasome inhibitors that act through a noncompetitive mechanism might overcome some forms of bortezomib resistance.  Methods: 5-amino-8-hydroxyquinoline (5AHQ) was identified through a screen of a 27-compd. chem. library based on the quinoline pharmacophore to identify proteasome inhibitors.  Inhibition of proteasome activity by 5AHQ was tested by measuring 7-amino-4-methylcoumarin (AMC) release from the proteasome substrate Suc-LLVY-AMC in intact human and mouse leukemia and myeloma cells and in tumor cell protein exts.  Cytotoxicity was assessed in 5AHQ-treated cell lines and primary cells from myeloma and leukemia patients using AlamarBlue fluorescence and MTS assays, trypan blue staining, and annexin V staining. 5AHQ-proteasome interaction was assessed by NMR. 5AHQ efficacy was evaluated in three leukemia xenograft mouse models (9-10 mice per group per model).  All statistical tests were two-sided.  Results 5AHQ inhibited the proteasome when added to cell exts. and intact cells (the mean concn. inhibiting 50% [IC50] of AMC release in intact cells ranged from 0.57 to 5.03 μM), induced cell death in intact cells from leukemia and myeloma cell lines (mean IC50 values for cell growth ranged from 0.94 to 3.85 μM), and preferentially induced cell death in primary myeloma and leukemia cells compared with normal hematopoietic cells.  5AHQ was equally cytotoxic to human myelomonocytic THP1 cells and to THP1/BTZ500 cells, which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of their overexpression and mutation of the bortezomib-binding β5 proteasome subunit (mean IC50 for cell death in the absence of bortezomib, wild-type THP1: 3.7 μM, 95% confidence interval = 3.4 to 4.0 μM; THP1/BTZ500: 6.6 μM, 95% confidence interval = 5.9 to 7.5 μM).  5AHQ interacted with the α subunits of the 20S proteasome at noncatalytic sites.  Orally administered 5AHQ inhibited tumor growth in all three mouse models of leukemia without overt toxicity (eg, OCI-AML2 model, median tumor wt. [interquartile range], 5AHQ vs control: 95.7 mg [61.4-163.5 mg] vs 247.2 mg [189.4-296.2 mg], P = .002).  Conclusions: 5AHQ is a noncompetitive proteasome inhibitor that is cytotoxic to myeloma and leukemia cells in vitro and inhibits xenograft tumor growth in vivo. 5AHQ can overcome some forms of bortezomib resistance in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4TcOS6iYs7Vg90H21EOLACvtfcHk0lindJ4JCpotdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D&md5=45a19957639165d2673f2dc72a0387a4</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjq198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjq198%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BM.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DMao%26aufirst%3DX.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAdomat%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DJamal%26aufirst%3DN.%26aulast%3DMessner%26aufirst%3DH.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DD.%2BR.%26aulast%3DNavon%26aufirst%3DA.%26aulast%3DGuns%26aufirst%3DE.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DEffect%2520of%2520noncompetitive%2520proteasome%2520inhibition%2520on%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2010%26volume%3D102%26spage%3D1069%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Edelmann, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases</span> <span class="citation_source-journal">Expert Rev. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">e35</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=e35&author=M.+J.+Edelmannauthor=B.+Nicholsonauthor=B.+M.+Kessler&title=Pharmacological+targets+in+the+ubiquitin+system+offer+new+ways+of+treating+cancer%2C+neurodegenerative+disorders+and+infectious+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdelmann%26aufirst%3DM.%2BJ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DPharmacological%2520targets%2520in%2520the%2520ubiquitin%2520system%2520offer%2520new%2520ways%2520of%2520treating%2520cancer%252C%2520neurodegenerative%2520disorders%2520and%2520infectious%2520diseases%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3De35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>, version <span class="NLM_edition">1.5.0.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16','PDB','2F16'); return false;">PDB: 2F16</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i15"><a href="/doi/suppl/10.1021/jm300434z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_37004"></div></div></div></div></div><hr /></hr><p class="last">Proteasome inhibitor cross-resistance and a comprehensive overview of PI resistant cell lines (two tables). This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300434z/suppl_file/jm300434z_si_001.pdf">jm300434z_si_001.pdf (347.84 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300434z&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-23%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm300434z%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300434z" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a7a4ad67d1cb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
